Page last updated: 2024-12-05

nimodipine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4497
CHEMBL ID3197349
CHEBI ID7575
SCHEMBL ID34041
SCHEMBL ID22882841
MeSH IDM0014859

Synonyms (240)

Synonym
CBIOL_001832
MLS002154061
MLS001076550
MLS002172461
HMS3266O22
HMS3394M05
AB00053314-03
BRD-A58048407-001-06-3
brd-8407
brd8407
smr000058300
MLS000069381
DIVK1C_006812
eg-1961
admon
bay-e-9736
nimogel
nimovent
1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
EU-0100891
drg-0139
nimodipino [inn-spanish]
brn 0459792
bay e 9736
einecs 266-127-0
nimodipinum [inn-latin]
isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
SPECTRUM_001880
nimotop
periplum
BIO1_001096
BIO1_000607
BIO1_000118
BIO2_000117
BIO2_000597
BSPBIO_002412
IDI1_033867
BSPBIO_001397
PRESTWICK2_000918
SPECTRUM5_001687
nimotop(tm)
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester
o5-isopropyl o3-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
AB00513963
66085-59-4
C07267
nimodipine
2,6-dimethyl-4-(3'-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-beta-methoxyethyl ester 5-isopropyl ester
isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
DB00393
D00438
nimodipine (usp/inn)
nymalize (tn)
nimotop (tn)
LOPAC0_000891
PRESTWICK3_000918
BSPBIO_000796
MLS000863294 ,
NCGC00024675-03
NCGC00024675-04
NCGC00024675-08
NCGC00024675-05
NCGC00024675-07
KBIO2_002403
KBIO3_000234
KBIOGR_001262
KBIO2_007539
KBIOSS_000117
KBIOGR_000117
KBIO2_004971
KBIO3_000233
KBIOSS_002408
KBIO2_002685
KBIO1_001756
KBIO3_001632
KBIO2_000117
KBIO2_005253
SPBIO_001464
SPECTRUM3_000766
SPECTRUM2_001562
PRESTWICK0_000918
SPBIO_002985
SPECPLUS_000716
SPECTRUM4_000791
PRESTWICK1_000918
SPECTRUM1503600
BPBIO1_000876
NCGC00024675-02
NCGC00024675-06
NCGC00024675-09
o5-(2-methoxyethyl) o3-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
nymalize
gtpl2523
NCGC00015714-04
HMS2052M05
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-
N-149 ,
HMS2093G11
HMS1989F19
3,5-pyridinecarboxylic acid 2-methoxyethyl 1-methylethyl ester
HMS2089H13
NCGC00015714-12
nemotan
chebi:7575 ,
nimodipine ap
nsc-758476
bay-e 9736
HMS1361F19
HMS1791F19
bdbm50101971
HMS1922E04
HMS1570H18
3-isopropyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3-o-(2-methoxyethyl) 5-o-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
NCGC00015714-09
NCGC00021456-02
HMS2097H18
HMS3262D04
N0896
3-(2-methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
nsc758476
pharmakon1600-01503600
MLS001424155
dtxcid003370
dtxsid5023370 ,
tox21_110202
HMS2234B05
2-methoxyethyl propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
STK642934
CCG-101085
CCG-39340
NCGC00015714-11
NCGC00015714-13
NCGC00015714-10
NCGC00015714-08
NCGC00015714-05
NCGC00015714-06
NCGC00015714-07
AKOS005174934
nsc 758476
nimodipino
nimodipine [usan:usp:inn:ban]
unii-57wa9qz5wh
57wa9qz5wh ,
nimodipinum
smr002530605
MLS003899190
FT-0602600
LP00891
S1747
AKOS015852459
HMS3369G07
nimodipine [orange book]
nimodipine [inn]
nimodipine [usp-rs]
nimodipine [jan]
nimodipine [ep monograph]
nimodipine [who-dd]
nimodipine [usp monograph]
nimodipine [vandf]
(+/-)-nimodipine
nimodipine [usan]
nimodipine [usp impurity]
nimodipine [mart.]
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 3-(2-methoxyethyl) 5-(1-methylethyl) ester
nimodipine [mi]
CA-211
HY-B0265
NC00335
BBL028286
SCHEMBL34041
NCGC00015714-16
tox21_110202_1
KS-1304
2-methoxyethyl 1-methylethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate
AB00053314-04
NCGC00261576-01
tox21_500891
isopropyl 2-methoxyethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
nimodipine, british pharmacopoeia (bp) reference standard
1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methyloxyethyl 1-methylethyl ester
3-isopropyl 5-(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate #
1,4-dihydropyridine-3,5-dicarboxylate
CHEMBL3197349
HMS3402F19
OPERA_ID_14
AB00053314_05
AB00053314_06
mfcd00153848
AC-8484
SR-01000075335-2
sr-01000075335
nimodipine, united states pharmacopeia (usp) reference standard
HMS3657I03
nimodipine, european pharmacopoeia (ep) reference standard
nimodipine, pharmaceutical secondary standard; certified reference material
nimodipine for peak identification, europepharmacopoeia (ep) reference standard
SR-01000075335-4
SR-01000075335-1
SR-01000075335-7
SR-01000075335-5
SBI-0050866.P003
HMS3714H18
SW219238-1
BCP21152
bay e 9736 pound>> bay-e-9736 pound>> baye97
Q421429
nimodipine - cas 66085-59-4
F20554
nimodipine (nimotop)
HMS3675I12
nimodipime,(s)
2,6-dimethyl-4-(3-nitrophenyl)-
3-isopropyl 5-(2-methoxyethyl)
HMS3411I12
BRD-A58048407-001-09-7
SDCCGSBI-0050866.P004
NCGC00015714-28
AMY40399
nimodipine 100 microg/ml in acetonitrile
SCHEMBL22882841
3-isopropyl5-(2-methoxyethyl)2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
EN300-123527
PD003072
3,5-pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-,?2-methoxyethyl 1-methylethyl ester
Z53829207
SY076731
PD033038
nimodipine (usp monograph)
nimodipinum (inn-latin)
nimo
nimodipine (usp impurity)
nimodipina
nimodipine (usan:usp:inn:ban)
nimodipine (ep monograph)
nimodipino (inn-spanish)
c08ca06
nimodipine (usp-rs)
nimodipine (mart.)

Research Excerpts

Overview

Nimodipine (NMD) is a 1,4-dihydropyridine calcium antagonist. It is effective in the prevention and treatment of cerebral arterial vasospasm and cerebral ischemic injury caused by subarachnoid hemorrhage.

ExcerptReferenceRelevance
"Nimodipine seem to be a promising agent to reduce secondary damage and reduce excitotoxic damage."( Nimodipine Exerts Time-Dependent Neuroprotective Effect after Excitotoxical Damage in Organotypic Slice Cultures.
Dehghani, F; Ghadban, C; Hohmann, T; Hohmann, U; Kleine, J; Scheller, C; Schmidt, M; Strauss, C, 2022
)
2.89
"Nimodipine (NMD) is a 1,4-dihydropyridine calcium antagonist that is effective in the prevention and treatment of cerebral arterial vasospasm and cerebral ischemic injury caused by subarachnoid hemorrhage. "( Study on the Nasal Drug Delivery System of NMD Liposomes In Situ Thermosensitive Gel.
Ma, L; Mao, H; Piao, J; Piao, M; Xu, J, 2023
)
2.35
"Nimodipine is a dihydropyridine calcium channel antagonist that blocks the flux of extracellular calcium through L-type, voltage-gated calcium channels. "( Nimodipine Reappraised: An Old Drug With a Future.
Carlson, AP; Hänggi, D; Macdonald, RL; Shuttleworth, CW, 2020
)
3.44
"Nimodipine is a calcium channel blocker frequently used in critical care settings. "( Preparation of Liquid Oral Mucoadhesive Gastro-retentive System of Nimodipine.
Donia, A; Essa, E; Maghraby, GE; Mamdouh, M, 2019
)
2.19
"Nimodipine is a 1,4-Dihydropyridine type calcium antagonist routinely used to control blood pressure and reduce the risk of secondary ischemia after aneurismal subarachnoid hemorrhage. "( Electrospun Nimodipine-loaded fibers for nerve regeneration: Development and in vitro performance.
Göttel, B; Greiner, A; Knolle, W; Leisz, S; Mäder, K; Scheller, C; Strauss, C; Syrowatka, F; Zech, J, 2020
)
2.38
"Nimodipine is a dihydropyridine calcium channel blocker that exhibits higher selectivity toward cerebral blood vessels compared with other members of the same class. "( Enantioselective assay of nimodipine in human plasma using liquid chromatography-tandem mass spectrometry.
Isse, FA; Le, T; Mahmoud, SH, 2021
)
2.36
"Nimodipine is a highly prescribed drug for the treatment of cognitive impairment and dementia in Argentina. "( Effect of a Social Norm Email Feedback Program on the Unnecessary Prescription of Nimodipine in Ambulatory Care of Older Adults: A Randomized Clinical Trial.
Ajzenman, N; Bustin, J; Lopez Boo, F; Mastai, R; Tomio, A; Torrente, F; Triskier, F, 2020
)
2.23
"Oral nimodipine is an established prophylactic agent for cerebral vasospasm after subarachnoid hemorrhage (SAH). "( Systemic and Cerebral Concentration of Nimodipine During Established and Experimental Vasospasm Treatment.
Albanna, W; Clusmann, H; Conzen, C; Höllig, A; Müller, M; Reinsch, M; Schneider, T; Schubert, GA; Weiss, M; Wiesmann, M, 2017
)
1.24
"Nimodipine is a clinical commonly used calcium antagonistscan lowering the apoptosis rate of hippocampal neuron to reduce the incidence of postoperative cognitive dysfunction (POCD). "( Effects of nimodipine on postoperative delirium in elderly under general anesthesia: A prospective, randomized, controlled clinical trial.
Guo, YY; Huo, SP; Li, YN; Wang, L; Wang, QJ; Yin, CP; Zhang, Q, 2017
)
2.29
"Nimodipine (NIM) is a calcium channel-blocking agent, which in the solid state exhibits two crystalline modifications, Mode I and Mode II. "( Chemometrics-assisted study of the interconversion between the crystalline forms of nimodipine.
Antonio, M; Balzaretti, NM; Calvo, NL; Kaufman, TS; Maggio, RM, 2018
)
2.15
"Nimodipine is a calcium channel blocker that has been used to treat hypertension and vasospasm. "( Nimodipine improves vocal fold and facial motion recovery after injury: A systematic review and meta-analysis.
Klein-Fedyshin, M; Lin, RJ; Rosen, CA, 2019
)
3.4
"Nimodipine is a calcium (Ca"( Effects of nimodipine, vinpocetine and their combination on isoproterenol-induced myocardial infarction in rats.
Ansari, MA; Ekbbal, R; Haque, SE; Iqubal, A, 2019
)
1.63
"Nimodipine (NMP) is a clinical dihydropyridine calcium antagonist. "( Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability.
Ding, Y; Jiang, M; Liu, P; Opoku-Damoah, Y; Shen, Y; Teng, Z; Webster, TJ; Yu, M; Zhang, H; Zhou, J, 2019
)
2.23
"Nimodipine is a Ca2+-channel antagonist mainly used for the management of aneurysmal subarachnoid hemorrhage (aSAH) to prevent cerebral vasospasms. "( Neuroprotective and neuroregenerative effects of nimodipine in a model system of neuronal differentiation and neurite outgrowth.
Bork, K; Gnanapragassam, VS; Haller, H; Horstkorte, R; Scheller, C; Strauss, C; Wurm, F, 2015
)
2.11
"Nimodipine is an L-type calcium channel blocker and is used to treat vasospasm in patients with subarachnoid hemorrhage. "( Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation.
Ahtola-Sätilä, T; Frantzén, J; Koskimäki, J; Laakso, A; Saloranta, L; Tarkia, M, 2016
)
2.11
"Nimodipine is a widely used medication for treating delayed cerebral ischemia (DCI) after subarachnoid hemorrhage. "( Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model.
Ahtola-Sätilä, T; Forsback, AP; Frantzén, J; Koskimäki, J; Laakso, A; Saloranta, L; Simola, O; Tarkia, M, 2015
)
2.13
"Nimodipine is a dihydropyridine calcium-channel blocker that has been recently shown to be effective on the function of central nervous system. "( Microdialysis combined with liquid chromatography-tandem mass spectrometry for the determination of nimodipine in the guinea pig hippocampus.
Li, L; Li, S; Lu, X; Shi, T; Wang, C; Zhang, R, 2016
)
2.09
"Nimodipine (NMD) is a Ca(2+) channel blocker that has been extensively investigated for therapy of central nervous system (CNS) disorders."( Antidepressant-like activity of liposomal formulation containing nimodipine treatment in the tail suspension test, forced swim test and MAOB activity in mice.
Freitas, RM; Moreno, LCGEAI; Rolim, HML; Santos-Magalhães, NS, 2016
)
1.39
"Nimodipine is an L-type calcium channel antagonist that reduces excessive calcium influx during pathological conditions (contributing to its neuroprotective properties)."( Autophagy and Akt/CREB signalling play an important role in the neuroprotective effect of nimodipine in a rat model of vascular dementia.
Hu, M; Liu, Z; Lv, P; Qi, Q; Wang, H; Xu, J; Zhu, Y, 2017
)
1.4
"Nimodipine is a 1,4-dihydropyridine-derivative Ca(2+)-channel blocker developed approximately 30 years ago. "( Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies.
Amenta, F; Lanari, A; Silvestrelli, G; Tomassoni, D; Traini, E, 2008
)
3.23
"Nimodipine is a calcium channel blocker and is still used in vasospasm therapy either oral or intravenously."( Comparison of intrathecal cilostazol and nimodipine treatments in subarachnoid hemorrhage: an experimental study in rabbits.
Bilginer, B; Narin, F; Onal, MB; Ozgen, T; Soylemezoglu, F; Ziyal, MI, 2011
)
1.36
"Nimodipine is an effect-proven agent in CVS, but dotarizine may take place of it."( Comparison of intrathecal dotarizine and nimodipine treatments in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits.
Civelek, E; Erdogan, E; Gonul, E; Izci, Y; Kircelli, A; Onal, MB; Solmaz, I; Tehli, O, 2011
)
1.36
"Nimodipine is a potent drug for vessel relaxation, but side effects may preclude a sufficient dose."( Continuous local intra-arterial nimodipine administration in severe symptomatic vasospasm after subarachnoid hemorrhage.
Coburger, J; Henkes, H; Hopf, N; Musahl, C; Vajda, Z, 2011
)
1.37
"Nimodipine is a dihydropyridinic calcium antagonist with a role in neuroprotection, making it a promising therapy for vascular cognitive impairment and dementia."( Rationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE).
Feng, T; Ju, Y; Shi, W; Wang, P; Wang, Y; Zhao, X; Zhou, Y, 2012
)
1.31
"Nimodipine is an isopropyl calcium channel blocker which readily crosses the blood-brain barrier."( Nimodipine for primary degenerative, mixed and vascular dementia.
Birks, J; López-Arrieta, JM, 2002
)
2.48
"Nimodipine is a dihydropyridine calcium channel blocker used in the treatment of ischemic damage in subarachnoid hemorrhage. "( Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia.
Auteri, A; Blardi, P; De Lalla, A; Perri, TD; Urso, R; Volpi, L, 2002
)
3.2
"Nimodipine (ND) is a centrally active calcium antagonist that blocks the voltage-dependent L-type channels. "( Antioxidant effect of nimodipine in young rats after pilocarpine-induced seizures.
D'alva, MS; Fonteles, MM; Freitas, RM; Nascimento, VS; Oliveira, AA; Sousa, FC; Vasconcelos, SM, 2005
)
2.09
"Nimodipine is a dihydropyridine calcium antagonist used in clinical trials in the treatment of ischemic damage in subarachnoid hemorrhage and commercially available as nimotop intravenous infusion solution and tablets. "( Preparation, characterization, and pharmacokinetics of sterically stabilized nimodipine-containing liposomes.
Ge, L; Yang, D; Zhang, G; Zheng, Y; Zhu, J, 2006
)
2.01
"Nimodipine is a therapy that reduces morbidity and mortality in patients with subarachnoid hemorrhage (SAH), though the mechanisms by which it does so are not well understood. "( Dynamic CT perfusion imaging in subarachnoid hemorrhage-related vasospasm.
Chen, FX; Eastwood, JD; Laslo, AM; Lee, TY, 2006
)
1.78
"3H-Nimodipine (3H-NIM) is a high affinity radioligand suitable to study Ca2+ -channels in a variety of tissues. "( Identification of voltage operated calcium channels by binding studies: differentiation of subclasses of calcium antagonist drugs with 3H-nimodipine radioligand binding.
Ferry, DR; Glossmann, H; Hofmann, F; Lübbecke, F; Mewes, R, 1983
)
1.09
"Nimodipine is a new calcium antagonist that has been advocated as a specific treatment for the cerebral vasospasm accompanying subarachnoid hemorrhage in humans because of reports that it selectively inhibits the constriction of cerebral arteries in vitro. "( Effect of the calcium antagonist nimodipine on contractile responses of isolated canine basilar arteries induced by serotonin, prostaglandin F2 alpha, thrombin, and whole blood.
Cunningham, MP; Robertson, JT; White, RP, 1982
)
1.99
"Nimodipine is an established drug in the treatment of symptomatic subarachnoid haemorrhage. "( Nimodipine levels in breast milk.
Tonks, AM, 1995
)
3.18
"Nimodipine is a very promising drug with demonstrated effectiveness to reduce the neurologic deficits caused by vasospasm."( Nimodipine: a drug therapy for treatment of vasospasm.
Counsell, C; Gilbert, M; Snively, C, 1995
)
2.46
"Nimodipine is a lipophilic dihydropyridine calcium antagonist which is used to reduce the incidence and severity of delayed cerebral ischaemia in patients with subarachnoid haemorrhage. "( Nimodipine.
Pickard, JD; Whitfield, PC,
)
3.02
"Nimodipine is an L-type Ca(2+)-channel blocking agent with Na+/K(+)-ATPase stimulating properties at concentrations as low as 1.5 nM."( The effect of nimodipine on cochlear potentials and Na+/K(+)-ATPase activity in normal and hydropic cochleas of the albino guinea pig.
Albers, FW; de Wildt, DJ; Huizing, EH; Klis, SF; Smoorenburg, GF; van Benthem, PP; Veldman, JE, 1994
)
1.37
"Nimodipine is a 1,4-dihydropyridine (DHP) calcium channel blocker which is used in the treatment of neurological deficits associated with subarachnoid hemorrhage. "( Favorable amphiphilicity of nimodipine facilitates its interactions with brain membranes.
Herbette, LG; Mason, PE; Mason, RP; Sweeney, KR; Trumbore, MW, 1994
)
2.03
"Nimodipine is a calcium channel blocker reported to have beneficial effects on treatment of ischemic damage as well as the potential for retarding aspects of brain and behavioral aging when provided chronically to rats. "( Chronic nimodipine treatment in aged rats: analysis of motor and cognitive effects and muscarinic-induced striatal dopamine release.
Fanelli, RJ; Hengemihle, J; Ingram, DK; Joseph, JA; Roberts, D; Spangler, EL,
)
2.01
"Nimodipine is an effective cerebral vasodilator and may be useful in the management of eclamptic patients with severe vasospasm."( The use of nimodipine in a patient with eclampsia: color flow Doppler demonstration of retinal artery relaxation.
Belfort, MA; Carpenter, RJ; Kirshon, B; Moise, KJ; Saade, GR, 1993
)
1.4
"Nimodipine is an effective vasodilator. "( The haemodynamic and respiratory effects of intravenous nimodipine used in the treatment of eclampsia.
Anthony, J; Dommisse, J; Johanson, R; Mantel, G, 1996
)
1.98
"Nimodipine is a highly lipophilic, centrally acting calcium channel blocker. "( Use of nimodipine in the medical treatment of Menière's disease: clinical experience.
Hirsch, BE; Kamerer, DB; Lassen, LF, 1996
)
2.19
"Nimodipine is a calcium-channel antagonist that has provided protection from cisplatin-induced neurotoxicity in a rat model system."( Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin.
Cassidy, J; Habeshaw, T; Kaye, SB; Parkin, D; Paul, J; Reed, NS; Soukop, M, 1998
)
1.35
"Nimodipine, which acts as an antagonist to L-type voltage-gated calcium channels, has been shown to be neuroprotective in various lesion models of the central and peripheral nervous systems."( Nimodipine-induced improved survival rate of facial motor neurons following intracranial transection of the facial nerve in the adult rat.
Aldskogius, H; Mattsson, P; Svensson, M, 1999
)
2.47
"Nimodipine is a 1, 4-dihydro- pyridine antagonist of L-VSCC which crosses the blood-brain barrier."( Nimodipine premedication and induction dose of propofol.
Asher, MJ; Buggy, DJ; Lambert, DG, 2000
)
2.47
"Nimodipine is an isopropyl calcium channel blocker which can easily cross the blood brain barrier."( Nimodipine for primary degenerative, mixed and vascular dementia.
Birks, J; López-Arrieta, JM, 2000
)
2.47
"Nimodipine is an isopropyl calcium channel blocker which can easily cross the blood brain barrier."( Nimodipine for primary degenerative, mixed and vascular dementia.
Birks, J, 2001
)
2.47
"Nimodipine is a calcium antagonist which improves learning and memory in brain-lesioned or aged animals (LeVere & Sandin, 1989; Schuurman & Traber, 1989). "( Global rating, symptoms, behavior, and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes.
Bergener, M; Schmage, N, 1992
)
1.94
"Nimodipine is a dihydropyridine calcium antagonist which dilates cerebral blood vessels and increases cerebral blood flow in animals and humans. "( Nimodipine. A review of its pharmacological properties, and therapeutic efficacy in cerebral disorders.
McTavish, D; Wadworth, AN,
)
3.02
"Nimodipine is a calcium antagonist that binds with high affinity to neuronal membranes. "( Nimodipine decreases the minimum alveolar concentration of isoflurane in dogs.
Backus, WW; Kanchuger, MS; Maneksha, FR; Schwartz, AE; Young, WL, 1991
)
3.17
"Nimodipine is a 1,4-dihydropyridine derivative that shows a preferential cerebrovascular activity in experimental animals. "( Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction.
Bigorra, J; Carbonell, A; Gil, P; Guillén, F; Martínez-Lage, JM; Martínez-Vila, E; Matías-Guiu, J; Villanueva, JA, 1990
)
2.02
"Nimodipine is a 1,4 dihydropyridine with Ca++ channel blocking properties. "( Nimodipine reduces morbidity, mortality after disruption of cerebral blood flow.
Carmody, J; Lilly, JK, 1990
)
3.16
"Nimodipine is a dihydropyridine calcium antagonist which has been shown to dilate cerebral arterioles and increase cerebral blood flow in animals and humans. "( Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease.
Langley, MS; Sorkin, EM, 1989
)
3.16
"Nimodipine is a 4-5-dihydropyridine calcium antagonist with selective spasmolytic and vasodilatory properties on cerebral vessels."( [Treatment of sudden deafness with the calcium antagonist nimodipine. Results of a comparative study].
Lenarz, T, 1989
)
1.24
"Nimodipine is a compound that is thought to block the influx of calcium through channels in vascular smooth muscle. "( Nimodipine in migraine prophylaxis.
Ansell, E; Fazzone, T; Festenstein, R; Johnson, ES; Thavapalan, M; Wilkinson, M; Wozniak, I, 1988
)
3.16
"Nimodipine is a 1,4-dihydropyridine with Ca2+ channel antagonist properties."( Pharmacology of nimodipine. A review.
Scriabine, A; van den Kerckhoff, W, 1988
)
1.34
"Nimodipine is a highly lipid-soluble dihydropyridine derivative that readily crosses the blood-brain barrier."( Use of nimodipine for prevention and treatment of cerebral arterial spasm in patients with subarachnoid hemorrhage.
Welty, TE, 1987
)
1.45
"Nimodipine is a calcium slow channel blocker with several pharmacologic properties suggesting the potential to favorably modify outcome in focal cerebral ischemia. "( Effects of nimodipine on acute focal cerebral ischemia.
Barnett, GH; Bose, B; Friel, HT; Jones, SC; Little, JR,
)
1.96

Effects

Nimodipine has a protective action on brain injury by blocking a series of pathological reactions induced by neuronal calcium overload. It reduces the spasm of brain vessels and improving cerebral blood flow.

Nimodipine has been studied in the prevention and treatment of cerebral arterial spasm in patients with subarachnoid hemorrhage. TCCS can be used to evaluate the therapeutic effects on CVS.

ExcerptReferenceRelevance
"Nimodipine has a good effect on releasing spasm and diminishing the cerebral blood flow velocity."( Mechanism and treatment principle for cerebral vessel spasm caused by concussion.
Guo, X; Wang, D; Xiao, X; Xue, G, 2002
)
1.04
"Nimodipine has a protective action on brain injury by blocking a series of pathological reactions induced by neuronal calcium overload, and by reducing the spasm of brain vessels and improving cerebral blood flow."( Therapeutic effect of nimodipine on experimental brain injury.
Wang, ZG; Yang, SY, 2003
)
2.08
"Nimodipine has been shown to decrease the incidence of delayed cerebral ischemia and improve outcomes."( The Impact of Nimodipine Administration through Feeding Tube on Outcomes in Patients with Aneurysmal Subarachnoid Hemorrhage.
Abdallah, YEH; Isse, FA; Mahmoud, SH, 2020
)
1.64
"Nimodipine has been shown to improve outcomes following aneurysmal subarachnoid hemorrhage. "( Nimodipine Pharmacokinetic Variability in Various Patient Populations.
Isse, FA; Ji, X; Mahmoud, SH, 2020
)
3.44
"Nimodipine has emerged as a promising strategy for protection of cranial nerves following vestibular schwannoma (VS) resections. "( Perioperative Nimodipine to Improve Cranial Nerve Function: A Systematic Review and Meta-Analysis.
Brant, J; Chorath, K; Go, BC; Kaufman, A; Moreira, A; Rajasekaran, K, 2021
)
2.42
"Nimodipine has improving effects on CVS in different degrees, and TCCS can be used to evaluate the therapeutic effects on CVS."( Evaluation function of transcranial two-dimensional and color Doppler ultrasonography (TCCS) for patients with different degrees of cerebral vasospasm before and after the nimodipine treatment.
Li, X; Li, XN; Wang, JL; Yang, YL; Zhang, YH, 2017
)
2.09
"Nimodipine has been investigated in the treatment of anxiety. "( Development and evaluation of liposomal formulation containing nimodipine on anxiolytic activity in mice.
Cavalcanti, IM; da Silva Oliveira, GZ; de Freitas, RM; Moreno, LC; Rolim, HM; Santos-Magalhães, NS, 2014
)
2.08
"Nimodipine has been shown to be beneficial for recovery from acute vocal fold paralysis (AVFP) in an animal model."( Prospective investigation of nimodipine for acute vocal fold paralysis.
Krishna, P; Muldoon, MF; Munin, MC; Rosen, CA; Smith, L; Young, V, 2014
)
2.14
"Nimodipine has been shown to have an inhibitory action on seizures and brain damage in rodents. "( Acute toxicity and anticonvulsant activity of liposomes containing nimodipine on pilocarpine-induced seizures in mice.
Cavalcanti, IM; Freitas, RM; Moreno, LC; Rolim, HM; Santos-Magalhães, NS; Satyal, P, 2015
)
2.1
"Nimodipine has been used in adults to reduce the incidence of cerebral vasospasm after subarachnoid hemorrhage and improve long-term outcomes."( Nimodipine for the prevention of cerebral vasospasm after subarachnoid hemorrhage in 12 children.
Heffren, J; McIntosh, AM; Reiter, PD, 2015
)
2.58
"Nimodipine has received attention as a drug that might improve learning and reduce cognitive deficits in Alzheimer's disease, but the mechanism of action is poorly known."( Nimodipine inhibits IL-1β release stimulated by amyloid β from microglia.
Chiozzi, P; Colaianna, M; Di Virgilio, F; Ferrari, D; Sanz, JM; Trabace, L; Zotti, M; Zuliani, G, 2012
)
2.54
"Nimodipine has a good effect on releasing spasm and diminishing the cerebral blood flow velocity."( Mechanism and treatment principle for cerebral vessel spasm caused by concussion.
Guo, X; Wang, D; Xiao, X; Xue, G, 2002
)
1.04
"Nimodipine has a protective action on brain injury by blocking a series of pathological reactions induced by neuronal calcium overload, and by reducing the spasm of brain vessels and improving cerebral blood flow."( Therapeutic effect of nimodipine on experimental brain injury.
Wang, ZG; Yang, SY, 2003
)
2.08
"Nimodipine has been shown to improve neurological outcome after subarachnoid hemorrhage (SAH); the mechanism of this improvement, however, is uncertain. "( The effect of nimodipine on cerebral oxygenation in patients with poor-grade subarachnoid hemorrhage.
Abrahams, JM; Bloom, S; Grady, MS; Heuer, GG; LeRoux, PD; Maloney-Wilensky, E; Smith, MJ; Stiefel, MF, 2004
)
2.13
"Oral nimodipine has minimal antiplatelet activity in young, healthy subjects."( Effect of oral nimodipine on platelet function.
Bruck, DC; Feinberg, WM, 1993
)
1.15
"Nimodipine therapy has become a standard component of the treatment regimen used in patients with aneurysmal subarachnoid hemorrhage (SAH). "( The efficacy of an abbreviated course of nimodipine in patients with good-grade aneurysmal subarachnoid hemorrhage.
Toyota, BD, 1999
)
2.01
"Nimodipine has in some experimental studies, when administered either before or up to 90 min after induction of cerebral ischemia, resulted in a reduction of infarct size."( Effect of nimodipine on final infarct volume after acute ischemic stroke.
Erilä, T; Fogelholm, R; Kaste, M; Murros, K; Palomäki, H,
)
1.26
"Nimodipine has proven to be effective in preventing this complication in a majority of patients studied, with hypotension the most severe adverse effect."( Nimodipine: the use of calcium antagonists to prevent vasospasm following subarachnoid hemorrhage.
Sosnowski, C, 1990
)
2.44
"Nimodipine has no consistent effect on brain oxygen consumption or cortical ATP or phosphocreatine levels, although the ischemia-induced fall of brain ATP levels in gerbils or the lowering of intracellular brain pH in rabbits with focal cerebral ischemia were antagonized by the drug."( Pharmacological basis for the use of nimodipine in central nervous system disorders.
Schuurman, T; Scriabine, A; Traber, J, 1989
)
1.27
"Nimodipine has low oral bioavailability (2.7-27.9 percent), a short half-life (2 h), is highly protein bound (98-99 percent), and is hepatically metabolized."( Nimodipine in the treatment of subarachnoid hemorrhage.
Tietze, KJ; Yasuda, SU, 1989
)
2.44
"Nimodipine has recently been approved for the treatment of cerebral ischemia caused by subarachnoid hemorrhage. "( Nimodipine in subarachnoid hemorrhage.
DiPalma, JR, 1989
)
3.16
"Nimodipine has very effective actions on learning performance that low levels of discrimination ability in SHR might be improved on learning performance on schedule controlled learning task."( Effect of nimodipine on brightness discrimination learning test in Wistar Kyoto and spontaneously hypertensive rats.
Nomura, M, 1988
)
1.4
"Nimodipine has been studied in the prevention and treatment of cerebral arterial spasm in patients with subarachnoid hemorrhage."( Use of nimodipine for prevention and treatment of cerebral arterial spasm in patients with subarachnoid hemorrhage.
Welty, TE, 1987
)
1.45

Actions

Nimodipine was found to cause the down-regulation of lncRNA NEAT1 and MAPT. It can cause arterial hypotension requiring either a dosage reduction or its discontinuation.

ExcerptReferenceRelevance
"Nimodipine was found to cause the down-regulation of lncRNA NEAT1 and MAPT, as well as the up-regulation of miR-27a."( Nimodipine Improves Cognitive Impairment After Subarachnoid Hemorrhage in Rats Through IncRNA NEAT1/miR-27a/MAPT Axis.
Hao, XD; Ji, HM; Li, JW; Li, LR; Ren, JR; Ren, SH; Zhen, ZG, 2020
)
2.72
"Nimodipine can cause arterial hypotension requiring either a dosage reduction or its discontinuation."( Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage.
Bele, S; Dettmer, K; Eissnert, C; Graf, B; Gruber, M; Kieninger, M; Knott, I; Oefner, PJ; Tuemmler, S; Wendl, C, 2019
)
1.45
"Oral nimodipine solutions cause drops in blood pressure more frequently than tablets."( Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage.
Bele, S; Dettmer, K; Eissnert, C; Graf, B; Gruber, M; Kieninger, M; Knott, I; Oefner, PJ; Tuemmler, S; Wendl, C, 2019
)
1.19
"Nimodipine could increase clearance rate [CL(S)] from (20.8+/-1.5) to (31+/-11) mL/kg/s and reduce AUC of C(+/-)P(-)soman from (2.08+/-0.15) to (1.6+/-0.4) mg/s."( Influence of nimodipine on elimination of soman in rabbit blood and distribution of [3H]soman in mice.
Li, JT; Ruan, JX; Song, ZY; Wang, XY; Yuan, SL; Zhang, ZQ, 2002
)
1.41
"Nimodipine can inhibit IL-1beta and IL-6 production of KC by preventing its mRNA transcription, down-regulating its level of plasma."( [Inhibition of nimodipine on production of proinflammatory by Kupffer cells in severe burned rats].
Ge, SD; Tang, HT; Wang, GY; Xia, ZF; Zhu, SH, 2003
)
1.39
"Nimodipine can inhibit the expression of VEGF at certain degrees."( [Experimental study of nimodipine and vascular endothelial growth factor in proliferative retinopathy].
Deng, DY; Han, LR; Kong, Y; Peng, YJ, 2004
)
1.36
"nimodipine produced an increase in cerebral blood flow with no change in cerebral O2 consumption."( Effects of nimodipine on cerebral blood flow.
Gourley, JK; Haws, CW; Heistad, DD, 1983
)
1.38
"Nimodipine does not inhibit carbonic anhydrase and does not stimulate the oxygen consumption of brain tissue in vitro."( Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments.
Garthoff, B; Kazda, S; Krause, HP; Schlossmann, K, 1982
)
1.21
"Nimodipine did, however, enhance performance of rats during the first and second probe trials of reversal training."( Enhanced acquisition of reversal training in a spatial learning task in rats treated with chronic nimodipine.
Fanelli, RJ; McMonagle-Strucko, K, 1993
)
1.22
"Nimodipine did not enhance recovery on any of the behavioral measures."( Neurological correlates of unilateral and bilateral "strokes" of the middle cerebral artery in the rat.
Andersen, AB; Andersen, CS; Finger, S, 1991
)
1
"Nimodipine caused an increase in the striatal concentrations of 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA); these changes were not seen in the limbic region."( In vivo effects of the Ca2+-antagonist nimodipine on dopamine metabolism in mouse brain.
Carlsson, A; Pileblad, E, 1986
)
1.26
"Nimodipine did not increase the rate of rebleeding."( Survey of clinical experience with nimodipine in patients with subarachnoid hemorrhage.
Battye, R; Porto, L; Ryman, T; Strugo, V; Taquoi, G; Tettenborn, D, 1987
)
1.27
"The nimodipine-induced increase in vascular conductance in the skeletal muscles showed regional variation; the effect was most pronounced in the cheek muscles, followed by the muscles of the chest, abdominal, trunk and gluteal regions."( Nimodipine-induced changes in the distribution of carotid blood flow and cardiac output in pentobarbitone-anaesthetized pigs.
Duncker, DJ; Heiligers, J; Mylecharane, EJ; Saxena, PR; Verdouw, PD, 1986
)
2.19

Treatment

Nimodipine treatment resulted in a statistically significant reduction in systolic BP and diastolic BP from baseline compared with placebo during the first few days. Pre-treatment significantly attenuated the loss of cortical cholinergic innervation and preserved the functional integrity of Cholinergic projection neurons.

ExcerptReferenceRelevance
"Nimodipine treatment provides SAH patients with short-term neurological benefits."( Nimodipine Attenuates Early Brain Injury by Protecting the Glymphatic System After Subarachnoid Hemorrhage in Mice.
Cui, X; Hou, C; Li, J; Liu, Q; Ren, W; Wang, B; Wang, W; Yang, X; Zhang, H, 2022
)
2.89
"Nimodipine treatment also increased the number of myelinated fibers while decreasing their thickness, as shown by histomorphometry."( Enhancement of nerve regeneration with nimodipine treatment after sciatic nerve injury.
Abdolmaleki, A; Al-Saedi, HF; Asadi, A; Ghanimi, HA; Panahi, Y, 2023
)
1.9
"Nimodipine treatment significantly increased the time spent in the target quadrant and the number of entries into the target quadrant compared to the scopolamine group alone. "( The effect of the calcium channel blocker nimodipine on hippocampal BDNF/Ach levels in rats with experimental cognitive impairment.
Kaya, AK; Ozturk, A; Saral, O; Saral, S; Topcu, A, 2023
)
2.62
"Nimodipine is the treatment of choice for aSAH with the goal of reduction of delayed cerebral ischemia."( Pharmacogenomics of Cytochrome P450 of Nimodipine Metabolism After Aneurysmal Subarachnoid Hemorrhage.
Cowart, JB; Freeman, WD; James, C; Peacock, SH; Reid, JM; Turnbull, MT, 2019
)
1.5
"Nimodipine treatment attenuated clinical EAE and spinal cord degeneration and promoted remyelination."( Nimodipine fosters remyelination in a mouse model of multiple sclerosis and induces microglia-specific apoptosis.
Ergün, S; Hell, JW; Jörg, S; Koeniger, T; Kuerten, S; Linker, RA; Schampel, A; Scholz, CJ; Volovitch, O; Wischmeyer, E; Wunsch, M, 2017
)
2.62
"Nimodipine treatment attenuated CCH induced tau phosphorylation by up-regulating expression of miR-132."( Nimodipine attenuates tau phosphorylation at Ser396 via miR-132/GSK-3β pathway in chronic cerebral hypoperfusion rats.
Chen, Y; Liu, X; Tan, Z; Xie, W; Zhu, Y, 2018
)
2.64
"Nimodipine treatment for acute VFP yielded equal VF motion recovery rates regardless of when the medication was initiated. "( Timing of nimodipine therapy for the treatment of vocal fold paralysis.
Munin, MC; Rosen, CA; Smith, LJ; Sridharan, SS; Young, VN, 2015
)
2.26
"Nimodipine treatment was found to lower CaV1.2 mRNA, protein expression, and calcium uptake."( L-type calcium channel blocker ameliorates diabetic encephalopathy by modulating dysregulated calcium homeostasis.
Sandhir, R; Singhal, K, 2015
)
1.14
"Nimodipine treatment could reduce oxidative injury after spinal cord injury, reduce the whole dead space and inflammation, and repair spinal cord injury."( Effect of nimodipine on rat spinal cord injury.
Gao, HL; Jia, YF; Li, J; Ma, LJ, 2015
)
1.54
"Nimodipine treated animals showed significantly ameliorated development of ischemia and reperfusion tissue injury compared to those of other groups (P<0.05). "( Protective effects of intraperitoneal administration of nimodipine on ischemia-reperfusion injury in ovaries: Histological and biochemical assessments in a rat model.
Behroozi-Lak, T; Farhad, N; Mohammadi, R; Moloody-Tapeh, M; Zarei, L, 2017
)
2.14
"Both nimodipine treatments prevented the memory deficits when these were measured between 1 and 2 months after alcohol withdrawal."( Nimodipine prior to alcohol withdrawal prevents memory deficits during the abstinence phase.
Brooks, SP; Croft, AP; Little, HJ; Norman, G; Shaw, SG, 2008
)
2.24
"Nimodipine pre-treatment in MP rats enhanced hippocampal phenobarbital concentrations (C(max): 10.2+/-1.0 microg ml(-1), p<0.05) as compared with vehicle pre-treatment."( Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid.
Girardi, E; Gonzalez, NN; Höcht, C; Lazarowski, A; Mayer, MA; Opezzo, JA; Taira, CA, 2009
)
1.07
"Nimodipine treatment in this model did not impact dopamine graft survival but allowed for increased graft reinnervation of striatum."( Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats.
Collier, TJ; Levine, ND; O'Malley, JA; Soderstrom, KE; Sortwell, CE; Steece-Collier, K, 2010
)
1.08
"Nimodipine treatment in cerebral vasospasm is useful."( Comparison of nimodipine delivery routes in cerebral vasospasm after subarachnoid hemorrhage: an experimental study in rabbits.
Bilginer, B; Civelek, E; Isikay, I; Kircelli, A; Narin, F; Onal, MB; Solmaz, I; Ugurel, S; Yakupoglu, H, 2011
)
1.45
"Nimodipine in both treatment forms prevented the memory impairment following spontaneous morphine withdrawal."( The effect of nimodipine on memory impairment during spontaneous morphine withdrawal in mice: Corticosterone interaction.
Hajhashemi, V; Rabbani, M; Vaseghi, G, 2012
)
1.46
"Nimodipine treatment resulted in atrial arrest with much slower but regular ventricular heart beating."( Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish.
Dong, QX; Gao, JM; He, JH; Huang, CJ; Li, CQ; Xu, YQ; Xuan, YX; Yu, HP; Zhu, JJ, 2014
)
1.12
"Nimodipine treatment caused a moderate reduction (approximately 30%) of the mRNA for Nav1.2 and a marked reduction (approximately 70%) of the mRNA for Nav1.3, whereas treatment with Bay K 8644 produced 90-130% increases in these same mRNAs."( L-type calcium channel activation up-regulates the mRNAs for two different sodium channel alpha subunits (Nav1.2 and Nav1.3) in rat pituitary GH3 cells.
Cota, G; Espinosa, JL; López-Domínguez, AM; López-Santiago, LF; Navarrete, A; Vega, AV, 2003
)
1.04
"Nimodipine pretreatment (4 mg/kg, i.p.) brought down these levels by 30 and 23%, respectively."( Nimodipine attenuates biochemical, behavioral and histopathological alterations induced by acute transient and long-term bilateral common carotid occlusion in rats.
Acharya, SB; Hota, D; Kumar, M; Rai, S; Yanpallewar, SU, 2004
)
2.49
"Nimodipine-treated animals were then matched with vehicle-treated controls for both study conditions."( Nimodipine does not affect the flow-metabolism couple in permanent cerebral ischemia.
Burnett, MG; Gomi, S; Greenberg, JH; Karp, A, 2004
)
2.49
"Nimodipine treatment partially prevented deficits in nerve conduction velocity and hippocampal long-term potentiation in diabetic rats."( Effects of the Ca2+ antagonist nimodipine on functional deficits in the peripheral and central nervous system of streptozotocin-diabetic rats.
Biessels, GJ; Gispen, WH; Kamal, A; ter Laak, MP, 2005
)
1.34
"3. Nimodipine treatment was not able to normalize elevated resting intracellular calcium ([Ca(2+)]( i )) levels in small DRG neurons."( The effect of nimodipine on calcium homeostasis and pain sensitivity in diabetic rats.
Belan, P; Gryshchenko, O; Khomula, E; Kruglikov, I; Shutov, L; Viatchenko-Karpinski, V; Voitenko, N,
)
1.01
"Nimodipine treatment decreased the CaMKII expression while MK-801 treatment decreased the CaMKIV expression."( [Effects of calcium and calmodulin dependent kinase against hypoxic neuronal injury].
Luo, XL; Mao, M; Sun, XM; Zhou, H, 2007
)
1.06
"Nimodipine-treated animals, regardless of surgery group, exhibited fewer emotional responses and had lower spontaneous alternation rates than untreated animals."( Behavioral and neuroanatomical consequences of a unilateral intraventricular infusion of AF64A and limitations on the neuroprotective effects of nimodipine.
Isaacson, RL; Maier, DL, 1994
)
1.21
"Nimodipine treatment did not affect the SP, neither in the control, nor in the EEH ears."( The effect of nimodipine on cochlear potentials and Na+/K(+)-ATPase activity in normal and hydropic cochleas of the albino guinea pig.
Albers, FW; de Wildt, DJ; Huizing, EH; Klis, SF; Smoorenburg, GF; van Benthem, PP; Veldman, JE, 1994
)
1.37
"Nimodipine treatment produced no significant effects on body weight, food intake, or survival of aged rats."( Chronic nimodipine treatment in aged rats: analysis of motor and cognitive effects and muscarinic-induced striatal dopamine release.
Fanelli, RJ; Hengemihle, J; Ingram, DK; Joseph, JA; Roberts, D; Spangler, EL,
)
1.29
"Nimodipine treatment was started within three days of delayed ischaemic deficit (DID) onset, at a low dose increased quickly to 30-45 ug/kg/hr, and reduced gradually over the last day or two of the course."( Treatment of symptomatic vasospasm with nimodipine.
Compton, JS; Dorsch, NW, 1993
)
1.27
"Nimodipine pretreatment inhibited both the convulsive activity and the cerebral hypermetabolic responses to intraventricular endothelin."( Metabolic and neuroanatomical correlates of barrel-rolling and oculoclonic convulsions induced by intraventricular endothelin-1: a novel peptidergic signaling mechanism in visuovestibular and oculomotor regulation?
Beninger, RJ; Espinosa, FJ; Gross, PM; Shaver, SW; Wainman, DS; Weaver, DF, 1993
)
1.01
"In nimodipine-treated pigs, total cerebral blood flow 10 min after ROSC was significantly higher than baseline values (P < 0.01) and in hypophysis, cerebellum, and medulla the blood flows were significantly higher than in placebo-treated pigs (P < 0.05)."( Effects of nimodipine on regional blood flow in heart and brain during cardiopulmonary resuscitation in pigs.
Gilly, H; Schindler, I; Steinbereithner, K; Susani, M; Weindlmayr-Goettel, M, 1994
)
1.19
"Nimodipine treatment was associated with a significant increase of survival (11.8%, P = 0.05) which was not the result of improved operative technique but of a lower incidence of deaths caused by postoperative vasospasm (G1 = 5 deaths, G2 = 0 deaths, P = 0.05) and by rebleeding (G1 = 15 deaths, G2 = 5 deaths, P = 0.03)."( [Comparison of 2 consecutive series of aneurysmal subarachnoid hemorrhage with or without nimodipine and study of the temperature curve].
Bazin, A; Bernard, MH; Bertault, R; Gomis, P; Graftieaux, JP; Peruzzi, P; Rousseaux, P; Scherpereel, B, 1993
)
1.23
"Nimodipine treatment had no significant effect on the MRI findings, but delayed resuscitation was associated with probable brain edema only in placebo-treated patients."( Magnetic resonance imaging findings associated with cardiac arrest.
Erkinjuntti, T; Kaste, M; Raininko, R; Roine, RO; Ylikoski, A, 1993
)
1.01
"Nimodipine or Mannitol treatment started 5 min before clipping the MCA."( The effect of mannitol and nimodipine treatment in a rat model of temporary focal ischemia.
Dietz, H; Gaab, MR; Heissler, H; Rickels, E, 1993
)
1.3
"2. Nimodipine treatment had no effect in grouped rats."( Chronic nimodipine and yawning behavior in grouped or individually housed rats.
Fundaro, A, 1996
)
1.24
"Nimodipine treatment of aged rats did not markedly affect the deficit in motor performance."( Effects of combined chronic nimodipine and acute metrifonate treatment on spatial and avoidance behavior.
Kuitunen, J; Riekkinen, M; Riekkinen, P; Schmidt, B, 1997
)
1.31
"Nimodipine treatment decreased cortical high voltage spindles (HVSs) in aged rats, but did not prevent the diminution of spontaneous locomotor activity."( Chronic nimodipine and acute metrifonate treatment decreases age-related cortical high voltage spindles in rats.
Björklund, M; Jäkälä, P; Koivisto, E; Riekkinen, P; Schmidt, B, 1997
)
1.45
"In nimodipine-treated rats the rotation behaviour after 1 week was more prominent (3.5+/-0.8 R/min; mean+/-SEM) with a similar slight decline until week 4."( Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine.
Earl, CD; Kupsch, A; Oertel, WH; Sautter, J, 1997
)
1
"Nimodipine-treated rats performed better than vehicle-treated, aged-matched controls in all the test series, making more correct choices every time a new series was initiated."( Effects of chronic nimodipine on working memory of old rats in relation to defects in synaptosomal calcium homeostasis.
Batuecas, A; Bogónez, E; Bollati, A; Centeno, C; Hernández, M; Pereira, R; Pulido, JA; Satrústegui, J, 1998
)
1.35
"Nimodipine treatment was associated with a significant decrease in mortality."( Cost-effectiveness analysis of nimodipine treatment after aneurysmal subarachnoid hemorrhage and surgery.
Karinen, P; Koivukangas, J; Koivukangas, P; Ohinmaa, A; Ohman, J, 1999
)
1.31
"Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days."( Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.
Ahmed, N; Näsman, P; Wahlgren, NG, 2000
)
1.34
"Nimodipine pre-treatment significantly attenuated the loss of cortical cholinergic innervation and preserved the functional integrity of cholinergic projection neurons in the magnocellular nucleus basalis."( Increased amyloid precursor protein expression and serotonergic sprouting following excitotoxic lesion of the rat magnocellular nucleus basalis: neuroprotection by Ca(2+) antagonist nimodipine.
Abrahám, I; Dijkstra, IM; Harkany, T; Horvath, KM; Keijser, J; Luiten, PG; Oosterink, BJ; Van der Zee, EA, 2000
)
1.22
"Nimodipine pre-treatment immediately attenuated the inactivation of Na(+)-K+/Mg+2 ATPase (p < 0.05) but there was no change on Ca+2/Mg+2 ATPase activity (p < 0.05)."( The effects of the pre-treatment of intravenous nimodipine on Na(+)-K+/Mg+2 ATPase, Ca+2/Mg+2 ATPase, lipid peroxidation and early ultrastructural findings following middle cerebral artery occlusion in the rat.
Cetinalp, E; Göçer, AI; Ildan, F; Isbir, T; Kaya, M; Polat, S; Tuna, M, 2001
)
1.29
"Nimodipine treatment prevented the declines in motor and cognitive behavior that were observed in untreated control rats."( Protective effect of nimodipine on behavior and white matter of rats with hydrocephalus.
Del Bigio, MR; Massicotte, EM, 2001
)
1.35
"Nimodipine pretreatment attenuated the perceived similarity of ketamine effects to ethanol as well as ketamine-induced euphoria and sedation."( Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists.
Burakov, AM; Fletcher, J; Grinenko, AY; Grinenko, NI; Krupitsky, EM; Krystal, JH; Petrakis, IL; Romanova, TN, 2001
)
1.31
"Nimodipine treatment decreased the incidence of moderate vertigo episodes by 78.8% and decreased severe vertigo episodes by 85.0%. "( New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study.
Abiuso, J; Alegría, J; Arenas, JE; Castañeda, JR; F, GV; Flaskamp, R; Gómez, JM; González, RH; Guerra, OJ; Hanuch, E; Hernández, J; Hidalgo, LO; Madrid, CE; Martínez, C; Morán, LM; Pedraza, A; Pianese, CP; Ponce, JE; Quijano, D; Ramírez, AM; Rubio, AT; Sanjuán, AP; Uribe, JO; Volpi, C, 2002
)
1.76
"Nimodipine pretreatment of the cells incubated with ouabain and monensin resulted in apparent protection of lysosomes and a reduction in the level of free radicals."( Cellular alterations produced by the experimental increase in intracellular calcium and the nature of protective effects from pretreatment with nimodipine.
Danks, AM; Hammond, DN; Isaacson, RL; Van Buskirk, RG; Wainer, BH, 1992
)
1.21
"The nimodipine treated animals were subdivided into hypotensive (MABP lower than 85 mmHG for more than 5 minutes after arterial occlusion) and normotensive groups."( [Effects of nimodipine in experimental permanent focal cerebral ischemia].
Marinov, M; Moskopp, D; Wassmann, H, 1992
)
1.14
"Nimodipine treatment from 16-30 months did not significantly change these morphometric aging-related changes."( Nimodipine effects on cerebral microvessels and sciatic nerve in aging rats.
de Jong, GI; Gispen, WH; Horvath, E; Jansen, AS; Luiten, PG,
)
2.3
"The nimodipine treated animals were subdivided into hypotensive (MABP lower than 85 mmHg for more than 5 min after arterial occlusion) and normotensive groups."( Effect of nimodipine in treatment of experimental focal cerebral ischaemia.
Marinov, M; Natschev, S; Wassmann, H, 1991
)
1.16
"Nimodipine treatment did not improve performance."( Behavioral and anatomical consequences of unilateral fornix lesions and the administration of nimodipine.
Danks, AM; Gispen, WH; Isaacson, RL; Oestreicher, AB; Spruijt, BM, 1991
)
1.22
"Nimodipine-treated animals learned the maze more rapidly than a placebo-treated group as indicated by the number of correct choices out of the first eight arms visited (p less than 0.001)."( Nimodipine improves spatial working memory and elevates hippocampal acetylcholine in young rats.
Kadar, T; Kong, RM; Levy, A; Lieberman, HR; Rauch, TM; Shukitt-Hale, B; Stillman, MJ, 1991
)
2.45
"Nimodipine treatment improved blood flow to the middle cerebral artery territory without evidence of a "vascular steal" and reduced the volume of the ischemic core (cortex with CBF of less than 25 ml/100 g/min) and accompanying edema by approximately 50% when compared with controls (p = 0.006 and 0.0004, respectively)."( Nimodipine pretreatment improves cerebral blood flow and reduces brain edema in conscious rats subjected to focal cerebral ischemia.
Brint, S; Jacewicz, M; Pulsinelli, WA; Tanabe, J; Wang, XJ, 1990
)
2.44
"The nimodipine-treated group performed better in tests of verbal fluency and visual retention, suggesting that some memory functions were preserved better in this group."( Effects of nimodipine on cerebral blood flow and neuropsychological outcome after cardiac surgery.
Forsman, M; Olsnes, BT; Semb, G; Steen, PA, 1990
)
1.15
"Nimodipine-treated as well as parathyroidectomied animals showed significantly fewer hypertensive cerebral lesions."( Therapy of diseased stroke-prone spontaneously hypertensive rats with nimodipine.
Kazda, S; Lenz, P; Luckhaus, G; Stasch, JP, 1990
)
1.23
"Nimodipine treatment given before experimental ischemic insult, resulting from either vascular occlusion or intracranial hemorrhage or after subarachnoid hemorrhage, maintained or improved blood flow and minimized the severity of subsequent brain damage."( Efficacy of nimodipine in cerebral ischemia or hemorrhage.
Graham, DI; Harper, AM; McCulloch, J; Mendelow, AD; Teasdale, G, 1990
)
1.38
"Nimodipine-treated rats developed 20-60% smaller cortical infarct volumes than controls (p less than 0.002)."( Continuous nimodipine treatment attenuates cortical infarction in rats subjected to 24 hours of focal cerebral ischemia.
Brint, S; Jacewicz, M; Pulsinelli, WA; Tanabe, J, 1990
)
1.39
"Nimodipine treatment resulted in an enhancement of the sciatic and caudal nerve conduction velocities."( Beneficial effect of nimodipine on peripheral nerve function in aged rats.
Gispen, WH; Schuurman, T; Traber, J; van der Hoop, RG; Van der Zee, CE,
)
1.17
"Nimodipine treatment enhanced the vascularization of the grafts in all four groups and induced a significant increase in the volume of grafts under the three suboptimal transplantation conditions (i.e., groups E17, E20, E14/6H)."( Nimodipine enhances growth and vascularization of neural grafts.
Dunnett, SB; Finger, S, 1989
)
2.44
"Nimodipine-treated rabbits made fewer crossings and more rears and grooms than the old controls."( Nimodipine ameliorates aging-related changes in open-field behaviors of the rabbit.
Deyo, RA; Disterhoft, JF; Moyer, JR; Straube, KT,
)
2.3
"The nimodipine-treated animals had less clinical evidence of infarction compared to controls."( The efficacy of intravenous nimodipine in the treatment of focal cerebral ischemia in a primate model.
Fifield, MS; Hadley, MN; Johnson, PC; Rigamonti, D; Spetzler, RF; Zabramski, JM, 1989
)
1.05
"Nimodipine treatment was associated with a significant reduction of delayed ischemic deterioration (all operation group combined, nimodipine vs."( Timing of operation for ruptured supratentorial aneurysms: a prospective randomized study.
Heiskanen, O; Ohman, J, 1989
)
1
"Nimodipine-treated rats received the drug as an intravenous infusion of 0.5 micrograms/kg/min starting 15 min after occlusion, and ending at decapitation 4 h postocclusion."( Nimodipine prevents hyperglycemia-induced cerebral acidosis in middle cerebral artery occluded rats.
Berger, L; Hakim, AM, 1989
)
2.44
"Nimodipine treatment was associated with a significant decrease in mortality rate (p = 0.03) in the early and subacute surgery groups."( Effect of nimodipine on the outcome of patients after aneurysmal subarachnoid hemorrhage and surgery.
Heiskanen, O; Ohman, J, 1988
)
1.4
"Nimodipine treatment significantly ameliorates mitochondrial respiratory conditions."( Effect of nimodipine on mitochondrial respiration in different rat brain areas after subarachnoid haemorrhage.
Gaetani, P; Marzatico, F; Rodriguez y Baena, R; Silvani, V; Spanu, G, 1988
)
1.4
"The nimodipine-treated animals, however, showed only a slight diminution in the slope of the curve but no real plateau, indicating impairment of CBF autoregulation."( The influence of nimodipine on cerebral blood flow autoregulation and blood-brain barrier.
Gaab, MR; Höllerhage, HG; Walter, GF; Zumkeller, M, 1988
)
1.1
"Nimodipine treatment was associated with a significantly better outcome (p less than 0.001): 21 (29.2%) of 72 nimodipine-treated patients had a good outcome at 3 months after subarachnoid hemorrhage (SAH) compared to eight (9.8%) of 82 placebo-treated patients."( Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial.
Benoit, BG; Disney, LB; Gentili, F; Grace, M; Holness, RO; Khan, MI; Mohr, G; Petruk, KC; Weir, BK; West, M, 1988
)
2.44
"One nimodipine-treated patient with a preserved CO2 response, in whom operation was complicated, developed DID."( Prediction and prevention of delayed ischemic dysfunction after aneurysmal subarachnoid hemorrhage and early operation.
Algotsson, L; Brandt, L; Ljunggren, B; Messeter, K; Romner, B; Ryding, E; Svendgaard, NA, 1987
)
0.75
"Treatment with nimodipine resulted in remarkable increment of total anti-oxidant capacity, while NF-κB p65, IL-6, TNF-α, and ICAM-1 showed great reduction."( POTENTIAL PROTECTIVE EFFECTS OF NIMODIPINE FROM CEREBRAI ISCHEMIA REPERFUSION INJURY IN RATS.
Al-Mudhafar, A; Fakharaldeen, Z; Hadi, N; Radhi, A, 2022
)
1.34
"Treatment with nimodipine restores spinal oxygenation and can rapidly improve function."( Nimodipine Reduces Dysfunction and Demyelination in Models of Multiple Sclerosis.
Davies, AL; Del Rossi, N; Desai, RA; Dyson, A; Golay, X; Gustavson, B; Harvey, AR; Kaynezhad, P; Linington, C; Mackenzie, L; McElroy, D; Schiza, D; Singer, M; Smith, KJ; Tachrount, M; Tachtsidis, I; van der Putten, MA, 2020
)
2.34
"Pretreatment with nimodipine can lower the apoptosis rate of hippocampal neuron to reduce the incidence of postoperative cognitive dysfunction (POCD)."( Pretreatment with nimodipine reduces incidence of POCD by decreasing calcineurin mediated hippocampal neuroapoptosis in aged rats.
Bao, Y; Gao, F; Guo, Y; Huo, S; Li, Y; Wang, Q; Wang, X; Xin, X; Yin, C; Zhang, Q, 2018
)
1.14
"Pretreatment with nimodipine reduces the incidence of POCD by decreasing CaN mediated hippocampal neuroapoptosis in aged rats."( Pretreatment with nimodipine reduces incidence of POCD by decreasing calcineurin mediated hippocampal neuroapoptosis in aged rats.
Bao, Y; Gao, F; Guo, Y; Huo, S; Li, Y; Wang, Q; Wang, X; Xin, X; Yin, C; Zhang, Q, 2018
)
1.15
"Pretreatment with nimodipine (10 and 15 mg/kg, i.p), vinpocetine (10 mg/kg, p.o) and their combination significantly restored the antioxidant status, haemodynamic profile, cellular architecture and ultrastructural changes in the heart."( Effects of nimodipine, vinpocetine and their combination on isoproterenol-induced myocardial infarction in rats.
Ansari, MA; Ekbbal, R; Haque, SE; Iqubal, A, 2019
)
1.23
"Pretreatment with nimodipine reduced the degeneration of dopaminergic (DA) neurons induced by LPS in mesencephalic neuron-glia cultures in a dose-dependent manner."( Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation.
An, L; Bao, Y; Hu, X; Li, Y; Liu, Y, 2009
)
2.12
"Pre-treatment with nimodipine prior to iron sulfate exposure provided a significant (P < 0.05) increase in viable cell numbers for RBE4 (2.5-fold), Neuro2-α (~2-fold), and nearly abolished toxicity in primary neurons."( Differential effect of nimodipine in attenuating iron-induced toxicity in brain- and blood-brain barrier-associated cell types.
Allen, DD; Bohn, KA; Desilva, SF; Geldenhuys, WJ; Lockman, JA; Van der Schyf, CJ, 2012
)
1.01
"Treatment with nimodipine dramatically reduces the effects of brain damage induced by injection of PB."( Changes of neuronal calcium channel following brain damage induced by injection of pertussis bacilli in rats.
Cao, M; Chen, L; Liu, L; Yang, Y, 2002
)
0.65
"Treatment with nimodipine can dramatically reduce the damage of brain edema and demonstrate neuroprotective effect on brain edema by inhibiting the excess of Ca(2+) influx and reducing the permeability of BBB."( Neuroprotective effects of nimodipine and MK-801 on acute infectious brain edema induced by injection of pertussis bacilli to neocortex of rats.
Cao, MH; Chen, LH; Liu, LX; Liu, YS; Yang, YJ, 2003
)
0.96
"Pretreatment with nimodipine (10 mg/kg, i.p.), verapamil (10 mg/kg, i.p.) and diltiazem (10 mg/kg, i.p.) blocked nicotine-induced place conditioning."( Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents.
Biała, G,
)
0.45
"Pretreatment with nimodipine (40 mg/kg) did not affect the morphine level in the brain and also decreased the brain-to-serum ratio of morphine."( Role of pharmacokinetic effects in the potentiation of morphine analgesia by L-type calcium channel blockers in mice.
Fukazawa, Y; Kishioka, S; Maeda, T; Ozaki, M; Shimizu, N; Yamamoto, C; Yamamoto, H, 2004
)
0.65
"Treatment with nimodipine [an L voltage-sensitive calcium channel (LVSCC) antagonist], MK-801 (an NMDA channel antagonist) and thapsigarin (an inhibitor of efflux of calcium from internal stores) indicated that folate deprivation initially induced calcium influx via the LVSCC, with subsequent additional calcium derived from NMDA channels and internal stores."( Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation.
Dhivant, S; Mitton, K; Ortiz, DO; Rogers, E; Shea, TB; Tjiattas, L, 2004
)
0.66
"Pretreatment with nimodipine inhibited seizures in a dose-dependent manner, in terms of both percentage of positive responders and seizure scores against CD99 doses of both kainic acid and PTZ."( Evaluation of the modulatory role of nimodipine in seizures induced by kainic acid and pentylenetetrazole in mice.
Chakrabarti, A; Hota, D; Sahai, AK; Shitak, R,
)
0.73
"Pretreatment with nimodipine alone (0.1 mg kg-1, i.v.) was particularly effective in increasing the rat brain resistence to hypoxia when compared to the controls."( Brain electrobiogenesis protection induced by nimodipine and MK-801 during acute hypoxia in hypertensive rats.
Anania, V; Becciu, A; Caria, MA; De Riu, PL; Demontis, MP; Mameli, O; Tolu, E,
)
0.71
"Oral treatment with nimodipine (5 mg/kg and 20 mg/kg b.i.d., respectively, for 9 days) prior to, during and following administration of MPTP appeared to attenuate MPTP-induced neurochemical changes in a dose-related manner."( Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice.
Gerlach, M; Przuntek, H; Riederer, P; Russ, H; Stasch, JP; Traber, J; Winker, J; Witzmann, K, 1993
)
0.99
"Treatment with nimodipine did not have a neuroprotective effect on AF64A animals in either behavioral or histological results."( Behavioral and neuroanatomical consequences of a unilateral intraventricular infusion of AF64A and limitations on the neuroprotective effects of nimodipine.
Isaacson, RL; Maier, DL, 1994
)
0.83
"Treatment with nimodipine (20 mg kg-1) from week 6 onwards significantly increased the sciatic nerve blood flow as compared to placebo-treated diabetic BB/Wor rats."( Beneficial effect of the Ca2+ antagonist, nimodipine, on existing diabetic neuropathy in the BB/Wor rat.
Biessels, G; Bravenboer, B; de Wildt, DJ; Gispen, WH; Kappelle, AC; Traber, J; van Buren, T, 1994
)
0.89
"Treatment with nimodipine restored the reduced presynaptic responsiveness independent of the postsynaptic adrenergic hyporesponsiveness."( Effects of nimodipine on sciatic nerve blood flow and vasa nervorum responsiveness in the diabetic rat.
Biessels, GJ; De Wildt, DJ; Erkelens, DW; Gispen, WH; Kappelle, AC; Van Buren, T, 1993
)
1.02
"Pretreatment with nimodipine (200 micrograms/kg) potentiated this effect but to a lesser extent than it potentiated analgesia."( Potentiation of acute opioid-induced respiratory depression and reversal of tolerance by the calcium antagonist nimodipine in awake rats.
Dierssen, M; Flórez, J; Hurlé, MA; Ruiz, F, 1993
)
0.82
"Posttreatment with nimodipine (1 microM), calmidazolium (1 microM) or KN-62 (5 microM) up to 6 hr after the nicotine treatment significantly inhibited the increases of the long-term secretion of ME and proENK mRNA level induced by nicotine."( Long-term stimulation of nicotinic receptors is required to increase proenkephalin A mRNA levels and the delayed secretion of [Met5]-enkephalin in bovine adrenal medullary chromaffin cells.
Das, KP; Hong, JS; Hudson, PM; McMillian, MK; Suh, HW; Wilson, BC; Wu, GC, 1995
)
0.61
"The treatment with nimodipine yielded two beneficial effects."( Nimodipine accelerates axonal sprouting after surgical repair of rat facial nerve.
Andermahr, J; Angelov, DN; Mader, K; Neiss, WF; Stennert, E; Streppel, M, 1996
)
2.06
"Pretreatment with nimodipine (120 mg pellets) did neither attenuate the behavioural impairments in MPTP-treated animals nor antagonize the striatal neurotoxin-induced dopamine depletion, but almost completely prevented (in a dose-dependent manner) the MPTP-induced decrease of nigral tyrosine hydroxylase immunoreactive cells."( 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
Gerlach, M; Kupsch, A; Oertel, WH; Riederer, P; Sautter, J; Schwarz, J, 1996
)
0.82
"pretreatment with nimodipine, omega-conotoxin GVIA, calmidazolium or KN-62."( Differential effects of omega-conotoxin GVIA, nimodipine, calmidazolium and KN-62 injected intrathecally on the antinociception induced by beta-endorphin, morphine and [D-Ala2,N-MePhe4,Gly-ol5]-enkephalin administered intracerebroventricularly in the mous
Choi, SR; Huh, SO; Kim, YH; Song, DK; Suh, HW, 1997
)
0.88
"pretreatment with nimodipine did not affect the inhibition of the tail-flick response induced by CWSS."( Effects of intrathecal injection of nimodipine, omega-conotoxin GVIA, calmidazolium, and KN-62 on the antinociception induced by cold water swimming stress in the mouse.
Choi, SR; Huh, SO; Kim, YH; Song, DK; Suh, HW, 1997
)
0.9
"Pretreatment with nimodipine failed to antagonize or to ameliorate any of the lesion-induced deficits."( Degeneration of pre-labelled nigral neurons induced by intrastriatal 6-hydroxydopamine in the rat: behavioural and biochemical changes and pretreatment with the calcium-entry blocker nimodipine.
Earl, CD; Kupsch, A; Oertel, WH; Sautter, J, 1997
)
0.81
"Pretreatment with nimodipine, an L-type Ca(2+) channel blocker failed to alter AVP-induced glucagon release or increase in [Ca(2+)](i)."( Mechanisms of AVP-induced glucagon release in clonal alpha-cells in-R1-G9: involvement of Ca(2+)-dependent and -independent pathways.
Chen, TH; Cheng, H; Hsu, WH; Yibchok-Anun, S, 2000
)
0.63
"Treatment with nimodipine (30 microg/kg/hr iv) significantly decreased the pneumococci-induced rise in intracranial pressure irrespective of the time of administration. "( Reduction of intracranial pressure by nimodipine in experimental pneumococcal meningitis.
Koedel, U; Paul, R; Pfister, HW, 2000
)
0.93
"Pretreatment with nimodipine markedly prevented mice from delayed encephalopathy after CO poisoning."( Protective effect of nimodipine against cerebral injury induced by subacute carbon monoxide intoxication in mice.
Yang, JQ; Zhou, QX, 2001
)
0.96
"Pretreatment with nimodipine (a calcium channel blocker) and calmidazolium (a calmodulin antagonist) inhibited both the secretion of ME and the increase in proENK mRNA levels induced by pertussis toxin, while the intracellular calcium antagonist dantrolene and the protein kinase C inhibitors sphingosine and H7 [1-(5-isoquinolinylsulfonyl)-2-methylpiperazine] were ineffective in blocking pertussis toxin-induced responses."( Pertussis toxin stimulates the secretion of [Met5]-enkephalin and the expression of proenkephalin A mRNA in bovine adrenal medullary chromaffin cells.
Hong, JS; Hudson, P; McMillian, MK; Suh, HH,
)
0.45
"Pretreatment with nimodipine (0.19 and 0.38 mumol) potentiated the respiratory depression induced by sufentanil (0.26 nmol)."( Ca2+ channel modulation by dihydropyridines modifies sufentanil-induced respiratory depression in cats.
Dierssen, M; Flórez, J; Hurlé, MA; Ruiz, F, 1991
)
0.6
"Treatment with nimodipine was well tolerated (hypotension: 1 treated patient, 3 controls; bradycardia: 1 treated patient, 2 controls; sGPT increase: 1 treated patient, 1 control)."( Double-blind study of nimodipine in non-severe stroke.
Bogousslavsky, J; Köbberling, W; Regli, F; Zumstein, V, 1990
)
0.93
"Pretreatment with nimodipine inhibited vasoconstriction to 5-HT less effectively than to KCl both before and after application of blood."( Effect of nimodipine on canine cerebrovascular responses to 5-hydroxytryptamine and potassium chloride after exposure to blood.
Cook, DA; Tsuji, T, 1989
)
1
"Treatment with nimodipine significantly enhanced electroencephalographic activity recovery and normalization during recirculation, reduced the decrease in extracellular calcium concentration, and prevented the increased permeability of the blood-brain barrier."( Beneficial effect of nimodipine on metabolic and functional disturbances in rabbit hippocampus following complete cerebral ischemia.
Lazarewicz, JW; Pluta, R; Puka, M; Salinska, E, 1989
)
0.94
"Post-treatment with nimodipine showed qualitatively similar effects."( Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging.
Rudin, M; Sauter, A,
)
0.45
"Pretreatment with nimodipine thus retards the fall in ATP and facilitates the recovery of glucose in mongolian gerbils subjected to common carotid artery occlusion."( Effect of nimodipine on cerebral metabolism during ischemia and recirculation in the mongolian gerbil.
Heffez, DS; Passonneau, JV, 1985
)
1
"Once treatment with nimodipine was begun, CBF was approximately double that of an untreated group."( Delayed treatment with nimodipine improves cerebral blood flow after complete cerebral ischemia in the dog.
Michenfelder, JD; Milde, JH; Milde, LN, 1986
)
0.9
"Pretreatment with nimodipine (1 microgram/kg/min x 30 min, intravenously [IV]) before SAO significantly prolonged survival time (274 +/- 4.7 min) and improved phagocytosis (38.1 +/- 0.6%) and killing (16.1 +/- 1.1%), but did not change leukopenia."( Splanchnic artery occlusion shock in the rat: effects of the calcium entry blockers nimodipine and verapamil.
Altavilla, D; Berlinghieri, MC; Caputi, AP; Squadrito, F; Sturniolo, R, 1988
)
0.82
"Treatment with nimodipine may counteract the development of DID in patients with an impaired CBF CO2 response."( Prediction and prevention of delayed ischemic dysfunction after aneurysmal subarachnoid hemorrhage and early operation.
Algotsson, L; Brandt, L; Ljunggren, B; Messeter, K; Romner, B; Ryding, E; Svendgaard, NA, 1987
)
0.61

Toxicity

Both verapamil and nimodipine pretreatment increased the LD50 and 95% confidence intervals for bupivacaine and increased survival. Symptomatic vasospasm, low density areas on computed tomography (CT), clinical outcomes, and adverse events were all recorded. The difference in recurrent haemorrhage and adverse reactions was not statistically significant.

ExcerptReferenceRelevance
" Three minutes after pretreatment, group 1 (n = 11), group 3 (n = 10), and their respective control groups (n = 11 and n = 9) received intravenous bupivacaine LD50 (median lethal dose)."( Nimodipine reduces the toxicity of intravenous bupivacaine in rats.
Horn, JL; Hyman, SA; Kambam, JR; Kinney, WW; Skelley, CC, 1992
)
1.73
" These toxic effects of endogenously produced neuroamines may be antagonized by nimodipine or flunarizine."( Ca2+ modulators as antidotes to imipramine and neurotransmitter toxicity.
Nahas, G; Trouve, R, 1987
)
0.5
" In addition to standard safety assessments (physical examination, electrocardiogram, laboratory studies, and adverse event reporting), supine and standing blood pressures and pulse rates were measured frequently."( Safety and tolerance of intravenous nimodipine.
Cutler, NR; Heller, AH; Lettieri, J; Sawin, S; Sramek, JJ; Sundaresan, PR, 1994
)
0.56
"Of 61 subjects, 55 completed the 48-hour infusion and 6 discontinued the study because of adverse events."( Safety and tolerance of intravenous nimodipine.
Cutler, NR; Heller, AH; Lettieri, J; Sawin, S; Sramek, JJ; Sundaresan, PR, 1994
)
0.56
" Results indicated that the calcium antagonists partly protected against toxic effects induced by cadmium in different manners."( Protective effects of calcium antagonists on cadmium-induced toxicity in rats.
Yang, XF; Yang, YN, 1997
)
0.3
" Both verapamil and nimodipine pretreatment increased the LD50 and 95% confidence intervals for bupivacaine and increased survival."( The effects of verapamil and nimodipine on bupivacaine-induced cardiotoxicity in rats: an in vivo and in vitro study.
Adsan, H; Onaran, O; Tulunay, M, 1998
)
0.91
" Caffeine was used 50, 150, 250 and 350 microM concentrations and the most toxic dose for it was found to be 350 microM."( Response to nimodipine in caffeine-induced neurotoxicity in cerebellar granular cell culture of rat pups.
Düzenli, S; Gepdiremen, A; Ikbal, M; Sönmez, S; Tuna, S, 1998
)
0.68
"Lidocaine is toxic in a dose dependent fashion to RGC in vitro."( Lidocaine toxicity to rat retinal ganglion cells.
Dreyer, EB; Freeman, EE; Grosskreutz, CL; Katowitz, WR, 1999
)
0.3
"Lidocaine is toxic to RGC both in vitro and in vivo."( Lidocaine toxicity to rat retinal ganglion cells.
Dreyer, EB; Freeman, EE; Grosskreutz, CL; Katowitz, WR, 1999
)
0.3
" Animal models for Cd poisoning were established by peritoneal injection of 1/5 LD50 CdCl2."( Influences of chloropazine, nimodipine and their combination on the toxic effects of cadmium in liver and kidney of mice.
Chen, YM; Feng, ZY; Song, L; Tang, LF; Yang, YN; Zhang, ZL, 1999
)
0.6
" Only two patients withdrew from the study because of adverse events possibly related to the study drug."( New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study.
Abiuso, J; Alegría, J; Arenas, JE; Castañeda, JR; F, GV; Flaskamp, R; Gómez, JM; González, RH; Guerra, OJ; Hanuch, E; Hernández, J; Hidalgo, LO; Madrid, CE; Martínez, C; Morán, LM; Pedraza, A; Pianese, CP; Ponce, JE; Quijano, D; Ramírez, AM; Rubio, AT; Sanjuán, AP; Uribe, JO; Volpi, C, 2002
)
0.31
" It was also found that depolarizing conditions with a high potassium concentration (30 mm) were toxic to motoneurons."( Survival-promoting activity of nimodipine and nifedipine in rat motoneurons: implications of an intrinsic calcium toxicity in motoneurons.
Arakawa, Y; Nishijima, C; Shimizu, N; Urushidani, T, 2002
)
0.6
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" There were no serious adverse effects observed."( Feasibility and safety of intrathecal nimodipine on posthaemorrhagic cerebral vasospasm refractory to medical and endovascular therapy.
Beseoglu, K; Hänggi, D; Steiger, HJ; Turowski, B, 2008
)
0.62
" Further investigation indicated that pre-treatment of pinacidil or nimodipine reversed toxic effect of MnCl(2) significantly."( Excitotoxicity in rat's brain induced by exposure of manganese and neuroprotective effects of pinacidil and nimodipine.
Deng, X; Deng, Y; Gao, J; Tian, Y; Xin, X; Xu, B; Xu, Z, 2009
)
0.8
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"To determine if the age of packed red blood cells (PRBCs) is associated with adverse events or outcomes in patients with subarachnoid haemorrhage (SAH)."( Packed red blood cell age does not impact adverse events or outcomes after subarachnoid haemorrhage.
Ault, ML; Duran, IM; Liebling, SM; Naidech, AM, 2011
)
0.37
"We prospectively recorded clinical and demographic data, acute adverse effects related to transfusion, major hospital events, radiographic cerebral infarction, PRBC age and outcomes in 119 patients with SAH who received a PRBC transfusion."( Packed red blood cell age does not impact adverse events or outcomes after subarachnoid haemorrhage.
Ault, ML; Duran, IM; Liebling, SM; Naidech, AM, 2011
)
0.37
" Age of PRBCs administered was not associated with vasospasm, cerebral infarction, acute adverse events or outcomes (P > 0·1 for all)."( Packed red blood cell age does not impact adverse events or outcomes after subarachnoid haemorrhage.
Ault, ML; Duran, IM; Liebling, SM; Naidech, AM, 2011
)
0.37
"In this small registry of patients with SAH, the age of transfused PRBCs was not associated with adverse events or outcomes."( Packed red blood cell age does not impact adverse events or outcomes after subarachnoid haemorrhage.
Ault, ML; Duran, IM; Liebling, SM; Naidech, AM, 2011
)
0.37
"Compared with placebo, nimodipine can significantly improve clinical outcomes, as assessed by self-formulated standards and Glasgow outcome scores, and it can significantly reduce the occurrence of symptomatic cerebral vasospasm and delayed neurological function deficits (all cases), as well as cerebral infarction, although the incidence rate of recurrent haemorrhage and adverse reactions is not significantly reduced by nimodipine."( Meta-analysis of the effectiveness and safety of prophylactic use of nimodipine in patients with an aneurysmal subarachnoid haemorrhage.
He, GH; Liu, GJ; Luo, J; Wang, YF; Wang, ZJ; Xu, LL; Zeng, YJ; Zhang, LP, 2011
)
0.91
" Symptomatic vasospasm, low density areas on computed tomography (CT), clinical outcomes, and adverse events were all recorded, and the results were compared between the fasudil and nimodipine groups."( Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine.
Guo, J; Mao, Y; Ren, Z; Wang, R; Wang, S; Xu, B; Zhang, X; Zhang, Y; Zhao, J; Zhao, K; Zhou, D; Zhou, L, 2011
)
0.77
" The CCBs nimodipine (NDP) and verapamil (VPM) both significantly suppressed toxic secretions from human astrocytes and astrocytoma U-373 MG cells that were induced by interferon (IFN)-γ."( Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers.
Hashioka, S; Klegeris, A; McGeer, PL, 2012
)
0.78
" No adverse event was reported during the study."( Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trial.
Gan, L; Liu, T; Wang, S; Yang, H; Zhang, B; Zhang, J; Zheng, J, 2016
)
0.69
" One serious adverse event related to EG-1962 (400 mg) and 2 EG-1962 dose-limiting toxicities were without clinical sequelae."( Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid
Aldrich, F; Diringer, MN; Etminan, N; Faleck, HJ; Hänggi, D; Hoh, BL; Macdonald, RL; Mayer, SA; Mocco, J; Steiger, HJ, 2017
)
0.66
"EG-1962 was safe and tolerable to 800 mg, and in this, aneurysmal subarachnoid hemorrhage population was associated with reduced delayed cerebral ischemia and rescue therapy."( Randomized, Open-Label, Phase 1/2a Study to Determine the Maximum Tolerated Dose of Intraventricular Sustained Release Nimodipine for Subarachnoid Hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid
Aldrich, F; Diringer, MN; Etminan, N; Faleck, HJ; Hänggi, D; Hoh, BL; Macdonald, RL; Mayer, SA; Mocco, J; Steiger, HJ, 2017
)
0.66
" Fourteen patients (22%) dropped out for reasons including consent withdrawal (n = 9), adverse reactions (n = 4), and stroke (n = 1)."( Efficacy and Safety of the Association of Nimodipine and Choline Alphoscerate in the Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease. The CONIVaD Trial.
Chiti, G; Donnini, I; Fierini, F; Melone, A; Pantoni, L; Pescini, F; Poggesi, A; Rinnoci, V; Salvadori, E; Squitieri, M; Tudisco, L, 2021
)
0.89

Pharmacokinetics

No significant effects of nimodipine on tirilazad mesylate pharmacokinetic parameters were observed (P > . A fast and sensitive ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed.

ExcerptReferenceRelevance
" The changes in the pharmacokinetic parameters were not accompanied by discernible haemodynamic effects or any change in the tolerability of nimodipine."( Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers.
Kuhlmann, J; Mück, W; Rämsch, KD; Seiberling, M; Wingender, W; Woelke, E, 1992
)
0.7
" A pharmacodynamic interaction may exist, inhibiting effective use of dihydropyridines as adjunctive therapy in epileptic patients."( Dihydropyridine calcium antagonists in mice: blood and brain pharmacokinetics and efficacy against pentylenetetrazol seizures.
Brodie, MJ; Drennan, JE; Forrest, G; Larkin, JG; Scobie, G; Thompson, GG,
)
0.13
"The interactions of propranolol, nimodipine, and amiodarone with membrane lipids were examined in an effort to explain their different pharmacokinetic and pharmacodynamic properties."( Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: propranolol, nimodipine and amiodarone.
Chester, DW; Herbette, LG; Katz, AM; Trumbore, M, 1988
)
0.77
" Nisoldipine had the lowest maximum plasma concentration and the longest elimination half-life among the four 1,4-dihydropyridines, resulting in no significant difference in the area under the plasma concentration-time curve."( Comparative study on acute antihypertensive effects and pharmacokinetics of nisoldipine, nifedipine, nimodipine and nicardipine administered orally to conscious renal hypertensive dogs.
Kato, H; Takata, Y, 1986
)
0.49
" Pharmacodynamic steady states developed slowly within about 25 min."( A comparative study of the pharmacodynamic effects of nimodipine and nifedipine in the isolated spontaneously beating rabbit heart.
Askholt, J; Jensen, PH; Nielsen-Kudsk, F, 1983
)
0.51
" No significant effects of nimodipine on tirilazad mesylate pharmacokinetic parameters were observed (P > ."( Lack of a pharmacokinetic/pharmacodynamic interaction between nimodipine and tirilazad mesylate in healthy volunteers.
Fleishaker, JC; Hulst, LK; Peters, GR, 1994
)
0.83
" The pharmacokinetic findings in Chinese patients are comparable to previously reported values in Caucasians."( Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage.
Chang, CM; Fong, KY; Fung, CF; Kou, M; Kumana, CR; Lauder, IJ; Mück, W; Yu, YL, 1993
)
0.63
"The article determined the bioavailability and pharmacokinetic parameters of two kinds of nimodipine tablets produced by Tianjin Center Pharmaceutical Factory in 6 healthy volunteers using HPLC method."( [Studies on the bioavailability and pharmacokinetics of nimodipine tablet in human body].
Ding, DY; Liu, RJ; Yan, XF, 1993
)
0.75
" This might be partly due to the short half-life of the peptide, leading to a transient increase in cortical blood flow and short neuronal exposure time, suggesting that prolonged infusion of the neuropeptide might be required."( The effects of gamma 2-melanocyte-stimulating hormone and nimodipine on cortical blood flow and infarction volume in two rat models of middle cerebral artery occlusion.
De Wildt, DJ; Herz, RC; Versteeg, DH, 1996
)
0.54
" for 6 days), however, resulted in pronounced differences in AUC and Cmax between elderly and young subjects when the same doses were given."( The influence of age on the pharmacokinetics of nimodipine.
Breuel, HP; Kuhlmann, J; Mück, W, 1996
)
0.55
" The results inferred that nicardipine is absorbed rapidly and has a relatively short half-life in healthy individuals."( A high-performance liquid chromatographic method for the determination of nicardipine in plasma and its application to pharmacokinetics in humans.
Li, K; Yuan, YS; Zhang, X; Zhao, FL,
)
0.13
" This crossover study was carried out in rhesus monkeys to determine if any pharmacokinetic interaction was involved in such a potentiation."( Effect of nimodipine, a dihydropyridine calcium channel antagonist, on the steady state pharmacokinetics of phenytoin (DPH) in rhesus monkeys.
Garg, SK; Gupta, MC,
)
0.53
"To explore the contribution of renal failure to nimodipine overall pharmacokinetic variability after single and multiple oral dosing and to develop a population pharmacokinetic model by means of the nonparametric expectation maximization (NPEM2) algorithm based on sampled individual drug concentrations close to the estimated patients' C(SS)avs (NPEM2-C(SS)av)."( Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
Atanasova, I; Dimitrova, V; Mück, W; Robeva, R; Terziivanov, D; Unger, S, 1999
)
0.85
"24 hypertensive patients with normal and reduced renal function, without clinical and laboratory data for hepatic dysfunction, were enrolled in the study and their nimodipine plasma levels were analyzed by means of a parametric and nonparametric population pharmacokinetic modeling using a maximum a posteriori Bayesian (MAPB) estimator in an iterative two-stage Bayesian population modeling program and NPEM2-algorithm."( Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
Atanasova, I; Dimitrova, V; Mück, W; Robeva, R; Terziivanov, D; Unger, S, 1999
)
0.79
" The pharmacokinetic parameters of nimodipine after intravenous administration were as follows: peak concentration (C(max)), 319."( Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia.
Auteri, A; Blardi, P; De Lalla, A; Perri, TD; Urso, R; Volpi, L, 2002
)
2.03
"To investigate the differences of pharmacokinetic behavior and tissue distribution of nimodipine and its two enantiomers in rats."( Studies on differences of pharmacokinetic behavior and tissue distribution of nimodipine and its two enantiomers in rats using achiral and chiral liquid chromatography.
He, LC; Wang, SC, 2003
)
0.77
" The pharmacokinetic parameters Tmax, Cmax, AUC and CLs were: S-(-)-nimodipine (2."( Studies on differences of pharmacokinetic behavior and tissue distribution of nimodipine and its two enantiomers in rats using achiral and chiral liquid chromatography.
He, LC; Wang, SC, 2003
)
0.78
" A pharmacokinetic interaction may be involved in such potentiation."( Effect of nimodipine, a dihydropyridine calcium channel antagonist on the pharmacokinetics of carbamazepine in rhesus monkeys.
Bhargava, VK; Das, BP; Garg, SK; Gupta, MC, 2003
)
0.72
"The present study was designed to investigate the pharmacokinetic interaction of morphine with three classes of L-type calcium channel blockers (CCB) and its relationship to morphine-induced mechanical antinociception in mice."( Role of pharmacokinetic effects in the potentiation of morphine analgesia by L-type calcium channel blockers in mice.
Fukazawa, Y; Kishioka, S; Maeda, T; Ozaki, M; Shimizu, N; Yamamoto, C; Yamamoto, H, 2004
)
0.32
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" The pharmacokinetic parameters following orally and intravenously administration to New Zealand rabbits were determined and compared with those of commercial nimodipine formulations."( Preparation, characterization, and pharmacokinetics of sterically stabilized nimodipine-containing liposomes.
Ge, L; Yang, D; Zhang, G; Zheng, Y; Zhu, J, 2006
)
0.76
" The pharmacokinetic parameters of nimodipine changed significantly when encapsulated in liposomes."( Development and pharmacokinetics of nimodipine-loaded liposomes.
Deng, Y; Wang, T; Wang, Z; Wu, F; Zhang, X, 2006
)
0.89
"A fast and sensitive ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed for the determination and pharmacokinetic study of nimodipine in human plasma."( Determination of nimodipine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and pharmacokinetic application.
Chen, L; Li, F; Ma, Y; Qin, F; Wang, D; Wang, Y, 2008
)
0.88
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The physical compatibility, pharmacokinetic, and vascular irritability studies showed that, in comparison to the commercially available NIM injections, NIM-EPC-SGC-MMs presented better physical compatibility, the same pharmacokinetic profile, and less risk of local vascular irritation and phlebitis."( Nimodipine-loaded mixed micelles: formulation, compatibility, pharmacokinetics, and vascular irritability study.
Gong, T; Jiang, Y; Ren, C; Song, X; Sun, X; Zhang, Q; Zhang, Z, 2012
)
1.82
" The method was successfully applied to pharmacokinetic study of limonin in dogs."( Determination of limonin in dog plasma by liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study.
Ju, WZ; Li, CY; Liu, SJ; Liu, ZX; Yu, BY; Zhang, J; Zhou, L, 2013
)
0.39
" Despite these findings there is a lack of pharmacokinetic data in the literature, especially concerning its distribution in nerve tissue."( Enteral or parenteral nimodipine treatment: a comparative pharmacokinetic study.
Koman, G; Prell, J; Rachinger, J; Scheller, C; Scheller, K; Simmermacher, S; Strauss, C; Vogel, AS; Wienke, A; Wurm, F, 2014
)
0.72
"From a pharmacokinetic point of view, parenteral nimodipine medication leads to higher levels in serum and CSF."( Enteral or parenteral nimodipine treatment: a comparative pharmacokinetic study.
Koman, G; Prell, J; Rachinger, J; Scheller, C; Scheller, K; Simmermacher, S; Strauss, C; Vogel, AS; Wienke, A; Wurm, F, 2014
)
0.97
" With Nimotop(®) as the control, the dissolution rate was evaluated and the pharmacokinetic study was undertaken in beagle dogs."( Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies.
Fu, Q; Han, X; He, Z; Li, M; Lian, H; Ling, G; Liu, X; Luo, C; Sui, X; Sun, J; Sun, L; Sun, Y; Wang, S; Wang, Y; Zhang, D; Zhu, M, 2013
)
1.83
" The concentrations of nimodipine in plasma and tissues were determined by ultra performance liquid chromatography (UPLC) coupled with UV detection, and the pharmacokinetic parameters were calculated based on non-compartmental analysis."( Effect of natural borneol on the pharmacokinetics and distribution of nimodipine in mice.
Hou, X; Liao, Q; Wu, C; Xie, Z; Xu, X; Yao, M; Zhou, Y, 2014
)
0.95
"Volume of distribution is one of the most important pharmacokinetic properties of a drug candidate."( Volume of Distribution in Drug Design.
Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015
)
0.42
" However, NM suffers from poor oral bioavailability (5-13%) due to its low aqueous solubility, extensive first pass metabolism and short elimination half-life (1-2h)."( Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies.
Basalious, EB; Shamma, RN, 2015
)
0.62
" We aimed at providing a pharmacokinetic model for IA nimodipine therapy for this purpose."( Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm.
Brockmann, C; Brockmann, MA; Groden, C; Hesser, J; Neumaier-Probst, E; Schubert, R; Seker, F, 2017
)
0.97
"A two-compartment pharmacokinetic model for intravenous nimodipine therapy was modified and used to assess cerebral arterial nimodipine concentration during IA nimodipine infusion into the internal carotid artery (ICA)."( Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm.
Brockmann, C; Brockmann, MA; Groden, C; Hesser, J; Neumaier-Probst, E; Schubert, R; Seker, F, 2017
)
0.96
" Within the range of physiological and pharmacokinetic data available in the literature, ICA blood flow has more impact on cerebral arterial concentration than nimodipine clearance."( Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm.
Brockmann, C; Brockmann, MA; Groden, C; Hesser, J; Neumaier-Probst, E; Schubert, R; Seker, F, 2017
)
0.91
"The presented pharmacokinetic model is suitable for estimations of cerebral arterial nimodipine concentration during IA infusion."( Pharmacokinetic Modeling of Intra-arterial Nimodipine Therapy for Subarachnoid Hemorrhage-Related Cerebral Vasospasm.
Brockmann, C; Brockmann, MA; Groden, C; Hesser, J; Neumaier-Probst, E; Schubert, R; Seker, F, 2017
)
0.94
" The validated method had been successfully applied to compare the pharmacokinetic parameters of ginkgo flavonoids, terpene lactones and nimodipine in rat plasma after oral administration of Ginkgo biloba dispersible tablets, Nimodipine tablets with the combination of the both."( Development of two step liquid-liquid extraction tandem UHPLC-MS/MS method for the simultaneous determination of Ginkgo flavonoids, terpene lactones and nimodipine in rat plasma: Application to the pharmacokinetic study of the combination of Ginkgo biloba
Bi, K; Li, P; Li, Q; Liu, R; Wang, T; Xiao, J, 2016
)
0.84
" The pharmacokinetic and brain distribution were studied in SD mice administered intravenously with NMD/TMP-NPs in comparison with NMD-suspension, NMD/TMP-suspension and NMD-NPs, (NMD-NPs+TMP)-suspension."( [Pharmacokinetics and brain distribution of NMD/TMP-nanoparticles].
He, WJ; He, XW; Hong, Q; Liang, J; Zhu, FJ, 2016
)
0.43
" The concentration of NMD in rat plasma and tissues was determined by high-performance liquid chromatography, and the main pharmacokinetic parameters were calculated and compared."( Comparative Pharmacokinetics of Nimodipine in Rat Plasma and Tissues Following Intraocular, Intragastric, and Intravenous Administration.
Bai, L; Dai, M; Fei, Q; He, N; Li, F; Ma, Q; Mao, D; Si, Q; Zhang, H, 2020
)
0.84
" The in-vivo pharmacokinetic behaviour of IN NM loaded LNC in blood and brain was compared with NM-solution after IV administration in rats."( Intranasal lipid nanocapsules for systemic delivery of nimodipine into the brain: In vitro optimization and in vivo pharmacokinetic study.
Allam, NK; Azzazy, HME; Basalious, EB; Mohsen, K, 2020
)
0.81
" However, pharmacokinetic studies have suggested variability of nimodipine pharmacokinetics in subarachnoid hemorrhage and in other patient populations."( Nimodipine Pharmacokinetic Variability in Various Patient Populations.
Isse, FA; Ji, X; Mahmoud, SH, 2020
)
2.24

Compound-Compound Interactions

Donepezil hydrochloride combined with nimodipine had good efficacy in the treatment of patients with vascular dementia. Best results were obtained after 12 weeks of intervention. The underlying mechanism may be associated with the regulation of vascular endothelial dilatation function.

ExcerptReferenceRelevance
" Drug-drug interactions are further implicated through this study."( Cerebral blood flow effects of sumatriptan in drug combinations in the baboon model.
Dormehl, IC; Hugo, N; Oliver, DW, 1995
)
0.29
" The calcium channel blocker nimodipine (NIMO) was administered alone (1 or 10 mg kg-1) or in combination with 200 mg kg-1 of the phosphorothioate radioprotector WR-151327 (WR) (S-3-(3-methylaminopropylamino)propylphosphorothioic acid)."( Radioprotective and locomotor responses of mice treated with nimodipine alone and in combination with WR-151327.
Benson, KA; Castro, CA; Hogan, JB; Landauer, MR; Weiss, JF,
)
0.66
"The effect of nimodipine alone and in combination with diazepam or phenytoin was tested in the electroshock-induced mouse model of status epilepticus."( Anticonvulsant effect of nimodipine alone and in combination with diazepam and phenytoin in a mouse model of status epilepticus.
Khosla, P; Pandhi, P, 2000
)
0.97
" The protective effect of dantrolene potentialized in combination with nimodipine at all doses tested."( The effects of dantrolene alone or in combination with nimodipine in glutamate-induced neurotoxicity in cerebellar granular cell cultures of rat pups.
DüzenlI, S; GepdIremen, A; Hacimüftüoğlu, A; Oztaş, S; Süleyman, H, 2001
)
0.79
" Under these conditions, an antiischemic drug combination produced a pronounced but short increase in the local circulation in cortex of cerebrum (decreased by hemorrhagic stroke), with the subsequent decrease in the local flow."( [Effects of an antiischemic drug combination and nimodipine on cerebral blood supply in a hemorrhagic stroke model in rats].
Bero, RS; Gan'shina, TS; Kurdiumov, IN; Mirzoian, NR,
)
0.39
"To study the therapeutic effects of acupuncture combined with nimodipine for vascular dementia."( Clinical effects of acupuncture combined with nimodipine for treatment of vascular dementia in 30 cases.
Liu, J; Su, XX; Zhong, XY; Zhu, GQ, 2009
)
0.85
"Acupuncture was applied at Baihui (GV 20), Shenshu (BL 23), Geshu (BL 17), and the points selected according to the midnight-noon, ebb-flow eight methods of the intelligent turtle, combined with the drug nimodipine."( Clinical effects of acupuncture combined with nimodipine for treatment of vascular dementia in 30 cases.
Liu, J; Su, XX; Zhong, XY; Zhu, GQ, 2009
)
0.8
"Acupuncture at Baihui (GV 20), Shenshu (BL 23), Geshu (BL 17), and the points selected according to the midnight-noon, ebb-flow eight methods of the intelligent turtle combined with the drug nimodipine can yield definite therapeutic effects for vascular dementia."( Clinical effects of acupuncture combined with nimodipine for treatment of vascular dementia in 30 cases.
Liu, J; Su, XX; Zhong, XY; Zhu, GQ, 2009
)
0.8
"In order to decrease the fluctuation of blood concentration and to increase the oral bioavailability of nimodipine (NMD), a two-step strategy including the push-pull osmotic pump (PPOP) method in combination with micronization and solid dispersion techniques, was used to prepare the controlled-release high-bioavailability solid dosages."( A two-step strategy to design high bioavailable controlled-release nimodipine tablets: the push-pull osmotic pump in combination with the micronization/solid dispersion techniques.
Chai, L; Liu, X; Sun, J; Sun, Y; Wang, S; Xu, L; Zhang, D, 2014
)
0.85
"The effects of galantamine (GAL) on quality of life (QoL) and cognitive speed, as well its effects combined with nimodipine (NIM) in Alzheimer disease (AD) with cerebrovascular disease (mixed dementia), have not been explored."( Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study).
Barbosa, MT; Bottino, CM; Caramelli, P; Charchat-Fichman, H; Chaves, ML; Forlenza, OV; Laks, J; Lawson, FL; Machado, JC; Nitrini, R; Palmini, AL; Vale, Fde A, 2014
)
0.86
"Female mice received whole brain irradiation (WBI) and were treated with saline, nimodipine, hUC-MSCs, or hUC-MSCs combined with nimodipine."( Neuroprotective effects of human umbilical cord-derived mesenchymal stromal cells combined with nimodipine against radiation-induced brain injury through inhibition of apoptosis.
Duan, HF; Li, T; Liu, J; Liu, Y; Lu, Y; Qin, YR; Wang, GH; Wu, XB, 2016
)
0.88
" In the observation group, patients were given rosuvastatin in combination with nimodipine, and other patients were given nimodipine in the control group."( Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease.
Liu, N; Yang, C; Zhang, J, 2019
)
1
"This study aims to investigate the effect of nimodipine combined with betahistine on the levels of CRP and other inflammatory cytokines, as well as vascular endothelial function in patients with hypertensive cerebral vasospasm."( Effects of nimodipine combined with betahistine on CRP and other inflammatory cytokines and vascular endothelial function in patients with hypertensive cerebral vasospasm.
Liu, X; Luo, X; Sheng, P; Wang, Y; Xiao, P; Zeng, K; Zhao, N, 2020
)
1.21
" CG combined with NM is better than NM alone."( Cerebralcare Granule® combined with nimodipine improves cognitive impairment in bilateral carotid artery occlusion rats by reducing lipocalin-2.
Gao, WY; Han, XY; Ji, HX; Jing, SS; Li, X; Liu, CX; Man, SL; Qiao, O; Wang, J; Wang, WZ; Zhang, XY; Zhang, Y, 2021
)
0.9
"The drug combination of nimodipine and ulinastatin improved blood flow and neurological function in patients with CVS after SAH and enhanced the therapeutic efficacy; the underlying mechanism may be associated with the regulation of vascular endothelial dilatation function and the inhibition of relevant inflammatory factors' expression."( Influence of nimodipine combined with ulinastatin on neurological function and inflammatory reaction in patients with cerebral vasospasm after subarachnoid hemorrhage.
Chen, M; Liu, H; Wei, X; Zhang, Q; Zou, W, 2021
)
1.3
"To explore the curative effect of nimodipine combined with latanoprost in the treatment of open-angle glaucoma and its effect on ocular hemodynamics and visual field defects."( Efficacy of Nimodipine Combined with Latanoprost in Treating Open-Angle Glaucoma and Its Influence on Ocular Hemodynamics and Visual Field Defects.
Duan, HP; Liu, R, 2022
)
1.38
" According to different treatment plans, the patients were divided into two groups: an observation group (n = 46) treated with nimodipine combined with latanoprost, and a control group (n = 41) treated by latanoprost monotherapy."( Efficacy of Nimodipine Combined with Latanoprost in Treating Open-Angle Glaucoma and Its Influence on Ocular Hemodynamics and Visual Field Defects.
Duan, HP; Liu, R, 2022
)
1.31
"Nimodipine combined with latanoprost eye drops is effective in the treatment of primary open-angle glaucoma, which could effectively improve the ocular hemodynamics and visual field defects of patients with fewer adverse reactions and higher safety."( Efficacy of Nimodipine Combined with Latanoprost in Treating Open-Angle Glaucoma and Its Influence on Ocular Hemodynamics and Visual Field Defects.
Duan, HP; Liu, R, 2022
)
2.54
" Observe the effect of nimodipine combined with magnesium sulfate on serum heat shock protein 70 (HSP70) and pentamer 3 (PTX3) levels in patients with pregnancy-induced hypertension."( Clinical Effect of Nimodipine Combined with Magnesium Sulfate on Pregnancy-Induced Hypertension Syndrome.
Chang, R; Cui, A; Jiang, L; Miao, C; Miao, H; Yang, L, 2022
)
1.36
" Therefore, meta-analysis is employed in this study to evaluate the efficacy and safety of using donepezil hydrochloride combined with nimodipine in treating VaD to provide references for clinical treatments."( A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia.
Huang, KL; Liu, J; Ran, SM; Tan, AH; Wang, GY; Wang, MY; Yang, Q, 2022
)
1.15
"Donepezil hydrochloride combined with nimodipine had demonstrated satisfactory efficacy on the treatment of vascular dementia."( A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia.
Huang, KL; Liu, J; Ran, SM; Tan, AH; Wang, GY; Wang, MY; Yang, Q, 2022
)
1.22
"Donepezil hydrochloride combined with nimodipine had good efficacy in the treatment of patients with vascular dementia, mainly in terms of improving the Simple MMSE scores, the ability to use daily living scale (ADL) scores and the CDR, and the best results were obtained after 12 weeks of intervention."( A systematic review of the efficacy of donepezil hydrochloride combined with nimodipine on treating vascular dementia.
Huang, KL; Liu, J; Ran, SM; Tan, AH; Wang, GY; Wang, MY; Yang, Q, 2022
)
1.22
" Moreover, the potential drug-drug interaction with istradefylline was determined as well as underlied mechanism."( The effect of CYP3A4 genetic polymorphism and drug interaction on the metabolism of istradefylline.
Cai, J; Gao, N; Hu, G; Hu, X; Ni, J; Qian, J; Ye, Z, 2022
)
0.72
" The NMD-NAP was successfully prepared by quenching cooling combined with wet milling and spray drying."( Characterization of nimodipine amorphous nanopowder prepared by quenching cooling combined with wet milling and spray drying.
Gou, J; He, H; Tang, X; Wang, B; Wang, X; Wang, Y; Yin, T; Zhang, Y; Zhu, Y, 2022
)
1.04

Bioavailability

Pegylated nanoparticles (NMD-NP/PEG), with a size of 190 nm and a payload of 68’µg/mg, significantly improve the oral bioavailability of nimodipine.

ExcerptReferenceRelevance
" and cimetidine 1000 mg/d for 7 days led to a significant increase of the relative bioavailability of nimodipine."( Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers.
Kuhlmann, J; Mück, W; Rämsch, KD; Seiberling, M; Wingender, W; Woelke, E, 1992
)
0.72
" Nimodipine has low oral bioavailability (2."( Nimodipine in the treatment of subarachnoid hemorrhage.
Tietze, KJ; Yasuda, SU, 1989
)
2.63
" Mean bioavailability was 15."( Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage.
Andersson, KE; Brandt, L; Ljunggren, B; Nilsson, LG; Rosendal-Helgesen, S; Vinge, E, 1986
)
0.59
" Nimodipine was well absorbed in all species."( Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of [14C]nimodipine in rat, dog and monkey.
Maruhn, D; Rämsch, K; Siefert, HM; Suwelack, D; Weber, H, 1985
)
1.5
" Concomitant administration of cimetidine produced an approximate doubling of the bioavailability of nimodipine."( Nimodipine. Potential for drug-drug interactions in the elderly.
Ahr, G; Kuhlmann, J; Mück, W, 1995
)
1.95
" The relative bioavailability of propranolol was 104."( Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study.
Breuel, HP; Heine, PR; Kuhlmann, J; Mück, W; Niklaus, H; Schmage, N, 1995
)
0.59
"l-1, resulting in a mean relative bioavailability of nimodipine of 111% with a 90%-confidence interval of 96-128% for the combined medication."( Steady-state pharmacokinetics of nimodipine during chronic administration of indometacin in elderly healthy volunteers.
Breuel, HP; Heine, PR; Horkulak, J; Mück, W; Niklaus, H; Schmage, N, 1995
)
0.82
" Although the capsules could reach peak level faster, the bioavailability was not significantly different from that of the tablets."( Pharmacokinetics and relative bioavailability of nimodipine capsules and tablets in 8 Chinese healthy men.
Chen, G; Guo, LQ; Tan, HS, 1993
)
0.54
"h-1 x kg-1 respectively; in survivors receiving the drug orally, bioavailability of the 30 mg tablet was 9%."( Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage.
Chang, CM; Fong, KY; Fung, CF; Kou, M; Kumana, CR; Lauder, IJ; Mück, W; Yu, YL, 1993
)
0.63
"The article determined the bioavailability and pharmacokinetic parameters of two kinds of nimodipine tablets produced by Tianjin Center Pharmaceutical Factory in 6 healthy volunteers using HPLC method."( [Studies on the bioavailability and pharmacokinetics of nimodipine tablet in human body].
Ding, DY; Liu, RJ; Yan, XF, 1993
)
0.75
"Single and multiple dose pharmacokinetics and absolute bioavailability of the calcium antagonist nimodipine (Nimotop) were investigated in 24 young (age: 22 - 40 years) and 24 elderly (age: 59 - 79 years) healthy subjects."( The influence of age on the pharmacokinetics of nimodipine.
Breuel, HP; Kuhlmann, J; Mück, W, 1996
)
0.77
"The bioavailability of dihydropyridine calcium channel blockers following oral administration was shown to be increased by concomitant intake of grapefruit juice for all drugs of this class tested up to now."( Grapefruit juice increases oral nimodipine bioavailability.
Blume, H; Fuhr, U; Huschka, C; Kuhlmann, J; Maier-Brüggemann, A; Mück, W; Rietbrock, S; Staib, AH; Unger, S; Zaigler, M, 1998
)
0.58
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Relative bioavailability of NM-FSRT was 391."( [Studies on nimodipine sustained-release tablet capable of floating on gastric fluid with prolonged gastric resident time].
Fu, CD; Ma, GD; Wu, W; Zhang, HB; Zhou, Q, 1997
)
0.68
"A new analytical method was established for determining plasma level of nimodipine using HPLC and its application to determine the bioavailability of nimodipine."( [Comparison of bioavailability between nimotop and nimodipine tablet].
Shi, XJ; Wang, HT; Wei, Y; Zhang, JH; Zhang, LL; Zhong, MK, 1997
)
0.78
"This work examines the influence of modified gum karaya (MGK) on the oral bioavailability of a poorly water-soluble drug, nimodipine (NM), in comparison with that of gum karaya (GK)."( In vivo evaluation of modified gum karaya as a carrier for improving the oral bioavailability of a poorly water-soluble drug, nimodipine.
Kumar, NK; Kumar, NR; Murali Mohan Babu, GV; Murthy, KV; Ram, BJ; Sankar, KH, 2002
)
0.73
" The relative bioavailability of the two brands of nimodipine tablets was determined in healthy adult volunteers after a single dose in a randomized crossover study."( Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation.
Chen, X; He, Z; Liu, X; Tang, X; Zhao, L; Zhong, D, 2004
)
0.84
"It is known that digoxin, which is a liposoluble cardiac glycoside, is well absorbed from intestine."( Intestinal absorption of digoxin and interaction with nimodipine in rats.
Batu, O; Erol, K; Kilic, FS; Sirmagul, B; Yildirim, E,
)
0.38
"To determine whether nasally applied nimodipine (NM) could improve its systemic bioavailability and be transported directly from the nasal cavity to the brain."( Distribution of nimodipine in brain following intranasal administration in rats.
Jiang, XG; Wu, CH; Zhang, QZ, 2004
)
0.94
"Nasally administered NM could markedly improve the bioavailability and a fraction of the NM dose could be transported into brain via the olfactory pathway in rats."( Distribution of nimodipine in brain following intranasal administration in rats.
Jiang, XG; Wu, CH; Zhang, QZ, 2004
)
0.67
" After a single intranasal administration of this preparation at a dose of 2 mg/kg, the plasma concentration peaked at 1 h and the absolute bioavailability was about 32%."( Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain.
Jiang, W; Jiang, X; Lu, W; Shi, Z; Su, L; Zhang, Q, 2004
)
0.68
" The bioavailability studies in healthy human volunteers indicated that the TTS of nimodipine, designed in the present study, provided steady-state plasma concentration of the drug with minimal fluctuations for 20 hr with improved bioavailability in comparison with the immediate release tablet dosage form."( Formulation and evaluation of limonene-based membrane-moderated transdermal therapeutic system of nimodipine.
Bhaskar, P; Krishnaiah, YS; Satyanarayana, V,
)
0.57
" The results showed that the menthol-based TTS patch of nimodipine provided steady plasma concentration of the drug with minimal fluctuations with improved bioavailability in comparison with the immediate release tablet dosage form."( Studies on the transdermal delivery of nimodipine from a menthol-based TTS in human volunteers.
Bhaskar, P; Krishnaiah, YS, 2004
)
0.84
" However, due to its poor solubility in water, intravenous administration depends on the use of the dehydrated alcohol to achieve a clinically relevant concentrated infusion solution while the low bioavailability of the nimotop tablets were far away from content."( Preparation, characterization, and pharmacokinetics of sterically stabilized nimodipine-containing liposomes.
Ge, L; Yang, D; Zhang, G; Zheng, Y; Zhu, J, 2006
)
0.56
"The aim of this study was to investigate the effect of morin on the bioavailability of nimodipine after administering nimodipine (15 mg/kg) orally to rabbits either co-administered or pretreated with morin (2, 10 and 20 mg/kg)."( Enhanced nimodipine bioavailability after oral administration of nimodipine with morin, a flavonoid, in rabbits.
Burm, JP; Choi, JS, 2006
)
0.97
" The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetic, bioavailability or bioequivalence studies."( Liquid chromatographic-electrospray tandem mass spectrometric method for the quantification of nimodipine in human plasma.
Boosi, R; Kandikere, VN; Maurya, S; Mudigonda, K; Nirogi, RV, 2006
)
0.55
" The effect of NIMO on hippocampal concentrations of PHT suggests that P-glycoprotein has a role in reduced central bioavailability of PHT in our epileptic refractory model."( Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model.
Auzmendi, J; Bramuglia, GF; Girardi, E; Gonzalez, NN; Höcht, C; Lazarowski, A; Opezzo, JA; Taira, CA, 2007
)
1.78
"The aim of the present work was to investigate the in vitro dissolution properties and oral bioavailability of three solid dispersions of nimodipine."( Part II: bioavailability in beagle dogs of nimodipine solid dispersions prepared by hot-melt extrusion.
Tang, X; Wang, Z; Yang, R; Zhang, Y; Zheng, L; Zheng, X, 2007
)
0.8
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"The ability of self-emulsifying drug delivery systems (SEDDS) to improve solubility, dissolution rate and bioavailability of a poorly water-soluble calcium channel blocker, nimodipine (NM) was evaluated in the present investigation."( Design and evaluation of self-emulsifying drug delivery systems (SEDDS) of nimodipine.
Kale, AA; Patravale, VB, 2008
)
0.77
"The aim of this study was to improve the dissolution and, therefore, bioavailability of the poorly water-soluble and highly permeable drug nimodipine (NMD)."( Nimodipine semi-solid capsules containing solid dispersion for improving dissolution.
Rui, Y; Sun, Y; Tang, X; Wenliang, Z, 2008
)
1.99
"The objectives of the present work were, first, to develop a new solid self-microemulsifying drug delivery system (SMEDDS) for oral poorly water-soluble drugs such as nimodipine; and second, to evaluate its oral bioavailability in healthy rabbits."( A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs.
Wan, J; Xu, H; Yang, X; Yi, T, 2008
)
0.54
" Results of our work suggest that P-glycoprotein (P-gp) overexpression by repetitive seizures induced by MP administration does not modify brain bioavailability of carbamazepine."( Differential hippocampal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid.
Girardi, E; Gonzalez, NN; Höcht, C; Lazarowski, A; Mayer, MA; Opezzo, JA; Taira, CA, 2009
)
0.35
" The relative bioavailability was 103."( Liquid chromatography-mass spectrometry method for the determination of amlodipine in human plasma and its application in a bioequivalence study.
Ge, Z; Ouyang, P; Wei, P; Zhan, Y; Zou, Q, 2009
)
0.35
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
" The wafers were tested for their physical characteristics, ex vivo mucoadhesion strength, ex vivo mucoadhesion time, in vitro drug release, and in vitro permeation and in vivo bioavailability studies."( Development and evaluation of novel buccoadhesive wafers of nimodipine for treatment of hypertension.
Ali, J; Ali, M; Hassan, N, 2010
)
0.6
"The oral bioavailability of some drugs is markedly lower in cynomolgus monkeys than in humans."( Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
Komuro, S; Mizuki, Y; Nishimuta, H; Sato, K; Yabuki, M, 2011
)
0.37
" N-(1-adamantyl)-2-oxo-chromene-3-carboxamide (8), N-adamantan-1-yl-5-dimethyl-amino-1-naphthalenesulfonic acid (11) and N-(1-cyano-2H-isoindol-2-yl) adamantan-1-amine (12) were found to possess a high degree of multifunctionality with favourable physical-chemical properties for bioavailability and blood-brain barrier permeability."( Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
Green, IR; Joubert, J; Malan, SF; van Dyk, S, 2011
)
0.37
"The reduced bioavailability of nimodipine after oral administration might not only be due to the metabolizing enzyme cytochrome P450 3A4(CYP3A4) but also to the P-glycoprotein efflux transporter in the small intestine."( Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein.
Burm, JP; Cho, YA; Choi, JS, 2011
)
0.89
"To compare the dissolution and bioavailability for nimodipine microcrystals and nanocrystals, and to determine the critical size range in improving the oral absorption of nimodipine."( Relationship between dissolution and bioavailability for nimodipine colloidal dispersions: the critical size in improving bioavailability.
Fu, Q; Gong, C; He, Z; Kou, L; Li, M; Liu, K; Liu, M; Sui, X; Sun, J; Wang, S; Zhang, D, 2012
)
0.88
"In an attempt to increase oral bioavailability and to target intestinal lymphatic transport system, Nimodipine loaded solid lipid nanoparticles (NMD-SLNs) were prepared."( Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system.
Belgamwar, VS; Chalikwar, SS; Patil, MU; Surana, SJ; Talele, VR, 2012
)
0.88
" Consequently, the absolute bioavailability (AB) of nimodipine with pravastatin (1 mg/kg) was 31."( Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin.
Choi, DH; Choi, JS; Lee, CK,
)
0.62
"The enhanced oral bioavailability of nimodipine might be mainly due to inhibition of the CYP3A-mediated metabolism of nimodipine in the small intestine and/or in the liver and due to reduction of the total body clearance rather than both to inhibition of the P-gp efflux transporter in the small intestine and reduction of renal elimination of nimodipine by pravastatin."( Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin.
Choi, DH; Choi, JS; Lee, CK,
)
0.65
"We had conducted a comprehensive study on preparation, characterization and pharmacokinetics of nimodipine nanocrystals for oral administration previously, and nimodipine nanocrystals displayed lower dissolution profiles but higher bioavailability than Nimotop(®)."( Nimodipine nanocrystals for oral bioavailability improvement: role of mesenteric lymph transport in the oral absorption.
Ai, X; Fu, Q; Han, X; He, Z; Li, M; Liu, X; Sui, X; Sun, J; Sun, L; Sun, Y; Wang, S; Wang, Y; Zhang, P; Zhang, Y; Zhu, M, 2013
)
2.05
" Exudates of nanocrystals from enterocytes were detected in mesenteric lymphatic fluids using a transmission electron microscope, and the bioavailability was only about half of the control after the mesenteric lymph was blocked."( Nimodipine nanocrystals for oral bioavailability improvement: role of mesenteric lymph transport in the oral absorption.
Ai, X; Fu, Q; Han, X; He, Z; Li, M; Liu, X; Sui, X; Sun, J; Sun, L; Sun, Y; Wang, S; Wang, Y; Zhang, P; Zhang, Y; Zhu, M, 2013
)
1.83
" The nanocrystals exhibited lower dissolution patterns than Nimotop(®) under non-sink condition, but bioavailability of the two nanocrystals (159."( Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies.
Fu, Q; Han, X; He, Z; Li, M; Lian, H; Ling, G; Liu, X; Luo, C; Sui, X; Sun, J; Sun, L; Sun, Y; Wang, S; Wang, Y; Zhang, D; Zhu, M, 2013
)
1.83
"In order to decrease the fluctuation of blood concentration and to increase the oral bioavailability of nimodipine (NMD), a two-step strategy including the push-pull osmotic pump (PPOP) method in combination with micronization and solid dispersion techniques, was used to prepare the controlled-release high-bioavailability solid dosages."( A two-step strategy to design high bioavailable controlled-release nimodipine tablets: the push-pull osmotic pump in combination with the micronization/solid dispersion techniques.
Chai, L; Liu, X; Sun, J; Sun, Y; Wang, S; Xu, L; Zhang, D, 2014
)
0.85
" These data shown that NMD-Lipo has an anticonvulsant activity significantly superior to free NMD, suggesting that the liposomes promoted a drug controlled release by improving its bioavailability and consequently increasing its pharmacological activity."( Acute toxicity and anticonvulsant activity of liposomes containing nimodipine on pilocarpine-induced seizures in mice.
Cavalcanti, IM; Freitas, RM; Moreno, LC; Rolim, HM; Santos-Magalhães, NS; Satyal, P, 2015
)
0.65
" In addition, the oral bioavailability of NIM-loaded MCLN in beagle dogs was compared with that of the immediate-release formulation, Nimotop®."( Synthesis and evaluation of mesoporous carbon/lipid bilayer nanocomposites for improved oral delivery of the poorly water-soluble drug, nimodipine.
Ai, F; Han, J; Lin, Q; Zhang, L; Zhang, Y; Zhao, Q; Zhu, W, 2015
)
0.62
" The relative bioavailability of NIM for NIM-loaded MCLN was 214%."( Synthesis and evaluation of mesoporous carbon/lipid bilayer nanocomposites for improved oral delivery of the poorly water-soluble drug, nimodipine.
Ai, F; Han, J; Lin, Q; Zhang, L; Zhang, Y; Zhao, Q; Zhu, W, 2015
)
0.62
" Absolute bioavailability was 22 %."( Absorption, elimination and cerebrospinal fluid concentrations of nimodipine in healthy beagle dogs receiving human intravenous and oral formulation.
Ahtola-Sätilä, T; Frantzén, J; Koskimäki, J; Laakso, A; Saloranta, L; Tarkia, M, 2016
)
0.67
"Enteral administration of nimodipine showed lower bioavailability during the 2nd week after SAH compared to parenteral application during the 1st week."( Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage.
Abboud, T; Andresen, H; Czorlich, P; Duehrsen, L; Koeppen, J; Regelsberger, J; Stenzig, J; Westphal, M, 2015
)
1.06
"An early prediction of solubility in physiological media (PBS, SGF and SIF) is useful to predict qualitatively bioavailability and absorption of lead candidates."( Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Bharate, SS; Vishwakarma, RA, 2015
)
0.42
" However, NM suffers from poor oral bioavailability (5-13%) due to its low aqueous solubility, extensive first pass metabolism and short elimination half-life (1-2h)."( Novel self-assembled nano-tubular mixed micelles of Pluronics P123, Pluronic F127 and phosphatidylcholine for oral delivery of nimodipine: In vitro characterization, ex vivo transport and in vivo pharmacokinetic studies.
Basalious, EB; Shamma, RN, 2015
)
0.62
"To explore the effect of the pore size of three-dimensionally ordered macroporous chitosan-silica (3D-CS) matrix on the solubility, drug release, and oral bioavailability of the loaded drug."( Effect of pore size of three-dimensionally ordered macroporous chitosan-silica matrix on solubility, drug release, and oral bioavailability of loaded-nimodipine.
Gao, Y; Jiang, T; Sun, H; Wang, S; Xie, Y; Zhao, Q; Zheng, X, 2016
)
0.63
"Our findings suggest that the oral bioavailability decreased with a decrease in the pore size of the matrix."( Effect of pore size of three-dimensionally ordered macroporous chitosan-silica matrix on solubility, drug release, and oral bioavailability of loaded-nimodipine.
Gao, Y; Jiang, T; Sun, H; Wang, S; Xie, Y; Zhao, Q; Zheng, X, 2016
)
0.63
" The pharmacokinetic results showed that the relative bioavailability was 397 % in comparison with Nimotop(®), suggesting that NCs are an efficient strategy for improving the oral bioavailability of poorly water-soluble drugs."( Formulation of nimodipine nanocrystals for oral administration.
Fu, Q; Li, J; Li, M; Liu, X; Wang, Y, 2016
)
0.79
" Therefore, Solutol(®) HS15-based self-assembled nanomicelles represent a promising delivery system to enhance the oral bioavailability of NIM."( One-step self-assembled nanomicelles for improving the oral bioavailability of nimodipine.
Fu, Y; Gong, T; Luo, JW; Zhang, ZR, 2016
)
0.66
"Frequent administration caused by short half-life and low bioavailability due to poor solubility and low dissolution rate limit the further application of poorly water-soluble nimodipine, although several new indications have been developed."( Development and Evaluation of High Bioavailable Sustained-Release Nimodipine Tablets Prepared with Monolithic Osmotic Pump Technology.
Cheng, X; Hu, X; Kong, H; Li, M; Li, Z; Liu, Y; Mei, X; Tang, X; Yang, Y; Yu, F, 2018
)
0.91
"The present study was intended to develop a controlled released osmotic pump capsule based on Nimodipine (NM)-loaded self-microemulsifying drug delivery systems (SMEDDSs) in order to improve the low oral bioavailability of NM."( Controlled Release of the Nimodipine-Loaded Self-Microemulsion Osmotic Pump Capsules: Development and Characterization.
Gao, C; Huang, Y; Li, J; Shen, H; Zhang, S, 2018
)
1
" Pegylated nanoparticles (NMD-NP/PEG), with a size of 190 nm and a payload of 68 µg/mg, significantly improve the oral bioavailability of nimodipine; about 7-times higher than for the control drug solution (62% vs 9%)."( Pegylated nanoparticles for the oral delivery of nimodipine: Pharmacokinetics and effect on the anxiety and cognition in mice.
Irache, JM; Martínez-Ohárriz, MC; Moreno, LCGEAI; Muñoz, E; Ramirez, MJ; Santos-Magalhães, NS; Solas, M, 2018
)
0.94
"Collectively, the NLCs significantly enhanced the oral bioavailability of NMP and might provide a promising nanoplatform for hydrophobic drug delivery."( Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability.
Ding, Y; Jiang, M; Liu, P; Opoku-Damoah, Y; Shen, Y; Teng, Z; Webster, TJ; Yu, M; Zhang, H; Zhou, J, 2019
)
0.79
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Solid dispersion is a widely used method to improve the dissolution and oral bioavailability of water-insoluble drugs."( The use of amphiphilic copolymer in the solid dispersion formulation of nimodipine to inhibit drug crystallization in the release media: Combining nano-drug delivery system with solid preparations.
Chen, MY; Du, LR; Fu, JJ; Huang, YG; Lei, XP; Li, JX; Li, X; Liang, L; Lin, YL; Liu, JP; Miao, YL; Wei, MY; Yu, XY; Zhang, Y, 2020
)
0.79
" The absolute bioavailability after io administration was higher than that after ig administration (40."( Comparative Pharmacokinetics of Nimodipine in Rat Plasma and Tissues Following Intraocular, Intragastric, and Intravenous Administration.
Bai, L; Dai, M; Fei, Q; He, N; Li, F; Ma, Q; Mao, D; Si, Q; Zhang, H, 2020
)
0.84

Dosage Studied

Nimodipine can cause arterial hypotension requiring either a dosage reduction or its discontinuation. We describe a patient with an apparent primary TCH, which repeatedly occurred immediately after micturition until she achieved a therapeutic dosage. In these animals, withdrawal of nimodipsine for 48 hr returned the dose-response curve of sufentanil to the tolerant values.

ExcerptRelevanceReference
" Dose-response curves for all the drugs tested were similar and a significant dose-dependent antinociceptive action was evident in the formalin and writhing tests."( Antinociceptive effects of Ca2+ channel blockers.
Bustamante, D; Fernandez, E; Kramer, V; Miranda, HF; Paeile, C; Pelissier, T; Pinardi, G; Saavedra, H, 1992
)
0.28
" This is associated with a decrease in reactivity of the vessels of the above mentioned brain structures determined by the dilatory reaction to the dosed inhalation of carbon dioxide."( [The effect of nimodipine and verapamil on the blood supply and vascular reactivity of the brain].
Beketov, AI; Polevik, IV,
)
0.48
" Adjustments in anaesthetic dosage may be necessary in patients receiving nimodipine."( Nimodipine decreases the minimum alveolar concentration of isoflurane in dogs.
Backus, WW; Kanchuger, MS; Maneksha, FR; Schwartz, AE; Young, WL, 1991
)
1.95
" Dose-response curves for Cd2+ and Ni2+ block of both sustained and transient currents had shallow slopes suggesting that the block was more complex than a simple bimolecular interaction between blocker and one blocking site."( Multiple components of both transient and sustained barium currents in a rat dorsal root ganglion cell line.
Boland, LM; Dingledine, R, 1990
)
0.28
" This treatment regimen was associated with a low incidence of delayed neurological dysfunction with no significant difference between the two dosage groups: three patients (1."( Early aneurysm surgery and preventive therapy with intravenously administered nimodipine: a multicenter, double-blind, dose-comparison study.
Brandt, L; Conzen, MA; Gilsbach, JM; Ljunggren, B; Mokry, M; Reulen, HJ; von Essen, C; von Holst, H, 1990
)
0.51
" In males, a dose-response study of nimodipine's effects on seizures induced by different doses of picrotoxin was conducted."( The effect of nimodipine on picrotoxin-induced seizures.
Thomas, J, 1990
)
0.91
" This preparation allows for convenient use of single dose application of pharmacologic agents as well as cumulative dose-response relationships."( Vascular responsiveness of constant flow perfused arteries with intact endothelium.
Lefer, AM; Lefer, DJ; Osborne, JA, 1989
)
0.28
" Chlordiazepoxide shifted the dose-response curves for TRH stimulation of PRL release and synthesis to the right, and did not change PRL release alone."( Pituitary thyrotropin-releasing hormone (TRH) receptors: effects of TRH, drugs mimicking TRH action, and chlordiazepoxide.
Hinkle, PM; Shanshala, ED, 1989
)
0.28
" Half the animals were pretreated with an intravenous infusion of the calcium antagonistic nimodipine, in a dosage comparable with clinical levels."( An experimental study of the effect of nimodipine in primate subarachnoid haemorrhage.
Bentivoglio, P; Branston, NM; Dorsch, NW; Harris, RJ; Symon, L, 1989
)
0.77
" An increasing dosage of nimodipine is accompanied by increasing cardiovascular effects."( [Hemodynamic effects in high-dose infusion of nimodipine, a new calcium antagonist].
Boldt, J; Hempelmann, G; Kling, D; Moosdorf, R; Ratthey, K; von Bormann, B, 1986
)
0.83
"During opiate anesthesia (standardized dosage of fentanyl) for operation of cerebral aneurysms after subarachnoid hemorrhage, different hemodynamic, respiratory, metabolic, and endocrine parameters were determined before (1 in Fig."( [Effect of the calcium antagonist nimodipine on hemodynamics, gas exchange and endocrine parameters in opiate anesthesia].
Adams, HA; Börner, U; Gips, H; Hempelmann, G; Marck, P; Müller, H; Otto, O, 1987
)
0.55
"03 mg/kg bwxh nimodipine, a dosage being used in neurosurgery, can be classified as safe."( [Hemodynamic changes in infusion with nimodipine].
Boldt, J; Görlach, G; Hempelmann, G; Kling, D; von Bormann, B, 1985
)
0.9
" The dosage used was 30 mg four times daily."( Efficacy of nimodipine in the prophylaxis of migraine.
Havanka-Kanniainen, H; Hokkanen, E; Myllylä, VV, 1985
)
0.65
" Cardiovascular parameters, including mean systemic arterial blood pressure, cardiac output, and heart rate, were recorded during infusion of nimodipine in a dose-response fashion."( Increase in rat spinal cord blood flow with the calcium channel blocker, nimodipine.
Guha, A; Piper, I; Tator, CH, 1985
)
0.7
" using a cumulative dosing regimen in conscious (6, 24 and 60 micrograms/kg) and anesthetized (6 and 60 micrograms/kg) rats."( Effects of nimodipine on cerebral blood flow in conscious rat.
Flaim, SF; Kanda, K, 1986
)
0.66
" [14C]nimodipine and/or its radiolabelled metabolites were secreted in milk of orally dosed lactating rats."( Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of [14C]nimodipine in rat, dog and monkey.
Maruhn, D; Rämsch, K; Siefert, HM; Suwelack, D; Weber, H, 1985
)
1.07
" Dosage adjustment of nimodipine appears to be necessary in renal failure."( Clinical pharmacokinetics of nimodipine in normal and impaired renal function.
Dührsen, U; Kirch, W; Ohnhaus, EE; Rämsch, KD, 1984
)
0.87
" The proportionately greatest increases in local CBF were observed during infusions of the lowest dosage of nimodipine (1 microgram kg-1 min-1), suggesting either that this dosage provokes maximum cerebrovascular relaxation or that effects of increasing concentrations are counteracted by the concomitant systemic hypotension."( Effect of the calcium antagonist nimodipine on local cerebral blood flow: relationship to arterial blood pressure.
Harper, AM; McCulloch, J; Mendelow, AD; Mohamed, AA; Teasdale, GM, 1984
)
0.76
" The effect of nimodipine on vessel caliber at this dosage was equivocal."( A randomized placebo-controlled double-blind trial of nimodipine after SAH in monkeys. Part 1: Clinical and radiological findings.
Boisvert, D; Castor, W; Espinosa, F; Grace, M; Overton, T; Weir, B, 1984
)
0.87
" Further increase of dosage led to additional marked dilation but also to a drop in blood pressure by almost 30%."( Pial arterial vasodilation by intravenous nimodipine in cats.
Auer, LM, 1981
)
0.53
" Chronic nimodipine dosing in cocaine-dependent individuals is now needed to confirm its efficacy in the treatment of cocaine dependence."( The effects of nimodipine on the EEG of substance abusers.
Guo, X; Herning, RI; Lange, WR, 1995
)
1.06
" Nifedipine released during Days 11-14 elicited an inverted U-shaped dose-response curve in the VDI with a peak increase of 30."( Calcium entry blockers stimulate vasoproliferation on the chick chorioallantoic membrane.
Dusseau, J; Hutchins, PM, 1993
)
0.29
" In these animals, withdrawal of nimodipine for 48 hr returned the dose-response curve of sufentanil to the tolerant values, whereas Ca++ channels remained increased."( Regulation of dihydropyridine-sensitive Ca++ channels during opioid tolerance and supersensitivity in rats.
Díaz, A; Flórez, J; Hurlé, MA; Pazos, A; Ruíz, F, 1995
)
0.57
" However, because of the decreased blood flow to the kidneys further dose-response studies are needed before clinical use in asphyctic newborns."( Effect of nimodipine on cerebral and organ blood flow in normal and posthypoxemic newborn piglets.
Bratlid, D; Hall, C; Odden, JP; Roll, EB, 1993
)
0.69
" Ex vivo platelet function was measured at baseline, 1 hour after the first dose at each dosage strength, and 1 hour after the last dose at each dosage."( Effect of oral nimodipine on platelet function.
Bruck, DC; Feinberg, WM, 1993
)
0.64
" Intraperitoneal treatment with the Ca2+ channel blocker, nimodipine, from week 4 onwards, in a dosage of 10 mg kg-1 or 20 mg kg-1 intraperitoneally per 48 h, resulted in a significant increase in sensory and motor nerve conduction velocity whereas treatment with 5 mg kg-1 intraperitoneally per 48 h was not effective."( Amelioration by the Ca2+ antagonist, nimodipine of an existing neuropathy in the streptozotocin-induced, diabetic rat.
Bravenboer, B; Erkelens, DW; Gispen, WH; Kappelle, AC; Traber, J; van Buren, T, 1993
)
0.8
"Fifty patients of either sex with acute and chronic cerebrovascular disorders were submitted to an observation protocol and treated with oral nimodipine (tablets or drops) at a daily dosage of 90 mg for 1 to 3 months."( [Nimodipine in ischemic cerebropathy].
Di Lascio, G; Salvini, S, 1993
)
1.4
" In these experiments, we started the administration of nimodipine before the induction of global brain ischemia, used 2 different dosage regimens and provided prolonged drug administration after restoration of cerebral blood flow in order to create optimal circumstances for a cerebroprotective effect to be detected."( Pharmacological influences on cardiopulmonary arrest-related brain damage in the rat.
Calle, PA, 1993
)
0.53
"To determine whether aging alters cardiac calcium dose responses or dihydropyridine receptor density or affinity, we performed (a) calcium (Ca2+) dose-response studies (3-5 mM) in Langendorff perfused hearts from 12 mature (4-7 month) and 12 old (23-27 month) Fischer 344 rats, and (b) quantitative autoradiography experiments with 3H-nimodipine (50-3,000 pM) in 20-microns tissue sections containing the compact AV node from hearts of eight mature and eight old F344 rats."( Responses to calcium and binding of 3H-nimodipine in the atrioventricular node, atria, and ventricles of mature and old male Fischer 344 rats.
Capili, H; Kusumoto, FM; Schwartz, JB; Sniezek, MJ, 1995
)
0.73
" The results indicate that nimodipine and BayK 8644 shifted the dose-response curve for cocaine's reinforcing action to the right and left, respectively."( Modulation of cocaine intravenous self-administration in drug-naive animals by dihydropyridine Ca2+ channel modulators.
Kuzmin, A; Ramsey, NF; Semenova, S; Van Ree, JM; Zvartau, EE, 1996
)
0.59
" When the calcium antagonist nimodipine was given at a dosage quickly escalated to 360 mg daily, the patient could be discharged in a state of complete remission after 26 days."( [Phase prevention in bipolar affective disorder with nimodipine. A case report].
Berger, M; Hellwig, B; Hesslinger, B; Riedel, H; Walden, J, 1996
)
0.83
" Tirilazad mesylate at dosage levels of up to 6 mg/kg per day for 8 to 10 days following SAH did not improve the overall outcome in patients with aneurysmal SAH in this trial."( A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America.
Alves, WM; Apperson-Hansen, C; Haley, EC; Kassell, NF; Maile, MH, 1997
)
0.3
" Pretreatment with nifedipine (10-30 mg/kg) produced dose-dependent rightward shifts of the (+/-)-Bay K 8644 dose-response curve."( Effects of dihydropyridine Ca2+ channel blockers on the discriminative stimulus and the motor impairing effects of (+/-)-Bay K 8644.
Cohen, C; Perrault, G; Sanger, DJ, 1997
)
0.3
" We conclude that PCA50938 and flunarizine may act as neuroprotective drugs with different patterns of dose-response and neuroprotective-morbidity-mortality relationships, in the model of global cerebral ischemia in the gerbil."( Neuroprotection by the novel calcium antagonist PCA50938, nimodipine and flunarizine, in gerbil global brain ischemia.
Horga, JF; Moreno, J; Zapater, P, 1997
)
0.54
" We performed a pilot study in 50 patients that demonstrated the feasibility of co-administration of nimodipine in a chronic oral dosing schedule with cisplatin-based chemotherapy in an open-label non-randomised trial."( Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin.
Cassidy, J; Habeshaw, T; Kaye, SB; Parkin, D; Paul, J; Reed, NS; Soukop, M, 1998
)
0.84
"), whereas the second group (group C, n = 22) was treated only with ceftriaxone in a dosage of 30 mg/day/i."( Effects of nimodipine on the cerebrovascular and neuronal changes during pneumococcal meningitis in the rat.
Ayaz, C; Ceviz, A; Geyik, MF; Hoşoglu, S; Inalöz, S; Kemaloglu, MS; Kökoglu, OF; Sari, I, 1997
)
0.69
" In the in vivo study, the dose-response curve for the 50% lethal dose (LD50) of bupivacaine was determined for rats."( The effects of verapamil and nimodipine on bupivacaine-induced cardiotoxicity in rats: an in vivo and in vitro study.
Adsan, H; Onaran, O; Tulunay, M, 1998
)
0.59
"Nimodipine, a dihydropyridine derivative central nervous system (CNS) selective calcium channel blocker was studied at four different dosage schedules in five different models of seizures in rats."( Dose-finding study with nimodipine: a selective central nervous system calcium channel blocker on aminophylline induced seizure models in rats.
Chakrabarti, A; Garg, SK; Saini, HK, 1998
)
2.05
"To explore the contribution of renal failure to nimodipine overall pharmacokinetic variability after single and multiple oral dosing and to develop a population pharmacokinetic model by means of the nonparametric expectation maximization (NPEM2) algorithm based on sampled individual drug concentrations close to the estimated patients' C(SS)avs (NPEM2-C(SS)av)."( Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
Atanasova, I; Dimitrova, V; Mück, W; Robeva, R; Terziivanov, D; Unger, S, 1999
)
0.85
" The most variable was mean residence time, MRT, whose coefficient of variation (CV) was 288% after the first dose and decreased by more than 2 times at steady-state, followed by terminal elimination half-life, t(1/2el), with CV = 171% after the first dosing and decreasing by more than 3 times at steady-state."( Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
Atanasova, I; Dimitrova, V; Mück, W; Robeva, R; Terziivanov, D; Unger, S, 1999
)
0.59
" Because of the lack of specificity of ibotenic acid for a glutamate receptor subtype, a dose-response study with alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate was undertaken and calcified areas (identified with Alizarin Red staining) as well as astro- and microglial reactions (by autoradiography with [3H]lazabemide and [3H]Ro 5-4864) were quantified at one month post-lesion."( Long-term effects of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and 6-nitro-7-sulphamoylbenzo(f)quinoxaline-2,3-dione in the rat basal ganglia: calcification, changes in glutamate receptors and glial reactions.
Cummins, DJ; Dewar, D; Dragunow, M; Mahy, N; Petegnief, V; Saura, J, 1999
)
0.3
" ED50 of nimodipine could not be established since a dose-response relationship was not obtained."( Anticonvulsant profile of nimodipine and nitrendipine against pentylenetetrazole induced seizures in rats.
Balakrishnan, S; Bhargava, VK; Pandhi, P, 1999
)
1.02
") was administered prior to a cumulative DZP or PCP dose-response determination."( Modulation of the ethanol-like discriminative stimulus effects of diazepam and phencyclidine by L-type voltage-gated calcium-channel ligands in rats.
Grant, KA; Green-Jordan, K, 2000
)
0.31
" Nimodipine was administered in dosage of 120 mg/day for 28 days."( A randomized double-blind controlled study of nimodipine in acute cerebral ischemic stroke.
Garg, RK; Nag, D; Varma, M, 1998
)
1.47
" Twenty-four hours later, a morphine dose-response study was conducted (tail flick); or mice were sacrificed and saturation binding studies ([3H]DAMGO) were performed in whole brain."( The effect of nimodipine on opioid antagonist-induced upregulation and supersensitivity.
Lee, SC; Yoburn, BC, 2000
)
0.67
" A nimodipine dosage of 30 mg four times daily (120 mg/d) did not affect CSF [Ca]."( Cations of cisternal cerebrospinal fluid in humans and the effect of different doses of nimodipine on CSF calcium after stroke.
Bereczki, D; Csiba, L; Fekete, I; Fülesdi, B; Köbberling, W; Loof, I; Németh, G; Valikovics, A,
)
0.97
"Two calcium antagonists were used to treat vertigo (nimodipine, 89 patients; cinnarizine, 92 patients), and all patients were maintained on the same dosage regimen until they completed 12 weeks of treatment."( New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study.
Abiuso, J; Alegría, J; Arenas, JE; Castañeda, JR; F, GV; Flaskamp, R; Gómez, JM; González, RH; Guerra, OJ; Hanuch, E; Hernández, J; Hidalgo, LO; Madrid, CE; Martínez, C; Morán, LM; Pedraza, A; Pianese, CP; Ponce, JE; Quijano, D; Ramírez, AM; Rubio, AT; Sanjuán, AP; Uribe, JO; Volpi, C, 2002
)
0.57
"Thirty-two healthy subjects (21-49 years old, mean age 28 years, 10 male, 22 female) received either nimodipine 30 mg twice a day or a placebo according to the same dosage regimen in a double-blind cross-over study design."( Visual function and perfusion of the optic nerve head after application of centrally acting calcium-channel blockers.
Bernd, AS; Boehm, AG; Breidenbach, KA; Koeller, AU; Mueller, MF; Pillunat, LE, 2003
)
0.53
"17 %, nasal dosing improved bioavailibility to 67."( Distribution of nimodipine in brain following intranasal administration in rats.
Jiang, XG; Wu, CH; Zhang, QZ, 2004
)
0.67
" At a sub-effective dose, pargyline could cause a leftward shift in the dose-response curve of 5-HTP-induced antinociception."( L-type calcium channel blockers enhance 5-HTP-induced antinociception in mice.
Chen, B; Han, R; Li, JX; Liang, JH; Lu, Y; Wang, XH; Ye, XF; Zhang, P, 2004
)
0.32
" The bioavailability studies in healthy human volunteers indicated that the TTS of nimodipine, designed in the present study, provided steady-state plasma concentration of the drug with minimal fluctuations for 20 hr with improved bioavailability in comparison with the immediate release tablet dosage form."( Formulation and evaluation of limonene-based membrane-moderated transdermal therapeutic system of nimodipine.
Bhaskar, P; Krishnaiah, YS; Satyanarayana, V,
)
0.57
" The animals were treated with either one of the drugs at previously defined relevant dosage or control."( Neuronal degeneration and iNOS expression in experimental brain contusion following treatment with colchicine, dexamethasone, tirilazad mesylate and nimodipine.
Gahm, C; Holmin, S; Mathiesen, T; Rudehill, S, 2005
)
0.53
" The results showed that the menthol-based TTS patch of nimodipine provided steady plasma concentration of the drug with minimal fluctuations with improved bioavailability in comparison with the immediate release tablet dosage form."( Studies on the transdermal delivery of nimodipine from a menthol-based TTS in human volunteers.
Bhaskar, P; Krishnaiah, YS, 2004
)
0.84
" In a placebo-controlled fashion, nimodipine was orally administered at a dosage of 30 mg three times a day for two periods of 5 days including a 9-day washout interval."( Nimodipine plasma concentration and retinal blood flow in healthy subjects.
Geisslinger, G; Leidig, S; Lötsch, J; Michelson, G; Wärntges, S, 2006
)
2.06
" If a sufficient absorption could be achieved with enterally administered nimodipine, this would be more feasible dosage form and result in a significant reduction in pharmaceutical costs given that the parenteral formulation of nimodipine currently used is tenfold more expensive than the enteral formulation."( Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study.
Helin-Tanninen, M; Koivisto, T; Kokki, H; Lehtola, S; Lehtonen, M; Rinne, J; Soppi, V, 2007
)
0.82
"The present study aimed at establishing the CD50 and CD99 doses along with complete dose-response profile of two convulsants, namely, kainic acid and pentylenetetrazole (PTZ), in mice and evaluating the modulatory role of the cerebroselective dihydropyridine calcium channel blocker nimodipine."( Evaluation of the modulatory role of nimodipine in seizures induced by kainic acid and pentylenetetrazole in mice.
Chakrabarti, A; Hota, D; Sahai, AK; Shitak, R,
)
0.58
"For CD-based formulations, it is important to directly monitor the complexation status of the drug present in final dosage form pharmaceuticals."( Detecting and identifying the complexation of nimodipine with hydroxypropyl-beta-cyclodextrin present in tablets by Raman spectroscopy.
Ke, W; Liu, F; Yang, X; Yu, L; Zi, P, 2008
)
0.6
" Thus, it is possible to control the in vitro release of poorly soluble drugs from solid oral dosage forms containing SMES."( Controlled poorly soluble drug release from solid self-microemulsifying formulations with high viscosity hydroxypropylmethylcellulose.
Wan, J; Xu, H; Yang, X; Yi, T, 2008
)
0.35
" Thus, this solid self-microemulsifying system may provide a useful solid dosage form for oral poorly water-soluble drugs."( A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs.
Wan, J; Xu, H; Yang, X; Yi, T, 2008
)
0.35
" Arterial rings were mounted in isolated tissue chambers equipped with isometric tension transducers to obtain pharmacologic dose-response curves."( N-methyl-D-aspartate (NMDA) antagonists--S(+)-ketamine, dextrorphan, and dextromethorphan--act as calcium antagonists on bovine cerebral arteries.
Carlsson, C; Chen, D; Harakal, C; Kamel, IR; Wendling, KS; Wendling, WW, 2008
)
0.35
" To investigate whether similar effects are present in the hippocampus, AMPA dose-response and calcium movement blockade were performed."( Nimodipine inhibits TMB-8 potentiation of AMPA-induced hippocampal neurodegeneration.
Bernal, F; Mahy, N; Petegnief, V; Pugliese, M; Rodríguez, MJ; Ursu, G, 2009
)
1.8
"To explore the dose-response effects of topical administration of nimodipine on cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH) in rabbits."( Effects of dose-response of topical administration of nimodipine on cerebral vasospasm after subarachnoid hemorrhage in rabbits.
Jiang, JY; Luo, QZ; Pan, YH; Wang, F; Wang, Y; Yin, YH, 2009
)
0.84
" We describe a patient with an apparent primary TCH, which repeatedly occurred immediately after micturition until she achieved a therapeutic dosage of nimodipine."( Thunderclap headache triggered by micturition: responsive to nimodipine.
Gui, W; Han, YY; Liu, YM; Wang, K; Wang, Y; Zhu, J, 2011
)
0.81
" Calpain activity in brain increased by 40% in TOCP hens compared to the control group when measured 24h after dosing and remained high (18% over control) 21 days after dosing."( Biochemical, histopathological and clinical evaluation of delayed effects caused by methamidophos isoforms and TOCP in hens: ameliorative effects using control of calcium homeostasis.
Deoliveira, GH; Ehrich, M; Emerick, GL; Jortner, BS; Oliveira, RV, 2012
)
0.38
" A total of 113 medical records were analysed; 53 patients received betahistine-dihydrochloride at on-label dosage (32 mg die) for six months, and 60 patients were treated with the same regimen and nimodipine (40 mg die) as an add-therapy during the same period."( Effect of a fixed combination of nimodipine and betahistine versus betahistine as monotherapy in the long-term treatment of Ménière's disease: a 10-year experience.
Aggazzotti Cavazza, E; Alicandri Ciufelli, M; Barillari, MR; Genovese, E; Monzani, D; Neri, V; Presutti, L, 2012
)
0.85
" With subsequent fractionated dosing (30 mg every two hours), the patient completed the prescribed 21-day course of nimodipine therapy."( Hypoxemia associated with nimodipine in a patient with an aneurysmal subarachnoid hemorrhage.
Baker, M; Bastin, MT; Cook, AM; Fraser, J; Hessel, E, 2015
)
0.93
" Dosing of nimodipine and associated hypotensive events were recorded."( Nimodipine for the prevention of cerebral vasospasm after subarachnoid hemorrhage in 12 children.
Heffren, J; McIntosh, AM; Reiter, PD, 2015
)
2.25
" It is a major determinant of half-life and dosing frequency of a drug."( Volume of Distribution in Drug Design.
Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015
)
0.42
" Key to the effective administration of continuous intra-arterial nimodipine is multimodal neuromonitoring and the individual adaptation of dosage and time of infusion for each patient."( Continuous intra-arterial nimodipine infusion in patients with severe refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a feasibility study and outcome results.
Bele, S; Brawanski, A; Bründl, E; Hochreiter, A; Kieninger, M; Proescholdt, MA; Schebesch, KM; Scheitzach, J; Schneiker, A; Schödel, P; Schuierer, G; Wendl, C, 2015
)
0.95
" Nimodipine was intended to be applied orally with a dosage of 60 mg every 4 h."( Nimodipine Dose Reductions in the Treatment of Patients with Aneurysmal Subarachnoid Hemorrhage.
Diesing, D; Sandow, N; Sarrafzadeh, A; Vajkoczy, P; Wolf, S, 2016
)
2.79
" Results showed that the combination of the two agents may avoid dosage adjustments in clinic and the combination is more convenient as well as efficient on different pathogenesis of cerebral ischemia."( Development of two step liquid-liquid extraction tandem UHPLC-MS/MS method for the simultaneous determination of Ginkgo flavonoids, terpene lactones and nimodipine in rat plasma: Application to the pharmacokinetic study of the combination of Ginkgo biloba
Bi, K; Li, P; Li, Q; Liu, R; Wang, T; Xiao, J, 2016
)
0.63
" In highly selected cases, intra-arterial (IA) or intravenous (IV) application of nimodipine may be considered; however, the optimum dosage and modality of application remain a matter of debate."( Systemic and Cerebral Concentration of Nimodipine During Established and Experimental Vasospasm Treatment.
Albanna, W; Clusmann, H; Conzen, C; Höllig, A; Müller, M; Reinsch, M; Schneider, T; Schubert, GA; Weiss, M; Wiesmann, M, 2017
)
0.95
" Nimodipine can cause arterial hypotension requiring either a dosage reduction or its discontinuation."( Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage.
Bele, S; Dettmer, K; Eissnert, C; Graf, B; Gruber, M; Kieninger, M; Knott, I; Oefner, PJ; Tuemmler, S; Wendl, C, 2019
)
1.64
"In a prospective setting, over a 1-year observation period, data on the course of arterial blood pressure and nimodipine dosage were collected for 38 patients undergoing treatment for aneurysmal or perimesencephalic SAH in an intensive care unit."( Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage.
Bele, S; Dettmer, K; Eissnert, C; Graf, B; Gruber, M; Kieninger, M; Knott, I; Oefner, PJ; Tuemmler, S; Wendl, C, 2019
)
0.95
" In patients suffering from higher-grade SAH, arterial hypotension and consequent dosage reduction or discontinuation of nimodipine were more frequent than in patients with lower-grade SAH."( Incidence of Arterial Hypotension in Patients Receiving Peroral or Continuous Intra-arterial Nimodipine After Aneurysmal or Perimesencephalic Subarachnoid Hemorrhage.
Bele, S; Dettmer, K; Eissnert, C; Graf, B; Gruber, M; Kieninger, M; Knott, I; Oefner, PJ; Tuemmler, S; Wendl, C, 2019
)
0.94
" Hypotension was mostly responsible for dosing change or discontinuation."( Poor Utilization of Nimodipine in Aneurysmal Subarachnoid Hemorrhage.
Clark, SL; Hajizadeh Barfejani, A; Rabinstein, AA; Wijdicks, EFM, 2019
)
0.84
" Nimodipine prophylaxis duration and dosage and the incidence of DCI were recorded."( Does Nimodipine Interruption due to High Catecholamine Doses Lead to a Greater Incidence of Delayed Cerebral Ischemia in the Setting of Aneurysmal Subarachnoid Hemorrhage?
Hernández-Durán, S; Malinova, V; Mielke, D; Rohde, V, 2019
)
1.94
" However, the impact of alternative dosing strategies on outcome remains unclear."( Safety of Modified Nimodipine Dosing in Aneurysmal Subarachnoid Hemorrhage.
Blake, C; Dai, X; Furie, KL; Mahmoud, L; Mahta, A; Reznik, ME; Thompson, BB; Wendell, LC; Zullo, AR, 2022
)
1.05
" Univariable and multivariable modified Poisson regression models were used to identify predictors of using modified nimodipine dosing (30 mg every 2 hours) versus standard dosing (60 mg every 4 hours)."( Safety of Modified Nimodipine Dosing in Aneurysmal Subarachnoid Hemorrhage.
Blake, C; Dai, X; Furie, KL; Mahmoud, L; Mahta, A; Reznik, ME; Thompson, BB; Wendell, LC; Zullo, AR, 2022
)
1.26
"Modified dosing of nimodipine is well tolerated and may not be associated with worse functional outcome."( Safety of Modified Nimodipine Dosing in Aneurysmal Subarachnoid Hemorrhage.
Blake, C; Dai, X; Furie, KL; Mahmoud, L; Mahta, A; Reznik, ME; Thompson, BB; Wendell, LC; Zullo, AR, 2022
)
1.38
" CONTENT: Nimodipine has been prescribed for patients with aSAH; however, little is known about factors to consider regarding dosing or patient-specific variables that may affect tolerability to nimodipine."( Nimodipine in Clinical Practice: A Pharmacological Update.
Aiyagari, V; Clough, B; Griffin, T; Gunter, E; Tenii, J; Wee, C, 2022
)
2.57
" However, 4-hourly dosing is a practical limitation and verapamil has been proposed as an alternative."( Verapamil in the treatment of reversible cerebral vasoconstriction syndrome: A systematic review.
Bacchi, S; Bagster, M; Collins, L; Goh, R; Gupta, A; Kleinig, O; Kleinig, T; Kovoor, J; Lam, L; Proudman, W; Schultz, D; Zhang, R, 2023
)
0.91
" The most common oral verapamil dosing regimen was controlled release 120 mg once daily."( Verapamil in the treatment of reversible cerebral vasoconstriction syndrome: A systematic review.
Bacchi, S; Bagster, M; Collins, L; Goh, R; Gupta, A; Kleinig, O; Kleinig, T; Kovoor, J; Lam, L; Proudman, W; Schultz, D; Zhang, R, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
calcium channel blockerOne of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools.
vasodilator agentA drug used to cause dilation of the blood vessels.
cardiovascular drugA drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
dihydropyridine
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
diesterA diester is a compound containing two ester groups.
dicarboxylic acids and O-substituted derivativesA class of carbonyl compound encompassing dicarboxylic acids and any derivatives obtained by substitution of either one or both of the carboxy hydrogens.
2-methoxyethyl esterA carboxylic ester resulting from the formal condensation between a carboxylic acid and the hydroxy group of 2-methoxyethanol. In contrast to many other water-solubilising esters, the 2-methoxyethyl esters of many amino acids are crystalline, allowing them to be easily purified.
isopropyl esterAny carboxylic ester resulting from the formal condensation of a carboxylic acid with the hydroxy group of propan-2-ol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Nimodipine Action Pathway478

Protein Targets (93)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.54810.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency16.20650.044717.8581100.0000AID485294; AID485341
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID2323
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
endonuclease IVEscherichia coliPotency11.22020.707912.432431.6228AID1708
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency17.05350.100020.879379.4328AID488772; AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency11.57980.004110.890331.5287AID493107; AID504467
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency3.16230.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency24.22820.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency28.39130.000221.22318,912.5098AID1259243; AID743035; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency10.66120.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency24.08440.000417.946075.1148AID1346784; AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency0.53230.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.23020.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency28.79680.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.39140.000214.376460.0339AID720692
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency21.57240.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency29.84700.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency0.94390.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.84930.000229.305416,493.5996AID743079
GVesicular stomatitis virusPotency0.54950.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency13.80290.00108.379861.1304AID1645840
ParkinHomo sapiens (human)Potency2.05960.819914.830644.6684AID720572
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency59.62170.707936.904389.1251AID504333
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency13.33220.023723.228263.5986AID743222
arylsulfatase AHomo sapiens (human)Potency0.47751.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency47.21320.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency3.20470.000723.06741,258.9301AID743085; AID743122
Bloom syndrome protein isoform 1Homo sapiens (human)Potency17.78280.540617.639296.1227AID2364; AID2528
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency75.686323.934123.934123.9341AID1967
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency44.66840.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency17.78280.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency18.83360.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency25.85710.000627.21521,122.0200AID743202; AID743219
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency50.11870.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency22.87410.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency8.51400.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency16.13660.005612.367736.1254AID624032
M-phase phosphoprotein 8Homo sapiens (human)Potency28.18380.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency6.65300.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency1.58490.015812.3113615.5000AID1461
Interferon betaHomo sapiens (human)Potency0.54950.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.54950.01238.964839.8107AID1645842
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency56.23413.981146.7448112.2020AID720708
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.54950.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.54950.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1CCavia porcellus (domestic guinea pig)IC50 (µMol)0.11000.02201.64228.9000AID1207677
Voltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)IC50 (µMol)14.00000.03700.89152.5000AID1612587
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)14.00000.00032.63119.0000AID1612587
Voltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)IC50 (µMol)14.00000.03201.04793.6000AID1612587
Bile salt export pumpHomo sapiens (human)IC50 (µMol)92.70000.11007.190310.0000AID1443980; AID1443986; AID1473738
Adenosine receptor A3Homo sapiens (human)Ki8.47000.00000.930610.0000AID34564
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)2.19000.00002.800510.0000AID1210069; AID625248
Cannabinoid receptor 1Homo sapiens (human)IC50 (µMol)1.73600.00010.275310.0000AID625235
Cannabinoid receptor 1Homo sapiens (human)Ki1.37100.00010.50779.6000AID625235
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki44.30000.00021.494010.0000AID33788
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)4.00000.00002.398310.0000AID625247
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)3.38000.01202.53129.4700AID1210069
Voltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)IC50 (µMol)7.01490.02980.06990.1100AID1612587; AID1912088
Voltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)IC50 (µMol)14.00000.04004.113710.0000AID1612587
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)14.00000.00032.59559.0000AID1612587
Voltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)IC50 (µMol)14.00000.11000.11000.1100AID1612587
Voltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)IC50 (µMol)7.01490.02980.02980.0298AID1612587; AID1912088
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)7.15000.00001.146310.0000AID1912099
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)14.00000.00032.63119.0000AID1612587
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)4.71330.00032.25459.6000AID1207677; AID1612587; AID1912088
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)IC50 (µMol)1.24300.23001.98149.0000AID1912032
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Bile acid receptorHomo sapiens (human)IC50 (µMol)8.96000.01834.560310.0000AID755454
Voltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)IC50 (µMol)14.00000.08600.65472.5000AID1612587
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)13.70000.00401.966610.0000AID1873206
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)0.39000.00203.519610.0000AID755445
Transient receptor potential cation channel subfamily A member 1Mus musculus (house mouse)EC50 (µMol)0.80000.40002.771410.0000AID482149
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (348)

Processvia Protein(s)Taxonomy
gamma-aminobutyric acid signaling pathwayVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
adult walking behaviorVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
negative regulation of cell population proliferationVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
gamma-aminobutyric acid secretionVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
neuronal action potential propagationVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
synaptic transmission, glutamatergicVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
cAMP metabolic processVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
spleen developmentVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
thymus developmentVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
Peyer's patch developmentVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
T cell receptor signaling pathwayVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
muscle cell developmentVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
regulation of voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
positive regulation of protein localization to nucleolusVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
cellular response to leukemia inhibitory factorVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycleVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
regulation of synaptic vesicle exocytosisVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
chemical synaptic transmissionVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
modulation of chemical synaptic transmissionVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
response to amyloid-betaVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
cellular response to amyloid-betaVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
chemical synaptic transmissionVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
sinoatrial node developmentVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
chemical synaptic transmissionVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
response to nickel cationVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
regulation of membrane potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
calcium ion importVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
SA node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
AV node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
SA node cell to atrial cardiac muscle cell signalingVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
AV node cell to bundle of His cell signalingVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
protein targetingVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
calcium ion transportVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
protein localizationVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
regulation of AMPA receptor activityVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
transmission of nerve impulseVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
neurotransmitter receptor internalizationVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
neurotransmitter receptor transport, postsynaptic endosome to lysosomeVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
postsynaptic neurotransmitter receptor diffusion trappingVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
muscle contractionVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
muscle organ developmentVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
myoblast fusionVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
regulation of heart contractionVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
aldosterone biosynthetic processVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
cellular response to hormone stimulusVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
cortisol biosynthetic processVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
cellular response to potassium ionVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
regulation of membrane potentialVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
calcium ion importVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
inorganic cation transmembrane transportVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
positive regulation of acrosome reactionVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
positive regulation of acute inflammatory response to antigenic stimulusCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
spermatogenesisCannabinoid receptor 1Homo sapiens (human)
axonal fasciculationCannabinoid receptor 1Homo sapiens (human)
response to nutrientCannabinoid receptor 1Homo sapiens (human)
memoryCannabinoid receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentCannabinoid receptor 1Homo sapiens (human)
negative regulation of serotonin secretionCannabinoid receptor 1Homo sapiens (human)
positive regulation of fever generationCannabinoid receptor 1Homo sapiens (human)
negative regulation of fatty acid beta-oxidationCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, GABAergicCannabinoid receptor 1Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 1Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 1Homo sapiens (human)
negative regulation of dopamine secretionCannabinoid receptor 1Homo sapiens (human)
response to nicotineCannabinoid receptor 1Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 1Homo sapiens (human)
response to cocaineCannabinoid receptor 1Homo sapiens (human)
glucose homeostasisCannabinoid receptor 1Homo sapiens (human)
positive regulation of apoptotic processCannabinoid receptor 1Homo sapiens (human)
response to ethanolCannabinoid receptor 1Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 1Homo sapiens (human)
negative regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
positive regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
regulation of insulin secretionCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCannabinoid receptor 1Homo sapiens (human)
maternal process involved in female pregnancyCannabinoid receptor 1Homo sapiens (human)
regulation of feeding behaviorCannabinoid receptor 1Homo sapiens (human)
regulation of penile erectionCannabinoid receptor 1Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoidCannabinoid receptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationCannabinoid receptor 1Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
T cell receptor signaling pathwayVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
protein localization to plasma membraneVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
regulation of membrane repolarization during action potentialVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
positive regulation of high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
chemical synaptic transmissionVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
regulation of voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
calcium ion transportVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
regulation of calcium ion transportVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
calcium ion transport into cytosolVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
membrane depolarization during bundle of His cell action potentialVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
regulation of membrane repolarization during action potentialVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
positive regulation of high voltage-gated calcium channel activityVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
cellular response to amyloid-betaVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
calcium ion transportVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
regulation of mRNA stabilityVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
positive regulation of dendrite extensionVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
regulation of AMPA receptor activityVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
neurotransmitter receptor internalizationVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
postsynaptic neurotransmitter receptor diffusion trappingVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
neurotransmitter receptor transport, postsynaptic endosome to lysosomeVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
transmission of nerve impulseVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
modulation of chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
response to amyloid-betaVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
chemical synaptic transmissionVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
cellular response to amyloid-betaVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
regulation of voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
chemical synaptic transmissionVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
positive regulation of muscle contractionVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
establishment of localization in cellVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
sarcoplasmic reticulum calcium ion transportVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
protein localization to plasma membraneVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
positive regulation of high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
regulation of voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
chemical synaptic transmissionVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-5 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of heart contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
establishment of endothelial barriercAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent R-type calcium channel subunit alpha-1EHomo sapiens (human)
chemical synaptic transmissionVoltage-dependent R-type calcium channel subunit alpha-1EHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent calcium channel subunit alpha-2/delta-4Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent calcium channel subunit alpha-2/delta-4Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent calcium channel subunit alpha-2/delta-3Homo sapiens (human)
calcium ion transportVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
regulation of AMPA receptor activityVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
postsynaptic neurotransmitter receptor diffusion trappingVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
neurotransmitter receptor internalizationVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
neurotransmitter receptor transport, postsynaptic endosome to lysosomeVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
transmission of nerve impulseVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodelingBile acid receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionBile acid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoterBile acid receptorHomo sapiens (human)
intracellular glucose homeostasisBile acid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
inflammatory responseBile acid receptorHomo sapiens (human)
cell-cell junction assemblyBile acid receptorHomo sapiens (human)
Notch signaling pathwayBile acid receptorHomo sapiens (human)
bile acid metabolic processBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBile acid receptorHomo sapiens (human)
regulation of low-density lipoprotein particle clearanceBile acid receptorHomo sapiens (human)
intracellular receptor signaling pathwayBile acid receptorHomo sapiens (human)
negative regulation of type II interferon productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-1 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-2 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-6 productionBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionBile acid receptorHomo sapiens (human)
positive regulation of interleukin-17 productionBile acid receptorHomo sapiens (human)
toll-like receptor 9 signaling pathwayBile acid receptorHomo sapiens (human)
regulation of urea metabolic processBile acid receptorHomo sapiens (human)
intracellular triglyceride homeostasisBile acid receptorHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
bile acid signaling pathwayBile acid receptorHomo sapiens (human)
intracellular bile acid receptor signaling pathwayBile acid receptorHomo sapiens (human)
cholesterol homeostasisBile acid receptorHomo sapiens (human)
defense response to bacteriumBile acid receptorHomo sapiens (human)
negative regulation of apoptotic processBile acid receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionBile acid receptorHomo sapiens (human)
innate immune responseBile acid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayBile acid receptorHomo sapiens (human)
fatty acid homeostasisBile acid receptorHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
regulation of bile acid biosynthetic processBile acid receptorHomo sapiens (human)
cellular response to lipopolysaccharideBile acid receptorHomo sapiens (human)
cellular response to fatty acidBile acid receptorHomo sapiens (human)
cellular response to organonitrogen compoundBile acid receptorHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionBile acid receptorHomo sapiens (human)
regulation of cholesterol metabolic processBile acid receptorHomo sapiens (human)
cellular response to bile acidBile acid receptorHomo sapiens (human)
positive regulation of adipose tissue developmentBile acid receptorHomo sapiens (human)
positive regulation of phosphatidic acid biosynthetic processBile acid receptorHomo sapiens (human)
positive regulation of glutamate metabolic processBile acid receptorHomo sapiens (human)
positive regulation of ammonia assimilation cycleBile acid receptorHomo sapiens (human)
cell differentiationBile acid receptorHomo sapiens (human)
negative regulation of inflammatory responseBile acid receptorHomo sapiens (human)
calcium ion transportVoltage-dependent calcium channel gamma-6 subunitHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent calcium channel gamma-6 subunitHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent calcium channel gamma-6 subunitHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent calcium channel subunit alpha-2/delta-2Homo sapiens (human)
organ growthVoltage-dependent calcium channel subunit alpha-2/delta-2Homo sapiens (human)
regulation of multicellular organism growthVoltage-dependent calcium channel subunit alpha-2/delta-2Homo sapiens (human)
positive regulation of organ growthVoltage-dependent calcium channel subunit alpha-2/delta-2Homo sapiens (human)
muscle cell developmentVoltage-dependent calcium channel subunit alpha-2/delta-2Homo sapiens (human)
rhythmic synaptic transmissionVoltage-dependent calcium channel subunit alpha-2/delta-2Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent calcium channel subunit alpha-2/delta-2Homo sapiens (human)
signal transductionVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
neuronal action potentialVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
sleepVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
response to cocaineVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
regulation of AMPA receptor activityVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
transmission of nerve impulseVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
neurotransmitter receptor internalizationVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
neurotransmitter receptor transport, postsynaptic endosome to lysosomeVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
postsynaptic neurotransmitter receptor diffusion trappingVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
regulation of AMPA receptor activityVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
postsynaptic neurotransmitter receptor diffusion trappingVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
neurotransmitter receptor transport, postsynaptic endosome to lysosomeVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
neurotransmitter receptor internalizationVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
transmission of nerve impulseVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein targeting to membraneVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
response to calcium ionVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
membrane depolarizationVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
membrane hyperpolarizationVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
eye blink reflexVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
neurotransmitter receptor localization to postsynaptic specialization membraneVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
positive regulation of protein localization to basolateral plasma membraneVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
regulation of AMPA receptor activityVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
neurotransmitter receptor internalizationVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
postsynaptic neurotransmitter receptor diffusion trappingVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
neurotransmitter receptor transport, postsynaptic endosome to lysosomeVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
transmission of nerve impulseVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (133)

Processvia Protein(s)Taxonomy
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
protein kinase bindingVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levelsVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
amyloid-beta bindingVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
protein bindingVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
syntaxin bindingVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
metal ion bindingVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
low voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
scaffold protein bindingVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
PDZ domain bindingVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
ionotropic glutamate receptor bindingVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
channel regulator activityVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
voltage-gated monoatomic ion channel activityVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
protein bindingVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
low voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
metal ion bindingVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
scaffold protein bindingVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 1Homo sapiens (human)
identical protein bindingCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor activityCannabinoid receptor 1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
calcium channel regulator activityVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
voltage-gated calcium channel activity involved in bundle of His cell action potentialVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
metal ion bindingVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
calcium channel regulator activityVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
protein bindingVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
channel regulator activityVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
amyloid-beta bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
calcium ion bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
protein bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
ATP bindingVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
calcium channel regulator activityVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
protein bindingVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
actin filament bindingVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levelsVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
enzyme bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
signaling receptor regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
beta-2 adrenergic receptor bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
ATPase bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
scaffold protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
heterocyclic compound bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent R-type calcium channel subunit alpha-1EHomo sapiens (human)
calcium ion bindingVoltage-dependent R-type calcium channel subunit alpha-1EHomo sapiens (human)
voltage-gated monoatomic cation channel activityVoltage-dependent R-type calcium channel subunit alpha-1EHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent R-type calcium channel subunit alpha-1EHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel subunit alpha-2/delta-4Homo sapiens (human)
metal ion bindingVoltage-dependent calcium channel subunit alpha-2/delta-4Homo sapiens (human)
metal ion bindingVoltage-dependent calcium channel subunit alpha-2/delta-3Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel subunit alpha-2/delta-3Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
calcium channel regulator activityVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
channel regulator activityVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
transcription coregulator bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activityBile acid receptorHomo sapiens (human)
nuclear receptor activityBile acid receptorHomo sapiens (human)
protein bindingBile acid receptorHomo sapiens (human)
zinc ion bindingBile acid receptorHomo sapiens (human)
nuclear receptor bindingBile acid receptorHomo sapiens (human)
bile acid bindingBile acid receptorHomo sapiens (human)
bile acid receptor activityBile acid receptorHomo sapiens (human)
sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
nuclear retinoid X receptor bindingBile acid receptorHomo sapiens (human)
chenodeoxycholic acid bindingBile acid receptorHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel gamma-6 subunitHomo sapiens (human)
calcium channel regulator activityVoltage-dependent calcium channel gamma-6 subunitHomo sapiens (human)
metal ion bindingVoltage-dependent calcium channel subunit alpha-2/delta-2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel subunit alpha-2/delta-2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
protein bindingVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
calcium channel regulator activityVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
ionotropic glutamate receptor bindingVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
channel regulator activityVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
monoatomic ion transmembrane transporter activityVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
channel regulator activityVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein bindingVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
ionotropic glutamate receptor bindingVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
channel regulator activityVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (88)

Processvia Protein(s)Taxonomy
cytosolVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
cytoplasmic side of plasma membraneVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
nuclear speckVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
presynapseVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
glutamatergic synapseVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit beta-4Homo sapiens (human)
nucleusVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
cytoplasmVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
plasma membraneVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
membraneVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
cell projectionVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
neuronal cell bodyVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
synapseVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
neuronal cell bodyVoltage-dependent P/Q-type calcium channel subunit alpha-1AHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
cytoplasmVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
synapseVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent T-type calcium channel subunit alpha-1GHomo sapiens (human)
plasma membraneVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
dendriteVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
endocytic vesicle membraneVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
somatodendritic compartmentVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
excitatory synapseVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
Schaffer collateral - CA1 synapseVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
glutamatergic synapseVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
AMPA glutamate receptor complexVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
postsynaptic density membraneVoltage-dependent calcium channel gamma-3 subunitHomo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
membraneVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent T-type calcium channel subunit alpha-1HHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
mitochondrial outer membraneCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
actin cytoskeletonCannabinoid receptor 1Homo sapiens (human)
growth coneCannabinoid receptor 1Homo sapiens (human)
presynaptic membraneCannabinoid receptor 1Homo sapiens (human)
membrane raftCannabinoid receptor 1Homo sapiens (human)
glutamatergic synapseCannabinoid receptor 1Homo sapiens (human)
GABA-ergic synapseCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
cytoplasmCannabinoid receptor 1Homo sapiens (human)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
cytosolVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
synapseVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit beta-3Homo sapiens (human)
plasma membraneVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
sarcoplasmic reticulumVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
extracellular exosomeVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
neuronal dense core vesicleVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent calcium channel subunit alpha-2/delta-1Homo sapiens (human)
early endosomeVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
plasma membraneVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
neuronal cell bodyVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
cerebellar mossy fiberVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
glutamatergic synapseVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
AMPA glutamate receptor complexVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
postsynaptic density membraneVoltage-dependent calcium channel gamma-7 subunitHomo sapiens (human)
plasma membraneVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
synapseVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
neuronal cell bodyVoltage-dependent N-type calcium channel subunit alpha-1BHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
synapseVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit beta-1Homo sapiens (human)
plasma membraneVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
T-tubuleVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
sarcolemmaVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent calcium channel gamma-1 subunitHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
photoreceptor ribbon synapseVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
presynapseVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit beta-2Homo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
apical plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
lysosomeCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
plasma membraneVoltage-dependent R-type calcium channel subunit alpha-1EHomo sapiens (human)
synapseVoltage-dependent R-type calcium channel subunit alpha-1EHomo sapiens (human)
neuronal cell bodyVoltage-dependent R-type calcium channel subunit alpha-1EHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent R-type calcium channel subunit alpha-1EHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent calcium channel subunit alpha-2/delta-4Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent calcium channel subunit alpha-2/delta-3Homo sapiens (human)
plasma membraneVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
postsynaptic densityVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
endocytic vesicle membraneVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
AMPA glutamate receptor complexVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
postsynaptic density membraneVoltage-dependent calcium channel gamma-8 subunitHomo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
nucleoplasmBile acid receptorHomo sapiens (human)
chromatinBile acid receptorHomo sapiens (human)
euchromatinBile acid receptorHomo sapiens (human)
receptor complexBile acid receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexBile acid receptorHomo sapiens (human)
nucleusBile acid receptorHomo sapiens (human)
plasma membraneVoltage-dependent calcium channel gamma-6 subunitHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent calcium channel gamma-6 subunitHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent calcium channel gamma-6 subunitHomo sapiens (human)
plasma membraneVoltage-dependent calcium channel subunit alpha-2/delta-2Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent calcium channel subunit alpha-2/delta-2Homo sapiens (human)
plasma membraneVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent T-type calcium channel subunit alpha-1IHomo sapiens (human)
plasma membraneVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
cell surfaceVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
endocytic vesicle membraneVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
somatodendritic compartmentVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
cell bodyVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
glutamatergic synapseVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
AMPA glutamate receptor complexVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
postsynaptic density membraneVoltage-dependent calcium channel gamma-4 subunitHomo sapiens (human)
glutamatergic synapseVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
postsynaptic densityVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
AMPA glutamate receptor complexVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
postsynaptic density membraneVoltage-dependent calcium channel gamma-5 subunitHomo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
cell surfaceVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
endocytic vesicle membraneVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
somatodendritic compartmentVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
cerebellar mossy fiberVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
Schaffer collateral - CA1 synapseVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
hippocampal mossy fiber to CA3 synapseVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
glutamatergic synapseVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
AMPA glutamate receptor complexVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
postsynaptic density membraneVoltage-dependent calcium channel gamma-2 subunitHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (321)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID1193498Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1301313Neuroprotective activity in hypoxic-ischemic neonatal Sprague-Dawley rat brain assessed as distribution of neurons in cortex at 1 mg/kg, ip administered 15 mins prior to examination measured after 48 hrs by hematoxylin/eosin staining based microscopic ana2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Protective effect of novel substituted nicotine hydrazide analogues against hypoxic brain injury in neonatal rats via inhibition of caspase.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID755450Partial agonist activity at human FXR expressed in african green monkey CV1 cells assessed as inhibition of CDCA-induced transactivation activity after 45 hrs by luciferase/beta-galactosidase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID366356Inhibition of potassium chloride-induced cytosolic calcium levels in human SH-SY5Y cells at 0.3 uM by fluorescence method relative to control2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties.
AID537139Cytotoxicity in BALB/c mouse erythrocytes assessed as hemolysis at 50 uM after 3 hrs2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID122704Anticonvulsant activity in the subcutaneous metrazole (scMet) screen test expressed as the number of animals protected to the number of animals tested; scMet at 100 mg/kg after 0.5 hrs; (0/1)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID537734Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID78018Calcium channel antagonist activity against carbachol-induced contractile response in guinea pig ileal longitudinal smooth muscle1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID1193494Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1210072Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID513626Induction of autophagy in rat stable inducible PC12 cells expressing A53T alpha-synuclein assessed as A53T alpha-synuclein clearance at 1 uM after 24 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID349879Antioxidant activity in human SH-SY5Y cells assessed as protection against H2O2-induced oxidative stress at 0.3 uM pretreated for 24 hrs before H2O2 challenge by lactate dehydrogenase assay relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID755447Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation at 2.5 uM after 16 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID467612Fraction unbound in human plasma2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID165388Antagonistic activity against 5-HT induced responses in rabbit basilar1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
New developments in Ca2+ channel antagonists.
AID122706Anticonvulsant activity in the subcutaneous metrazole (scMet) screen test expressed as the number of animals protected to the number of animals tested; scMet at 100 mg/kg after 4 hrs; (0/1)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID1210071Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1141989Antiapoptotic activity against serum deprivation-induced human SK-N-BE(2) cells assessed as viable cells at 10 uM after 36 hrs incubation by DePsipher agent relative to control2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
AID1232313Elimination half life in human2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID537733Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID620266Antagonist activity at voltage gated calcium channel in Sprague-Dawley rat striatal synaptoneurosomes assessed as inhibition of NMDA/glycine-induced calcium flux at 100 uM by spectrofluorimetric analysis relative to control2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID274655Viability of SH-SY5Y cells measured as neuroprotection activity in presence of hypertonic potassium at 0.3 uM relative to control2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID384296Blockade of high K+-induced increase in calcium uptake in human SH-SY5Y cells at 0.3 uM relative to control2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Synthesis of 6-amino-1,4-dihydropyridines that prevent calcium overload and neuronal death.
AID1141991Inhibition of NMDA receptor in Wistar rat brain synaptoneurosomes homogenate assessed as calcium flux at 100 uM after 30 mins incubation by Fura-2/AM assay2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1275775Selectivity index, ratio of IC50 for CHO cells to IC50 for chloroquine sensitive Plasmodium falciparum NF542016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Polycyclic amines as chloroquine resistance modulating agents in Plasmodium falciparum.
AID1210074Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID537137Selectivity index, ratio of IC50 for rhesus monkey LLC-MK2 cells to IC50 for amastigotes of Leishmania chagasi MHOM/BR/1972/LD2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID21233Partition coefficient of compound in to biological membranes1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1579018Anti-anoxic activity in rat PC12 cells reduction in assessed as sodium hydrosulfite-induced cell injury2019Journal of natural products, 07-26, Volume: 82, Issue:7
Naturally Occurring Lumazines.
AID1754610Inhibition of Ca2+ channel in mouse microglial cells assessed as inhibition of Abeta-stimulated NLRP3 inflammasome activation-mediated IL-1beta release at 36 nM by ELISA2021Bioorganic & medicinal chemistry letters, 08-15, Volume: 46Discovery of dronedarone and its analogues as NLRP3 inflammasome inhibitors with potent anti-inflammation activity.
AID537736Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID21234Partition coefficient of compound in to octanol/buffer1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
AID122696Anticonvulsant activity in the maximal electroshock (MES) screen test expressed as the number of animals protected to the number of animals tested; MES at 300 mg/kg after 0.5 hrs; (0/1)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1912088Inhibition of human alpha1c/beta2a/alpha2delta1 Cav1.2 expressed in HEK293 cells assessed as Ca2+ current at -80 mV holding potential by patch clamp technique2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID384299Neuroprotective activity against human SH-SY5Y cells assessed as reduction in H2O2-induced LDH release at 0.3 uM relative to control2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Synthesis of 6-amino-1,4-dihydropyridines that prevent calcium overload and neuronal death.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1741559Antagonist activity at NMDA receptor in human SH-SY5Y cells assessed as inhibition of calcium influx at 10 uM by Fura-2AM dye based fluorescence analysis relative to control2020European journal of medicinal chemistry, Oct-15, Volume: 204Open and rearranged norbornane derived polycyclic cage molecules as potential neuroprotective agents through attenuation of MPP
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1275774Cytotoxicity against CHO cells by MTT assay2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Polycyclic amines as chloroquine resistance modulating agents in Plasmodium falciparum.
AID274656Viability of SH-SY5Y cells measured as reduction in H2O2-induced LDH release at 0.3 uM relative to control2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1220557Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1193499Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID639486Neuroprotective activity against FPL64176-induced toxicity in human SH-SY5Y cells assessed as increase in cell viability at 3 uM treated 24 hrs before FPL64176 challenge measured after 24 hrs by MTT assay relative to control2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
AID1232307Lipophilicity, log P of the compound2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID1141990Inhibition of voltage gated calcium channel in Wistar rat brain synaptoneurosomes homogenate assessed as intracellular calcium at 100 uM after 30 mins incubation by Fura-2/AM assay2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID274657Viability of SH-SY5Y cells measured as neuroprotection activity in presence of H2O2 at 0.3 uM relative to control2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID604207Antagonist activity at VGCC in Sprague-Dawley rat brain synaptoneurosomes assessed as inhibition of Kcl-induced calcium flux at 100 uM after 5 mins using FURA-2AM by fluorescent spectrometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID1488339Cytoprotection against oxygen-glucose deprivation/reperfusion-induced cell death in human SH-SY5Y cells assessed as decrease in cleaved caspase-3 level at 100 umol/L pretreated for 24 hrs followed by oxygen-glucose deprivation for 10 hrs and reperfusion f2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
20(R)-Ginsenoside Rg3 protects SH-SY5Y cells against apoptosis induced by oxygen and glucose deprivation/reperfusion.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID537138Selectivity index, ratio of IC50 for rhesus monkey LLC-MK2 cells to IC50 for trypomastigotes of Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID604209Inhibition of nNOS in Sprague-Dawley rat brain homogenates assessed as conversion of oxyhemoglobin to methemoglobin measured for 10 mins by UV-visible spectrophotometer analysis2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID1386653Neuroprotective activity against glutamate-induced cell damage in rat PC12 cells assessed as increase in cell viability at 10 uM pretreated followed by glutamate challenge and measured after 24 hrs by MTT assay2018Journal of natural products, 09-28, Volume: 81, Issue:9
Absolute Configurations and Bioactivities of Guaiane-Type Sesquiterpenoids Isolated from Pogostemon cablin.
AID384297Neuroprotective activity against human SH-SY5Y cells assessed as reduction in K+-induced LDH release at 0.3 uM relative to control2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Synthesis of 6-amino-1,4-dihydropyridines that prevent calcium overload and neuronal death.
AID1275776Antiplasmodial activity against multidrug resistant Plasmodium falciparum Dd2 by spectroscopic method2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Polycyclic amines as chloroquine resistance modulating agents in Plasmodium falciparum.
AID681353TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in F4-6RADR cells1992Biochemical pharmacology, Jun-23, Volume: 43, Issue:12
Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID366582Neuroprotective effect against human SH-SY5Y cells assessed as extracellular LDH release at 0.3 uM after 24 hrs in presence of 60 uM H2O22008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties.
AID513627Induction of autophagy in rat stable inducible PC12 cells expressing EGFP-HDQ74 assessed as soluble EGFP-HDQ74 clearance at 1 uM after 96 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1533827Antagonist activity at NMDA receptor in human SH-SY5Y cells assessed as reduction in NMDA/glycine-stimulated calcium influx at 10 uM preincubated for 30 mins in presence of Mag-Fura-2/AM dye followed by NMDA/glycine stimulation and measured over 35 secs b2019European journal of medicinal chemistry, Feb-01, Volume: 163Design, synthesis and evaluation of pentacycloundecane and hexacycloundecane propargylamine derivatives as multifunctional neuroprotective agents.
AID1220560Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1857768Neuroprotective activity in retinoic acid and cAMP differentiated mouse HT-22 cells assessed as decrease in glutamate induced cellular ROS level at 2 ug/ml incubated for 1 hrs by DCFH-DA based fluorescent microscopy2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Selective
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID537135Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID537131Antileishmanial activity against amastigotes of Leishmania chagasi MHOM/BR/1972/LD after 24 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1220555Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID537136Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID1301317Neuroprotective activity in hypoxic-ischemic Sprague-Dawley rat brain assessed as regular shape of nucleus at 1 mg/kg, ip administered 15 mins prior to examination measured after 48 hrs by electron microscopic analysis2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Protective effect of novel substituted nicotine hydrazide analogues against hypoxic brain injury in neonatal rats via inhibition of caspase.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID274653Antagonist activity at calcium channel expressed in SH-SY5Y cells assessed as blockade of potassium-induced calcium influx increase at 0.3 uM relative to control2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID31706Displacement of [3H](R)-PIA binding to Adenosine A1 receptor in rat brain membranes1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1301311Neuroprotective activity in hypoxic-ischemic neonatal Sprague-Dawley rat brain assessed as reduction brain infarction at 1 mg/kg, ip administered 15 mins prior to examination by microscopic analysis2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Protective effect of novel substituted nicotine hydrazide analogues against hypoxic brain injury in neonatal rats via inhibition of caspase.
AID620265Antagonist activity at voltage gated calcium channel in Sprague-Dawley rat striatal synaptoneurosomes assessed as inhibition of KCl-induced calcium flux at 100 uM by spectrofluorimetric analysis relative to control2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands.
AID513629Cytotoxicity against human SK-N-MC cells expressing EGFP-HDQ74 at 1 uM after 48 hrs2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1193496Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1220559Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1220556Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1461775Antagonist activity at New Zealand rabbit L-type calcium channel assessed as dilation of K+-depolarization induced basilary artery contraction measured after 20 mins
AID1488346Cytoprotection against oxygen-glucose deprivation/reperfusion-induced cell death in human SH-SY5Y cells assessed as increase in Bcl2 m-RNA expression at 100 umol/L pretreated for 24 hrs followed by oxygen-glucose deprivation for 10 hrs and reperfusion for2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
20(R)-Ginsenoside Rg3 protects SH-SY5Y cells against apoptosis induced by oxygen and glucose deprivation/reperfusion.
AID29360Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1204005Neuroprotective activity against H2O2 -mediated injury in rat PC12 cells assessed as cell survival at 1 uM relative to control2015Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11
Design, synthesis and biological evaluation of pyridazino[3,4,5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors.
AID122697Anticonvulsant activity in the maximal electroshock (MES) screen test expressed as the number of animals protected to the number of animals tested; MES at 300 mg/kg after 4 hrs; (1/1)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1193500Thermodynamic equilibrium solubility, log S of the compound2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1275777Antiplasmodial activity against chloroquine sensitive Plasmodium falciparum NF54 by spectroscopic method2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Polycyclic amines as chloroquine resistance modulating agents in Plasmodium falciparum.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409942Inhibition of human recombinant MAOA by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1361155Inhibition of recombinant human AChE expressed in HEK293 cells using acetylthiocholine as substrate pretreated for 20 mins followed by substrate addition by Ellman's method2018European journal of medicinal chemistry, Jul-15, Volume: 155Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID101854Compound was tested for percent of fraction inhibition by anti-P-450 NF.1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450.
AID349878Neuroprotective activity in human SH-SY5Y cells assessed as protection against KCl-induced cell death at 0.3 uM pretreated for 24 hrs before KCl challenge by lactate dehydrogenase assay relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID384300Neuroprotective activity against calcium overload-induced cell death in human SH-SY5Y cells at 0.3 uM in presence of H2O2 relative to control2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Synthesis of 6-amino-1,4-dihydropyridines that prevent calcium overload and neuronal death.
AID1210073Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID384298Neuroprotective activity against calcium overload-induced cell death in human SH-SY5Y cells at 0.3 uM in presence of K+ relative to control2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Synthesis of 6-amino-1,4-dihydropyridines that prevent calcium overload and neuronal death.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1612586Inhibition of K+-induced voltage gated calcium channel opening in human SH-SY5Y cells assessed as decrease in Ca2+ level at 10 uM after 10 mins by Fluo-4 dye-based fluorescence assay relative to control2019European journal of medicinal chemistry, Feb-01, Volume: 163Polycyclic maleimide-based derivatives as first dual modulators of neuronal calcium channels and GSK-3β for Alzheimer's disease treatment.
AID1912099Inhibition of PDE4D (unknown origin) expressed in Escherichia coli BL21 [3H]-cAMP as substrate measured for 15 mins by liquid scintillation counter method2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.
AID1275779Inhibition of voltage-gated calcium channel in Wistar rat synaptoneurosomes after 30 mins by fluorescent ratiometric indicator method2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Polycyclic amines as chloroquine resistance modulating agents in Plasmodium falciparum.
AID165391Antagonistic activity against K+ induced responses in rabbit saphenous1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
New developments in Ca2+ channel antagonists.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID17662Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
AID478864Selectivity ratio of IC50 for Cav1.2 to IC50 for Cav1.32010Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9
Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1207676Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1193495Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1361160Inhibition of L-type voltage gated calcium channel in human SH-SY5Y cells assessed as blockade of K+-evoked calcium uptake at 1 uM pretreated for 10 mins followed by KCl/CaCl2 addition and measured for 55 secs by Fluo-4AM dye based fluorescence assay rela2018European journal of medicinal chemistry, Jul-15, Volume: 155Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1361156Inhibition of recombinant human serum BChE using butyrylthiocholine as substrate pretreated for 20 mins followed by substrate addition by Ellman's method2018European journal of medicinal chemistry, Jul-15, Volume: 155Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1912032Inhibition of PDE1C (147 to 531 residues) (unknown origin) expressed in Escherichia coli BL21 using [3H]-cGMP as substrate measured for 15 mins by liquid scintillation counter method2022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1232312Clearance in human2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID101858Rate of Oxidation in human liver microsomes is measured as mean (nmol product) formed / min per nmol cytochrome P-4501986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450.
AID1354700Neuroprotective activity against glutamate-induced neuronal cell death in rat PC12 cells assessed as increase in cell viability pretreated for 2 hrs followed by glutamate challenge measured after 24 hrs by MTT assay2018Journal of natural products, 06-22, Volume: 81, Issue:6
Sesquiterpenoids from Chloranthus anhuiensis with Neuroprotective Effects in PC12 Cells.
AID1488314Cytoprotection against oxygen-glucose deprivation/reperfusion-induced cell death in human SH-SY5Y cells assessed as reduction in LDH leakage at 100 umol/L pretreated for 24 hrs followed by oxygen-glucose deprivation for 10 hrs and reperfusion for 24 hrs2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
20(R)-Ginsenoside Rg3 protects SH-SY5Y cells against apoptosis induced by oxygen and glucose deprivation/reperfusion.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1873206Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells assessed as reversal of BCRP-mediated mitoxantrone resistance and measured after 90 mins by FACSflow cytometry analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID467613Volume of distribution at steady state in human2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
AID1220558Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID482149Agonist activity at mouse TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium influx2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID18735Partition coefficient; Kp = concentration of test compound in n-octanol/concentration of the test compound in phosphate buffer (pH 7.4)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID165387Antagonistic activity against 5-HT in rabbit saphenous1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
New developments in Ca2+ channel antagonists.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1612587Inhibition of K+-induced voltage gated calcium channel opening in human SH-SY5Y cells assessed as decrease in Ca2+ level after 10 mins by Fluo-4 dye-based fluorescence assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Polycyclic maleimide-based derivatives as first dual modulators of neuronal calcium channels and GSK-3β for Alzheimer's disease treatment.
AID1301324Neuroprotective activity in hypoxic-ischemic neonatal Sprague-Dawley rat brain assessed as inhibition of elevated caspase 3 expression levels at 1 mg/kg, ip administered 15 mins prior to examination measured after 48 hrs by Western blot analysis2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Protective effect of novel substituted nicotine hydrazide analogues against hypoxic brain injury in neonatal rats via inhibition of caspase.
AID1141992Inhibition of MAO-B in baboon liver mitochondrial fraction using MPTP substrate at 300 uM2014European journal of medicinal chemistry, Jun-10, Volume: 80Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents.
AID755445Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID537130Antileishmanial activity against promastigotes of Leishmania chagasi MHOM/BR/1972/LD after 18 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID34564Displacement of [125]AB-MECA binding to human Adenosine A3 receptor expressed in HEK cells1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID537132Antileishmanial activity against promastigotes of Leishmania amazonensis WHO/BR/00/LT0016 after 18 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID366580Neuroprotective effect against human SH-SY5Y cells assessed as extracellular LDH release at 0.3 uM after 24 hrs in presence of 70 mM K+2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties.
AID366581Neuroprotective effect against human SH-SY5Y cells assessed as extracellular LDH release at 0.3 uM after 24 hrs in presence of 70 mM K+ relative to basal level2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties.
AID122693Anticonvulsant activity in the maximal electroshock (MES) screen test expressed as the number of animals protected to the number of animals tested; MES at 100 mg/kg after 0.5 hrs; (0/3)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID122695Anticonvulsant activity in the maximal electroshock (MES) screen test expressed as the number of animals protected to the number of animals tested; MES at 100 mg/kg after 4 hrs; (1/3)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID274654Viability of SH-SY5Y cells measured as reduction in LDH release in presence of hypertonic potassium at 0.3 uM relative to control2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease.
AID755455Antagonist activity at human GTS-tagged FXR at 15 uM after 20 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1193497Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID1210070Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID227701Anticonvulsant activity; NC denotes that compound is not classified2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1301318Neuroprotective activity in hypoxic-ischemic Sprague-Dawley rat brain assessed as reduction in disruption of cell organelles at 1 mg/kg, ip administered 15 mins prior to examination measured after 48 hrs by electron microscopic analysis2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Protective effect of novel substituted nicotine hydrazide analogues against hypoxic brain injury in neonatal rats via inhibition of caspase.
AID1728786Neuroprotective activity in middle cerebral artery occlusion-induced Sprague-Dawley rat model of ischemia-reperfusion injury assessed as reduction in cerebral infarct volume at 1 mg/kg by TTC staining based microscopic analysis relative to control2021European journal of medicinal chemistry, Feb-15, Volume: 212Discovery of bardoxolone derivatives as novel orally active necroptosis inhibitors.
AID33788Displacement of [3H]-CGS- 21680 binding to Adenosine A2A receptor in rat striatal membranes1996Journal of medicinal chemistry, Jul-19, Volume: 39, Issue:15
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.
AID1741560Blockade of VGCC in human SH-SY5Y cells assessed as inhibition of membrane depolarisation-induced calcium influx at 10 uM by Fura-2AM dye based fluorescence analysis relative to control2020European journal of medicinal chemistry, Oct-15, Volume: 204Open and rearranged norbornane derived polycyclic cage molecules as potential neuroprotective agents through attenuation of MPP
AID604208Antagonist activity at NMDAR in Sprague-Dawley rat brain synaptoneurosomes assessed as inhibition of NMDA/glycine-induced calcium flux at 100 uM after 5 mins using FURA-2AM by fluorescent spectrometer analysis relative to control2011Bioorganic & medicinal chemistry, Jul-01, Volume: 19, Issue:13
Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID537134Antileishmanial activity against promastigotes of Leishmania braziliensis MHO/BR/75/M2903 after 18 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID537133Antileishmanial activity against promastigotes of Leishmania major MHOM/1L/80/Fredlin after 18 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Anti-leishmanial and anti-trypanosomal activities of 1,4-dihydropyridines: In vitro evaluation and structure-activity relationship study.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID165390Antagonistic activity against K+ induced responses in rabbit basilar.1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
New developments in Ca2+ channel antagonists.
AID1220554Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Species independence in brain tissue binding using brain homogenates.
AID1912100Selectivity ratio of IC50 for PDE4D (unknown origin) expressed in Escherichia coli BL21 to IC50 for PDE1C (147 to 531 residues) (unknown origin) expressed in Escherichia coli BL212022Journal of medicinal chemistry, 06-23, Volume: 65, Issue:12
Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects.
AID513628Induction of autophagy in human SK-N-MC cells expressing EGFP-HDQ74 assessed as reduction in EGFP-HDQ74 aggregation at 1 uM after 48 hrs by densitometric analysis2008Nature chemical biology, May, Volume: 4, Issue:5
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1193493Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID366583Neuroprotective effect against human SH-SY5Y cells assessed as extracellular LDH release at 0.3 uM after 24 hrs in presence of 60 uM H2O2 relative to basal level2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1488345Cytoprotection against oxygen-glucose deprivation/reperfusion-induced cell death in human SH-SY5Y cells assessed as decrease in Bax m-RNA expression at 100 umol/L pretreated for 24 hrs followed by oxygen-glucose deprivation for 10 hrs and reperfusion for 2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
20(R)-Ginsenoside Rg3 protects SH-SY5Y cells against apoptosis induced by oxygen and glucose deprivation/reperfusion.
AID1488337Cytoprotection against oxygen-glucose deprivation/reperfusion-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 100 umol/L pretreated for 24 hrs followed by oxygen-glucose deprivation for 10 hrs and reperfusion for 24 hrs2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
20(R)-Ginsenoside Rg3 protects SH-SY5Y cells against apoptosis induced by oxygen and glucose deprivation/reperfusion.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1207677Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID17659Equilibrium dissociation constant based on membrane concentration in rat smooth muscle1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1193492Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method2015Bioorganic & medicinal chemistry letters, Apr-01, Volume: 25, Issue:7
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
AID755454Antagonist activity at human GTS-tagged FXR after 20 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID349877Antagonist activity at voltage-dependent L-type calcium channel in human SH-SY5Y cells assessed as inhibition of KCl-induced increase in cytosolic calcium concentration at 0.3 uM pretreated for 10 mins before KCl challenge relative to control2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1301314Neuroprotective activity in hypoxic-ischemic neonatal Sprague-Dawley rat brain assessed as reduction in interstitial edema at 1 mg/kg, ip administered 15 mins prior to examination measured after 48 hrs by hematoxylin/eosin staining based microscopic analy2016Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13
Protective effect of novel substituted nicotine hydrazide analogues against hypoxic brain injury in neonatal rats via inhibition of caspase.
AID122707Anticonvulsant activity in the subcutaneous metrazole (scMet) screen test expressed as the number of animals protected to the number of animals tested; scMet at 300 mg/kg; (0/1)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID537735Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
AID1232310Volume of distribution at steady state in human2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID1443986Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID755453Agonist activity at human FXR expressed in african green monkey CV1 cells assessed as induction of transactivation activity after 45 hrs by luciferase/beta-galactosidase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1346660Rat Cav1.3 (Voltage-gated calcium channels)2001The Journal of biological chemistry, Oct-19, Volume: 276, Issue:42
Functional properties of Cav1.3 (alpha1D) L-type Ca2+ channel splice variants expressed by rat brain and neuroendocrine GH3 cells.
AID1346902Human Mineralocorticoid receptor (3C. 3-Ketosteroid receptors)2008Hypertension (Dallas, Tex. : 1979), Mar, Volume: 51, Issue:3
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.
AID1346660Rat Cav1.3 (Voltage-gated calcium channels)2001The Journal of neuroscience : the official journal of the Society for Neuroscience, Aug-15, Volume: 21, Issue:16
Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines.
AID1346664Rat Cav1.2 (Voltage-gated calcium channels)2001The Journal of neuroscience : the official journal of the Society for Neuroscience, Aug-15, Volume: 21, Issue:16
Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,748)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990502 (18.27)18.7374
1990's1016 (36.97)18.2507
2000's587 (21.36)29.6817
2010's482 (17.54)24.3611
2020's161 (5.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 79.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index79.41 (24.57)
Research Supply Index8.09 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index144.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (79.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials317 (10.80%)5.53%
Reviews198 (6.74%)6.00%
Case Studies155 (5.28%)4.05%
Observational8 (0.27%)0.25%
Other2,258 (76.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (33)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE) [NCT01220622]Phase 4656 participants (Anticipated)Interventional2010-10-31Recruiting
Acupuncture Combined With Nimodipine for Prevention of Post-stroke Dementia:a Randomized Controlled Trial [NCT06007573]40 participants (Actual)Interventional2021-02-01Completed
A Prospective, Randomized, Cntrolled, Multi-center Clinical Study on Efficacy and Safety of Infusion Therapy by Comparing Original Perfusor Line (Orange,Art No.8723017) With Original Perfusor Line (Black,Art No.8723010) in Pump Infusion. [NCT04309708]300 participants (Actual)Interventional2018-05-01Completed
Intraoperative Application of Nimodipine to the Facial and Cochlear Nerves During Vestibular Schwannoma Resection to Avoid Spasm-related Postoperative Facial Paralysis and Deafness - a Prospective Randomized Pilot Study [NCT04801953]Phase 230 participants (Anticipated)Interventional2021-05-04Recruiting
Determination of Cerebral Nimodipine Concentrations Following Oral, Intra-venous and Intra-arterial Administration - a Descriptive Pharmacokinetic/Pharmacodynamics Study [NCT04649398]30 participants (Anticipated)Observational2020-11-25Recruiting
Targeting Carbonic Anhydrase Mediated Coupling as a Novel Vasospasm Prophylaxis in Aneurysmal Sub Arachnoid Hemorrhage [NCT02165644]Phase 20 participants (Actual)Interventional2015-09-30Withdrawn(stopped due to The PI is leaving the University of Florida.)
A Randomized, Open-label, Single Dose, Two Formulation, Two Period, Double Cross Over Bioavailability Comparison Study of Two Types of Nimodipine Injections in Healthy Volunteers [NCT03794843]Early Phase 126 participants (Anticipated)Interventional2018-08-23Recruiting
StudY of Effect of Nimodipine and Acetaminophen on Postictal Symptoms After ECT [NCT04028596]Phase 234 participants (Actual)Interventional2019-12-05Completed
Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage [NCT02790632]Phase 3374 participants (Anticipated)Interventional2016-07-31Terminated(stopped due to DMC review concluded study has a low probability of meeting its primary endpoint)
Treatment of Depression Occurring in the Setting of Cerebrovascular Risk -- A Pilot Study [NCT00781326]Phase 49 participants (Actual)Interventional2008-08-31Terminated(stopped due to Final cost of study medication was significantly greater than initial estimate,)
The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life [NCT00814658]Phase 422 participants (Actual)Interventional2008-06-30Completed
A Phase 1, Randomized, Two-Period Crossover Study to Evaluate the Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules at Steady State in Healthy Male and Female Subjects [NCT05418348]Phase 158 participants (Actual)Interventional2021-08-26Completed
Multicenter, Controlled, Randomized, Safety and Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage [NCT02893826]Phase 16 participants (Actual)Interventional2016-09-30Terminated(stopped due to Based on DMC recommendation to discontinue EG-01-1962-03)
Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared With Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): a Prospective, Randomized Trial [NCT05995405]Phase 3100 participants (Anticipated)Interventional2023-10-20Recruiting
The Effect of Nimodipine in the Preoperative Period on the Onset of Postoperative Cognitive Dysfunction in Adults [NCT02537080]15 participants (Actual)Interventional2015-09-30Terminated(stopped due to higher POCD in nimodipine Group)
Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimod [NCT01893190]Phase 1/Phase 273 participants (Actual)Interventional2013-09-30Completed
Glutaminergic Agents for Cocaine Abuse [NCT00000280]Phase 10 participants Interventional1994-09-30Completed
Randomized, Double-Blind, Placebo-Controlled Trial of Nimodipine for the Neurological Manifestations of HIV-1 [NCT00000738]Phase 136 participants InterventionalCompleted
Using Nimodipine, a Calcium Channel Blocker, to Prevent the LH Surge and Ovulation in Women Undergoing Assisted Reproduction [NCT01551368]Phase 212 participants (Actual)Interventional2012-12-31Terminated(stopped due to small number of patients got recruited)
The Role of Deep Cerebral Vein Variation in Patients With Angiographic Negative Subarachnoid Hemorrhage [NCT04941846]296 participants (Anticipated)Observational2013-01-31Recruiting
RCVS: The Rational Approach to Diagnosis and Treatment [NCT03150524]Phase 40 participants (Actual)Interventional2017-07-01Withdrawn(stopped due to Failure to recruit patients meeting inclusion criteria.)
Noninvasive Assessment of Cerebral Oxygenation and Cardiac Function in Patients With Neurovascular Diseases [NCT02991157]25 participants (Actual)Observational2016-12-31Completed
An Open Label Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations [NCT01835665]Phase 18 participants (Actual)Interventional2013-03-31Completed
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]Phase 42,414 participants (Anticipated)Interventional2020-04-30Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
Nimodipine for Treating Acute Massive Cerebral Infarction: a Randomized, Double-blind, Controlled Clinical Study [NCT02248233]Phase 472 participants (Actual)Interventional2014-10-31Completed
High Dose Nimodipine Pharmacotherapy Adjunct [NCT00000332]Phase 20 participants Interventional1998-05-31Completed
[NCT00004399]2,000 participants Interventional1995-09-30Completed
Cognitive Effects of Nimodipine in Patients With Schizophrenia [NCT03671525]Early Phase 118 participants (Actual)Interventional2018-10-05Completed
Effectiveness of Calcium Channel Blockade for Organophosphorus and Carbamate Pesticide Poisoning - an Open, Pragmatic, 3-arm RCT Repurposing Two Widely Available Licensed Medicines [NCT03925025]Phase 33,243 participants (Anticipated)Interventional2020-12-11Recruiting
Using Nimodipine, a Calcium Channel Blocker, to Prevent LH Surge in Women Undergoing Controlled Ovarian Stimulation and Intrauterine Insemination: a Double-blinded, Randomized Controlled Study [NCT01672801]18 participants (Actual)Interventional2012-09-30Completed
Stellate Ganglion Block as Adjuvant Therapy to ca Channel Blocker in Prevention of Cerebrovascular Spasm in Traumatic Subarachnoid Hemorrhage [NCT04100824]Phase 240 participants (Actual)Interventional2020-01-11Completed
Pharmacological Mechanisms of Low-intensity Focused Ultrasound for Motor Cortex Neuroplasticity [NCT04923659]Early Phase 120 participants (Anticipated)Interventional2021-05-25Recruiting
Management of Cerebral Vascular Spasm in Posttraumatic Subarachnoid Hemorrhage Using Combination Therapy of Oral Nimodipine and Intravenous Milrinone: Randomized Clinical Trial [NCT05131867]Phase 230 participants (Actual)Interventional2021-11-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00781326 (1) [back to overview]Hamilton Depression Rating Scale (24 Item) [Phase I Primary Outcome]
NCT00814658 (10) [back to overview]Reaction Time for Face Recognition Test at Baseline, Week 8, and Week 24
NCT00814658 (10) [back to overview]Reaction Time for Simple Reaction Time Test at Baseline, Week 8, and Week 24
NCT00814658 (10) [back to overview]Reaction Time for Two-choice Reaction Time Test at Baseline, Week 8, and Week 24
NCT00814658 (10) [back to overview]Reaction Time for Word Recognition and Learning Test at Baseline, Week 8, and Week 24
NCT00814658 (10) [back to overview]The Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) at Baseline, Week 8, and Week 24
NCT00814658 (10) [back to overview]The Neuropsychiatric Inventory (NPI) at Baseline, Week 8, and Week 24
NCT00814658 (10) [back to overview]The Quality of Life Assessment for Caregivers of Patients With Alzheimer's Disease (QoL- AD) Total Scores at Baseline, Week 8, Week 24
NCT00814658 (10) [back to overview]The Quality of Life Assessment for Patients With Alzheimer's Disease (QoL- AD) Total Scores at Baseline, Week 8, Week 24
NCT00814658 (10) [back to overview]The Quality of Life Assessment for Patients With Alzheimer's Disease (QoL- AD) Total Scores, Based on the Caregiver's Opinion, at Baseline, Week 8, Week 24
NCT00814658 (10) [back to overview]The Clinical Global Impression (CGI) at Week 4, Week 8, Week 16, and Week 24
NCT01672801 (2) [back to overview]LH Surge
NCT01672801 (2) [back to overview]Number of Participants Experiencing Side Effects

Hamilton Depression Rating Scale (24 Item) [Phase I Primary Outcome]

Hamilton Depression Rating Scale (24 item) measures symptoms of major depression. We report total score which is the sum of all items. Total score range is 0 to 76 with higher scores indicating more severe depression. We reports scores at end of Phase I for subjects completing the phase. (NCT00781326)
Timeframe: End of Phase I (at 24 weeks)

Interventionunits on a scale (Mean)
Open Label Antidepressant9.5

[back to top]

Reaction Time for Face Recognition Test at Baseline, Week 8, and Week 24

The face recognition test is a computerized attention test in which ten unfamiliar faces were presented simultaneously on the computer screen for ten seconds to be remembered. After that, a single face was shown and the patient had to press the button one if he/she remembered or, otherwise, button five. It consisted of a random presentation of ten pre-exposed faces and ten new faces as distracters. The reaction time, assessed per patient, was averaged at each time point for each patient e.g., at baseline, Weeks 8 and 24. This test is part of the Computerized Neuropsychological Test Battery. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionmilliseconds (Mean)
Galantamine + Nimodipine (Baseline)3124.00
Galantamine + Placebo (Baseline)2684.45
Galantamine + Nimodipine (Week 8)2262.50
Galantamine + Placebo (Week 8)2734.25
Galantamine + Nimodipine (Week 24)2357.80
Galantamine + Placebo (Week 24)3099.38

[back to top]

Reaction Time for Simple Reaction Time Test at Baseline, Week 8, and Week 24

The Simple Reaction Time is a computerized attention test that evaluates the patient's reaction time. The number one was presented in the center of the computer screen and the patient had to press this number in the response box as quickly as possible. The reaction time, assessed 100 times per patient, was averaged at each time point for each patient e.g., at baseline, Week 8 and Week 24. The patient's finger was put over button one before the test begun. This test is part of the Computerized Neuropsychological Test Battery (CNTB). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionmilliseconds (Mean)
Galantamine + Nimodipine (Baseline)1024.06
Galantamine + Placebo (Baseline)729.18
Galantamine + Nimodipine (Week 8)466.60
Galantamine + Placebo (Week 8)671.33
Galantamine + Nimodipine (Week 24)467.60
Galantamine + Placebo (Week 24)584.44

[back to top]

Reaction Time for Two-choice Reaction Time Test at Baseline, Week 8, and Week 24

The Two-choice reaction time test is a computerized attention test in which the numbers one or five were presented in the center of the computer screen in a random order. The patient had to press the correspondent button in the response box as quickly as possible. The patient's right finger was put over the button five and the left finger over button one before the test begun. The reaction time, assessed 100 times per patient, was averaged at each time point for each patient e.g., at baseline, Week 8 and Week 24.This test is part of the Computerized Neuropsychological Test Battery (CNTB). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionmilliseconds (Mean)
Galantamine + Nimodipine (Baseline)1919.72
Galantamine + Placebo (Baseline)1096.75
Galantamine + Nimodipine (Week 8)852.70
Galantamine + Placebo (Week 8)1187.78
Galantamine + Nimodipine (Week 24)727.60
Galantamine + Placebo (Week 24)1116.25

[back to top]

Reaction Time for Word Recognition and Learning Test at Baseline, Week 8, and Week 24

The reaction time for word recognition and learning test is a computerized attention test that evaluates the patient's reaction time. This test is similar to the Face Recognition test procedure using Words. The recognition procedure was repeated three times to evaluate a learning effect. The reaction time, assessed per patient, was averaged at each time point for each patient e.g., at baseline, Week 8 and Week 24. This test is part of the Computerized Neuropsychological Test Battery (CNTB). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionmilliseconds (Mean)
Galantamine + Nimodipine (Baseline)2022.17
Galantamine + Placebo (Baseline)2978.77
Galantamine + Nimodipine (Week 8)1966.40
Galantamine + Placebo (Week 8)2379.83
Galantamine + Nimodipine (Week 24)1722.00
Galantamine + Placebo (Week 24)3038.81

[back to top]

The Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) at Baseline, Week 8, and Week 24

The ADAS-Cog is a psychometric instrument that evaluates memory, attention, reasoning, language, orientation and praxis using an 11-point Assessment Scale. It has a minimum score of 0 and a maximum severity score of 70, and a higher score indicates more impairment. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionscores on a scale (Mean)
Galantamine + Nimodipine (Baseline)30.40
Galantamine + Placebo (Baseline)28.20
Galantamine + Nimodipine (Week 8)25.10
Galantamine + Placebo (Week 8)31.03
Galantamine + Nimodipine (Week 24)25.02
Galantamine + Placebo (Week 24)27.70

[back to top]

The Neuropsychiatric Inventory (NPI) at Baseline, Week 8, and Week 24

The NPI evaluates 12 neuropsychiatric domains: delusions, hallucinations, dysphoria, anxiety, aggression, euphoria, dis-inhibition, irritability/lability, apathy, aberrant motor activity, eating disorders, and night-time behavior disturbances. For present domains, the severity and frequency of the behavior are determined. Frequency is rated 1 (rarely) to 4 (very often) and Severity is scored 1 (mild) to 3 (severe). The product scores vary from 1 (mild and rarely) to 12 (very often and severe). Total scores vary from 0 (no present domain) to 144 (all domains are present, are often and severe). (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionscores on a scale (Mean)
Galantamine + Nimodipine (Baseline)24.0
Galantamine + Placebo (Baseline)26.92
Galantamine + Nimodipine (Week 8)20.20
Galantamine + Placebo (Week 8)22.11
Galantamine + Nimodipine (Week 24)15.00
Galantamine + Placebo (Week 24)19.75

[back to top]

The Quality of Life Assessment for Caregivers of Patients With Alzheimer's Disease (QoL- AD) Total Scores at Baseline, Week 8, Week 24

The Quality of Life assessment scale for caregivers of patients with Alzheimer's disease (QoL-AD) is a 13-item scale with four possible scores for each question (score 1: poor and score 4: excellent). It evaluates the caregivers own perceived quality of life. Total score ranges from 13 to 52. Higher scores represent a better outcome. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionscores on a scale (Mean)
Galantamine + Nimodipine (Baseline)34.00
Galantamine + Placebo (Baseline)36.50
Galantamine + Nimodipine (Week 8)32.00
Galantamine + Placebo (Week 8)33.56
Galantamine + Nimodipine (Week 24)36.60
Galantamine + Placebo (Week 24)34.88

[back to top]

The Quality of Life Assessment for Patients With Alzheimer's Disease (QoL- AD) Total Scores at Baseline, Week 8, Week 24

The Quality of Life assessment scale for patients with Alzheimer's disease (QoL-AD) is a 13-item scale with four possible scores for each question (score 1: poor and score 4: excellent). Total score ranges from 13 to 52. Higher scores represent a better outcome. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionscores on a scale (Mean)
Galantamine + Nimodipine (Baseline)33.56
Galantamine + Placebo (Baseline)32.67
Galantamine + Nimodipine (Week 8)35.60
Galantamine + Placebo (Week 8)33.11
Galantamine + Nimodipine (Week 24)36.60
Galantamine + Placebo (Week 24)33.86

[back to top]

The Quality of Life Assessment for Patients With Alzheimer's Disease (QoL- AD) Total Scores, Based on the Caregiver's Opinion, at Baseline, Week 8, Week 24

The Quality of Life assessment scale for patients with Alzheimer's disease (QoL-AD), according to the opinion of the caregiver is a 13-item scale with four possible scores for each question (score 1: poor and score 4: excellent). It evaluates the opinion of the caregiver about the patient's quality of life. Total score ranges from 13 to 52. Higher scores represent a better outcome. (NCT00814658)
Timeframe: Baseline, Week 8, Week 24

Interventionscores on a scale (Mean)
Galantamine + Nimodipine (Baseline)28.33
Galantamine + Placebo (Baseline)29.33
Galantamine + Nimodipine (Week 8)27.80
Galantamine + Placebo (Week 8)29.78
Galantamine + Nimodipine (Week 24)29.80
Galantamine + Placebo (Week 24)29.13

[back to top]

The Clinical Global Impression (CGI) at Week 4, Week 8, Week 16, and Week 24

The Clinical Global Impression (CGI) is a scale to assess treatment response in patients with mental disorders. The Clinical Global Impression Improvement scale (CGI-I) requires the clinician to rate how much the patient's illness has improved or worsened relative to a baseline state. A patient's illness is compared to change over time and rated as: very much improved, much improved, minimally improved, no change, minimally worse, much worse, or very much worse. (NCT00814658)
Timeframe: Week 4, Week 8, Week 16, Week 24

,,,,,,,
Interventionparticipants (Number)
Very much improvedMuch improvedMinimally improvedNo changeMinimally worseMuch worseVery much worse
Galantamine + Nimodipine (Week 16)0121100
Galantamine + Nimodipine (Week 24)0131000
Galantamine + Nimodipine (Week 4)0114100
Galantamine + Nimodipine (Week 8)0022100
Galantamine + Placebo (Week 16)0035000
Galantamine + Placebo (Week 24)0241100
Galantamine + Placebo (Week 4)0154000
Galantamine + Placebo (Week 8)0162000

[back to top]

LH Surge

Compare the change between placebo treated and nimodipine treated patients by the presence or absence of an LH surge on intervention Day 1 and Day 2. LH surge will be determined by serum LH levels at least two times the baseline serum LH (baseline serum LH = (cycle day 3 serum [LH] + cycle day 7 serum [LH])/2). (NCT01672801)
Timeframe: 7 days

InterventionParticipants (Count of Participants)
Placebo9
Nimodipine9

[back to top]

Number of Participants Experiencing Side Effects

Medication side effect profile including: symptomatic hypotension (Note: vital signs will be recorded), symptomatic tachycardia (Note: vital signs will be recorded), headache, nausea. These will be self-reported with constructed questionnaire. (NCT01672801)
Timeframe: Starting day 0 of intervention to pregnancy test (approximately 15 days)

InterventionParticipants (Count of Participants)
Placebo3
Nimodipine4

[back to top]